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ABSTRACT 
 
VACCINE STRAIN SELECTION FOR INFLUENZA A VIRUSES IS COMPLICATED BY 
UNIQUE PRE-EXPOSURE HISTORIES AND RAPID MUTATION OF GLYCOPROTEINS 
Benjamin S. Chambers 
Scott E. Hensley 
Influenza viruses cause millions of infections worldwide each year. Influenza viruses constantly 
acquire mutations in their surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA), 
through a process called antigenic drift. HA is the main target of anti-influenza neutralizing 
antibodies (Abs). Due to antigenic drift, the seasonal influenza vaccines must be updated annually 
to include the most antigenically relevant strains. Each year, the World Health Organization 
collects thousands of clinical influenza isolates, propagates them in cell culture, and performs 
both sequencing and serological analyses to assess the antigenic characteristics of circulating viral 
strains. In this dissertation, we investigate multiple factors associated with surveillance and 
vaccine strain selection that could be improved to produce more reliable and effective seasonal 
influenza vaccines. We first demonstrate that recent H3N2 subtype viral isolates rapidly acquire 
mutations in both HA and NA when propagated in cell culture, resulting in increased receptor 
binding avidity or NA-dependent receptor binding, respectively. These mutations impact 
antigenic analyses that are routinely used for viral surveillance. We then explore how a single 
mutation in HA antigenic site B contributed to the antigenic drift and subsequent vaccine 
mismatch of newly emerged H3N2 viruses during the 2014-2015 influenza season. Finally, we 
find that antisera collected from previously naïve ferrets infected for the first time with influenza 
(that are commonly used for antigenic analyses during vaccine selection) do not accurately 
represent the Ab repertoires found in humans that have been infected or vaccinated multiple times 
with different influenza virus strains. We identified some individuals who have an Ab response 
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targeted to a region of the HA of H1N1 viruses that recently acquired a mutation. Overall, our 
studies identify ways to improve the process of choosing seasonal influenza virus vaccine strains. 
We propose that the implementation of “sequence-first” surveillance, new cell culture systems, 
and the use of clinical human antisera for antigenic characterization of viruses will improve the 
process of selecting seasonal influenza vaccine strains. 
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CHAPTER 1: INTRODUCTION 
 
Influenza Virus: The Basics 
Influenza virus was first isolated and characterized by Wilson Smith, Sir 
Christopher Andrewes, and Sir Patrick Laidlaw at the National Institute for Medical 
Research in London in 1933 (Smith et al., 1933). Since that day, much research has been 
carried out to better understand the importance of influenza virus in the human 
population. A member of the Orthomyxoviridae family, three main genera of influenza 
viruses have been discovered, isolated, and characterized. Influenza A viruses, which my 
work focuses on, circulate most widely and cause the most severe disease in humans 
(Taubenberger and Morens, 2008). Influenza B viruses only infect mammals and cause 
less severe infections (Guan et al., 2011). And a lineage of influenza C viruses that 
mostly infects pigs has also been discovered (Guo et al., 1983). The natural reservoir of 
influenza A virus is aquatic birds or waterfowl, such as ducks and geese (Hinshaw et al., 
1980). However, it is able to infect a wide array of species including pigs, horses, whales, 
bats, dogs, and of course, humans (Webster et al., 1992). 
 Influenza viruses cause millions of infections and thousands of deaths in the 
United States each year (Kostova et al., 2013; Reed et al., 2015). During 2013 alone, 
influenza infections resulted in an estimated 57,000 deaths in the United States (Xu et al., 
2016). The secret behind influenza’s ability to remain such a large public health threat on 
an annual basis is its ability to adapt and mutate to escape detection by prior immunity in 
the population. Influenza viruses possess a negative-sense single-stranded RNA genome 
with eight separate gene segments that encode at least 15 proteins (Muramoto et al., 
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2013). The viral capsid consists of matrix protein 1 (M1) and matrix protein 2 (M2) 
(Lamb et al., 1981). There are two glycoproteins, hemagglutinin (HA) and neuraminidase 
(NA), present on the surface of the virion that are used for attachment and release, 
respectively (Gamblin and Skehel, 2010). Nonstuctural protein 1 (NS1) is an immune 
system antagonist with multiple functions (Fernandez-Sesma et al., 2006), and nuclear 
export protein (NEP) is used primarily for nuclear export of replication products (O'Neill 
et al., 1998). Within the virion, influenza carries its own RNA-dependent RNA 
polymerase that consists of polymerase basic protein 1 (PB1), polymerase basic protein 2 
(PB2), and polymerase acidic protein (PA). The polymerase forms a complex with the 
viral RNA genome and nucleoprotein (NP), called the viral ribonucleoprotein (vRNP) 
particle, which is essential for replication (Biswas et al., 1998). The RNA-dependent 
RNA polymerase encoded by influenza lacks proofreading and introduces an average of 
one mutation in each replicated genome (Drake, 1993). The introduction of point 
mutations by the polymerase and the rearrangement of gene segments between different 
influenza strains leads to the high adaptive ability of influenza viruses.  
 
The Immune Response Against Influenza A Virus 
 During a human infection, influenza virus mainly replicates within the epithelial 
cells of the host’s upper respiratory tract. The first line of defense for the host is the 
innate immune response. Like in many other viral infections, the innate immune response 
is key in fighting off severe influenza infections. Influenza virus is recognized by 
multiple pattern recognition receptors: Toll-like receptors (TLRs) recognize dsRNA and 
ssRNA (Finberg et al., 2007), retinoic acid-inducible gene I (RIG-I) recognizes the 5’-
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triphosphate of viral RNA (Kato et al., 2006), and NOD-, LRR-, and pyrin domain-
containing 3 (NLRP3) detects cellular damage due to influenza replication (Allen et al., 
2009). Type I interferons (IFNs) are produced and IFN-stimulated genes (ISGs) are 
activated to limit influenza replication. A few of the key ISGs include MX proteins, IFN-
inducible transmembrane (IFITM) proteins, and ribonuclease L (RNase L). MX proteins 
expressed in humans have potent anti-influenza virus activity by blocking assembly of 
functional vRNPs (Verhelst et al., 2012). IFITM3 is a transmembrane host protein that 
limits influenza entry into the cytosol and IFITM3-deficient mice are highly susceptible 
to influenza infection (Bailey et al., 2012; Feeley et al., 2011). RNase L works in 
conjunction with 2’-5’-oligoadenylate synthase (OAS) to bind and degrade viral and 
cellular ssRNAs (Wreschner et al., 1981), and RNaseL-deficient mice are more 
susceptible to influenza infection (Zhou et al., 2013). The innate immune response is so 
effective that the influenza virus encodes its own protein, NS1, which is responsible for 
antagonizing and inhibiting the innate immune response. NS1 has been shown to bind 
and sequester dsRNA away from OAS so that RNase L remains inactive (Min and Krug, 
2006). NS1 also interacts with TRIM25 to inhibit ubiquitination of RIG-I, and thus 
prevent RIG-I signal transduction (Gack et al., 2009). NS1 plays multiple other roles in 
evading host cell detection and limiting the innate immune response. 
 Early during infection, professional antigen-presenting cells (APCs), such as 
dendritic cells and macrophages, take up and process influenza virus antigen. This 
antigen can come from whole virus, from replication intermediates, or from influenza-
infected cells taken up by phagocytosis (Mintern and Villadangos, 2015). The influenza 
antigens are then presented on the surface of the APCs in association with major-
4	  
histocompatibility complexes (MHCs) I or II, to activate both CD8+ and CD4+ T cells 
(Alam and Sant, 2011; Turner et al., 2013). Mature B cells expressing a B cell receptor 
(BCR) on their surface are also activated by recognizing viral antigen, and experience 
proliferation through CD4+ T cell-mediated help in the germinal centers (Victora and 
Nussenzweig, 2012). B cells activated early after infection produce IgM antibodies (Abs). 
Activated B cells then undergo class-switching and begin producing IgG Abs that are 
capable of neutralizing influenza virus in multiple ways, including binding to HA and 
blocking receptor binding, inhibiting membrane fusion, or initiating Ab-dependent cell-
mediated cytotoxicity (ADCC) (Jegaskanda et al., 2013). Some B cells in the mucosal 
tissues produce high levels of IgA instead, in order to prevent further infection of 
mucosal surfaces, especially in the nasal passage (Renegar et al., 2004). Two to four 
weeks after primary infection, Ab production is at its peak (Clements and Murphy, 1986). 
During the primary response, a long-lived memory B cell pool is established (Buchner et 
al., 1977; Skountzou et al., 2014). This memory B cell pool produces Abs specific for the 
influenza strain causing the primary infection, and these cells can be recalled following 
subsequent influenza virus exposures with antigenically similar strains. 
 Following a secondary infection with influenza, the memory B cell pool provides 
a rapid production of influenza-specific Abs that reach their peak production much earlier 
than in the primary response. However, in order to be reactivated, the memory B cell 
must be specific for an epitope that is conserved between the previous infecting strain and 
the current infecting strain. Once triggered, the B cell proliferates and undergoes somatic 
hypermutation in order to generate Abs with higher affinity and increased neutralization 
against the influenza antigen (Eisen, 2014). Once again, a new pool of memory B cells is 
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established during this secondary response. Throughout a lifetime, humans are infected 
and/or vaccinated multiple times with antigenically distinct influenza viruses. During 
each subsequent exposure, a memory B cell response is recalled and further shaped 
through somatic hypermutation.  
 
Genetic Reassortment and Antigenic Shift 
 The main targets of anti-influenza neutralizing Abs are the two surface 
glycoproteins, HA and NA. One mechanism employed by influenza viruses to escape B 
cell memory and the anti-HA/NA Ab response is to swap gene segments with other 
strains of influenza virus. Gene segments can be swapped between two different 
influenza virus strains during co-infection of the same cell. This process is called 
reassortment, and different combinations of the eight influenza gene segments can result 
in the emergence of new influenza subtypes or new influenza strains with altered host 
specificity and increased virulence (Steel and Lowen, 2014). The subtype of each virus is 
defined by the antigenic properties of their HA and NA glycoproteins. Currently, there 
are 18 known HA subtypes and 11 known NA subtypes (Tong et al., 2013). Over the past 
century, several different subtypes of influenza A virus have circulated in the human 
population (Fig. 1). Reassortment that results in the emergence of a new viral subtype 
with antigenically novel HAs and NAs is called antigenic shift (Nelson and Holmes, 
2007).  
 Antigenic shift occurs every time a new pandemic emerges in the human 
population (Fig. 1). The pandemic of 1918 that claimed an estimated 50 million lives has 
been attributed to the emergence of an H1N1 influenza A virus (Johnson and Mueller, 
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2002; Taubenberger et al., 1997). These H1N1 viruses continued circulating in the human 
population until 1957, when a new subtype (H2N2) emerged following the reassortment 
of the circulating human H1N1 viruses with the PB1, HA, and NA genes of an avian 
H2N2 virus (Schafer et al., 1993). The “Asian Flu” of 1957 was a milder pandemic but 
still claimed 70,000 lives in the United States (Noble, 1982). Another antigenic shift 
event occurred in 1968 when the H3N2 “Hong Kong Flu” pandemic emerged and killed 
34,000 people in the United States (Noble, 1982). In this case, the prior H2N2 viruses 
acquired the HA and PB1 genes from an avian H3N2 virus (Gething et al., 1980). 
Antigenically drifted H3N2 viruses from this pandemic are still circulating today. In 
1977, H1N1 viruses returned to circulation, likely following a lab containment accident 
that reintroduced H1N1 viruses into a partially naïve population (Kendal et al., 1978; 
Webster et al., 1992). These H1N1 viruses were genetically similar to those that had 
circulated in the early 1950s (Nakajima et al., 1978; Scholtissek et al., 1978). Older 
adults had prior immunity from exposure to similar strains, and therefore the majority of 
disease burden occurred in children and young adults under the age of 25 (Kilbourne, 
2006). These H1N1 viruses are now referred to as the seasonal H1N1 (sH1N1) viruses as 
a way to separate them from the antigenically distinct pandemic (pH1N1) viruses that 
emerged in 2009. 
 The “Swine Flu” of 2009 resulted in many severe infections, surprisingly only 5% 
of them being in adults over the age of 51 (Dawood et al., 2009). Elderly individuals 
were thought to be protected due to similarities in the HA between the pH1N1 viruses of 
2009 and the H1N1 viruses that circulated prior to the 1950s (Skountzou et al., 2010). As 
discussed earlier in this chapter, memory B cells primed early in life can be recalled when 
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confronted with new strains that possess B cell epitopes conserved in older viral strains. 
The pH1N1 viruses were the result of a quadruple reassortment between gene segments 
from human H3N2 viruses, classical swine viruses, Eurasian swine viruses, and a North 
American avian virus introduced through a swine lineage (Garten et al., 2009). 
Approximately 20-30% of the amino acid residues in HA are different between pH1N1 
viruses and sH1N1 viruses (Li et al., 2012). The sH1N1 viruses quickly became extinct 
following the emergence of pH1N1 viruses, possibly because pH1N1 viruses had higher 
fitness (Perez et al., 2009) or because pH1N1 viruses elicited cross-reactive stalk Abs and 
anti-NA Abs that bound with high affinity and completely neutralized the sH1N1 viruses 
(Palese and Wang, 2011). Currently, both pH1N1 and H3N2 influenza A viruses are 
actively circulating in the human population on an annual basis and both will be 
discussed further in this dissertation. 
 
Antigenic Importance of Hemagglutinin and Antigenic Drift  
 As stated previously, there are two glycoproteins exposed on the surface of 
influenza viruses. The surface is covered in a 10:1 ratio of HA to NA (Mitnaul et al., 
1996). NA is a tetramer that is mainly responsible for the release of newly formed virions 
from the surface of host cells. HA exists as a trimer on the virion surface and is 
responsible for binding to the target cell via its receptor, a terminal sialic acid residue on 
the surface of the host cell. HA is synthesized as a precursor, called HA0, which must be 
cleaved by a trypsin-like protease to form the activated confirmation of HA1 and HA2 
(Gething et al., 1986). After binding to the sialic acid receptor through HA1, the virus is 
taken into the cell through dynamin-dependent, clathrin-mediated endocytosis (Patterson 
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et al., 1979). A decrease in pH within the endosome triggers a conformational change that 
exposes the fusion peptide within HA2 (Skehel et al., 1982). The fusion peptide then 
imbeds into the host endosomal membrane and forms a pore for release of the vRNPs 
into the cytoplasm (Stegmann et al., 1991). Abs that bind to HA can neutralize the virus 
in multiple ways, including prevention of HA0 cleavage, obstruction of receptor binding, 
and inhibition of membrane fusion (Brandenburg et al., 2013).  
 Previous work completed in the 1970s and 1980s mapped the immunodominant 
epitopes on HA where most anti-influenza neutralizing Abs bind. These 
immunodominant epitopes are referred to as antigenic sites. Escape mutants were 
generated in the presence of monoclonal Abs to identify the four antigenic sites (Sa, Sb, 
Ca, and Cb) of H1N1 viruses (Caton et al., 1982). Sequence data and the interpretation of 
past antigenic drift mutations were studied to identify the five antigenic sites (A, B, C, D, 
and E) of H3N2 viruses (Wiley et al., 1981). The antigenic sites are located across the 
head of the HA trimer (Fig. 2). This region is the most exposed and thus the most 
accessible for binding of Abs. Neutralizing Abs that bind the more conserved stalk 
domain located closer to the membrane have also been identified (Corti et al., 2011; 
Ekiert et al., 2009; Okuno et al., 1993; Sangster et al., 2013; Sui et al., 2009), but the vast 
majority of anti-influenza neutralizing Abs bind to the easily accessible globular head 
domain of HA. It is also important to note that not all neutralizing Abs bind to one of 
these classic antigenic sites. The classic antigenic sites can be thought of as defining a 
general location on the HA trimer, rather than identifying a very specific set of individual 
residues that are involved in Ab binding. 
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 Because most neutralizing Abs bind to these antigenic sites, they are also the most 
common sites for the accumulation of antigenic drift mutations. Genetic drift is defined 
as the continuous accumulation of nonsynonymous mutations in viral gene segments; a 
result of the RNA-dependent RNA polymerase that lacks proofreading (Nelson and 
Holmes, 2007). Antigenic drift occurs when immune pressure leads to the fixation of 
those mutations that abrogate the binding of neutralizing Abs (Fitch et al., 1997). 
Throughout the evolution of H3N2 influenza viruses between 1968 and 2003, over 70 
mutations became fixed in the H3N2 HA; 94% of which were in the classic H3N2 
antigenic sites identified previously (Smith et al., 2004; Wiley et al., 1981). A recent 
transposon mutagenesis screen concluded that HA, the globular head domain in 
particular, is the most permissible region to mutations in the influenza genome (Heaton et 
al., 2013). Viral mutations can also alter viral fitness through mechanisms that do not 
involve abrogating Ab binding.  For example, mutations throughout the influenza 
genome can change receptor specificity (Zhang et al., 2013a), alter neuramindase activity 
(Richard et al., 2008), switch host tropism (Mehle et al., 2012), increase polymerase 
activity (Liu et al., 2016), and promote nuclear import of vRNP particles (Sediri et al., 
2015). 
 It is important to understand how mutations in HA can lead to changes in host 
tropism. Influenza viruses attach to cells by binding to sialic acid receptors. Sialic acid is 
linked to galactose through either an α2,3 or an α2,6 linkage. Most avian influenza 
viruses are specific for α2,3-linked sialic acids while most human influenza viruses are 
specific for α2,6-linked sialic acids (Rogers et al., 1983). Mutations in HA can alter sialic 
acid specificity and allow viruses to jump from one species to the other (Tharakaraman et 
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al., 2013). This scope of specificity makes sense when considered in the context of which 
sialic acids coat the cells in certain species. In aquatic birds, their guts (the main site of 
influenza virus replication in birds) are coated with predominantly α2,3-linked sialic 
acids (Pillai and Lee, 2010). However, the human upper respiratory tract (where 
influenza mainly replicates in humans) is mostly coated in α2,6-linked sialic acids 
(Shinya et al., 2006; Thompson et al., 2006). Interestingly, the human lower respiratory 
tract does contain α2,3-linked sialic acids, which may help to explain why avian-derived 
influenza viruses like H5N1 and H7N9 often spread lower into the lungs and cause 
pneumonia and death in human infections (Knepper et al., 2013; Zeng et al., 2013). The 
gut of swine contains a mixture of both α2,3- and α2,6-linked sialic acids, explaining why 
they can act as so-called “mixing vessels” for influenza reassortment of multiple types of 
strains (Trebbien et al., 2011). Other than switching host tropism, mutations in the HA 
receptor binding domain can simply increase or decrease receptor binding avidity (Lin et 
al., 2012). In fact, many mutations in HA that alter antigenicity also increase or decrease 
receptor binding avidity (Hensley et al., 2009). This leads to complications during 
antigenic analyses of recently emerged mutant viruses. 
 
Original Antigenic Sin 
 Over 50 years ago, Thomas Francis, Jr. coined the term “original antigenic sin” as 
a way to describe the observation that even when infected with a novel influenza strain, 
humans will produce Abs against previously encountered strains at the expense of 
mounting effective responses against the current novel strain (Davenport et al., 1953; 
Francis, 1960). Ever since then, original antigenic sin (OAS) has been explored more in 
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depth to better establish the role it plays in secondary immune responses against 
influenza virus. Various studies have focused on antigenic seniority and the role of OAS 
in H3N2 responses (Lessler et al., 2012), longitudinal analyses of H1N1, H2N2, and 
H3N2 responses (Miller et al., 2013), and Ab responses against the 2009 pH1N1 virus 
(Wrammert et al., 2011). OAS following influenza infection has been observed in 
multiple other animal models including rabbits (Fazekas de St and Webster, 1966b), mice 
(Virelizier et al., 1974b), and ferrets (Webster, 1966). Apart from other animal models, 
OAS has also been detected in other pathogens. For example, OAS has been observed 
following sequential dengue virus infections and may play a role in shaping the Ab 
response against human immunodeficiency virus (HIV) over time (Ciupe et al., 2011; 
Halstead et al., 1983). 
 Mechanisms that lead to OAS are not completely understood, but OAS likely 
occurs when cross-reactive B cell clones are recalled from the memory pool during 
infections with antigenically related influenza strains (Li et al., 2013b; Wrammert et al., 
2011). The cross-reactive OAS Abs these memory B cells produce quickly eliminate the 
new antigen before any novel Ab responses can be established (Kim et al., 2009). OAS 
has been hypothesized to lead to reduced vaccine efficacy. However, recent studies have 
shown that OAS Abs that bind with low affinity can afford protection against secondary 
viral challenges (Linderman and Hensley, 2016). Recent studies have also explored how 
the effects of OAS can be avoided during vaccination. Repeated vaccination with the 
same novel strain or the use of adjuvants potentially limits OAS (Kim et al., 2012). The 
impact of OAS on the secondary immune response against influenza virus will be 
explored in Chapter 4. 
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Current Vaccination Methods 
 The best approach for limiting influenza infection in the human population is 
annual vaccinations with currently circulating influenza strains. Jonas Salk and Thomas 
Francis, Jr. developed the first influenza vaccine in 1938 by using ultraviolet radiation to 
inactivate the virus (Salk et al., 1940). Today, the most common approach is still to 
vaccinate with an inactivated virus; specifically, an inactivated split virus or subunit 
vaccine that is grown in eggs (Wong and Webby, 2013). These inactivated vaccines 
contain an H1N1 influenza A virus component, an H3N2 influenza A virus component, 
and one or two influenza B components. They are called trivalent inactivated vaccines 
(TIVs) or quadrivalent inactivated vaccines (QIVs) depending on how many influenza B 
strains they include, and they are injected into the muscle of recipients. Inactivated 
vaccines have been used for over 70 years and have a good history of reducing disease in 
the human population (Hannoun, 2013). During a typical season, the inactivated vaccines 
have an efficacy of 60-70% (Treanor et al., 2012). Over the past couple decades, the 
recommendation for vaccination in the United States has expanded to include the entire 
population. Previously, influenza vaccination was focused primarily on at-risk groups 
including healthcare workers, pregnant women, young children (<6 years old), and the 
elderly (>65 years old) (Hannoun, 2013). However, as the public health impact and 
severity of influenza virus has increased and become better understood, the United States 
began recommending in 2010 that everyone over the age of 6 months be vaccinated 
against influenza virus on an annual basis (Fiore et al., 2010). 
 Another current method of influenza vaccination is the use of attenuated viruses. 
For example, FluMist is a licensed vaccine that contains a whole virus that can only grow 
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at lower temperatures (25°C). It is injected into the nose of the recipient where it can 
replicate and elicit an immune response. However, the vaccine strain is unable to expand 
into the lungs and cause an infection because it cannot replicate at the internal body 
temperature of 37°C. The live-attenuated influenza vaccines (LAIVs) do present a couple 
advantages over the inactivated subunit vaccine. First, LAIVs replicate in the nasal cavity 
and thus elicit T-cell responses that are an important part of influenza immunity (Mohn et 
al., 2015). Second, LAIVs also elicit robust mucosal IgA Ab responses (Ambrose et al., 
2012) compared to the inactivated subunit vaccines which elicit primarily IgG-dominated 
Ab responses (Cox et al., 1994). Although early uses of the LAIVs were successful, 
recent formulations of FluMist in particular have elicited very poor responses and have 
resulted in very low vaccine efficacies. For example, the LAIV vaccine efficacy was 
reported at only 3% during the 2015-2016 season (Anonymous, 2016). This has led to the 
recent recommendation by the CDC to only use inactivated subunit vaccines during the 
upcoming 2016-2017 influenza season (Anonymous, 2016). 
 The future of influenza vaccination is targeted at generating more cross-reactive 
vaccine responses, or even a universal vaccine that will elicit lifelong influenza 
immunity. One approach currently being explored is the use of peptide antigens that 
contain epitopes commonly recognized by B cell or T cell responses. For example, an NP 
epitope encased in a liposome has been shown to elicit potent T cell responses and reduce 
viral lung titers in influenza-infected mice (Ninomiya et al., 2002). A second approach 
being pursued is recombinant proteins. Headless HA proteins expressed on virus-like 
particles (VLPs) or on nanoparticles have shown promise in mice and ferrets by 
increasing the cross-reactivity of the anti-influenza Ab response by targeting it towards 
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the more conserved stalk domain of HA (Steel et al., 2010; Yassine et al., 2015). Another 
version of recombinant proteins being employed to elicit stalk-focused Abs is chimeric 
HA proteins. By sequentially vaccinating with recombinant proteins that all share the 
same HA stalk but contain different HA globular heads, the recalled Ab response is 
focused against the conserved stalk domain (Krammer et al., 2014; Krammer and Palese, 
2013). These along with many other approaches (such as M2-focused Abs, adjuvants, and 
DNA-based vaccines) could end up being the future of influenza vaccination. But in the 
mean time, it is important to continue improving the current method of vaccination, strain 
selection, and vaccine manufacturing. 
 
Influenza Virus Surveillance and Vaccine Strain Selection 
 Currently, the influenza vaccine must be updated each year to possess the most 
relevant strains of H1N1, H3N2, and influenza B viruses. The constant accumulation of 
mutations in HA via antigenic drift can make vaccine selection a very difficult process. In 
order to select the best possible vaccine strains on an annual basis, the World Health 
Organization (WHO) and Centers for Disease Control and Prevention (CDC) employ 
constant surveillance (Stöhr et al., 2012). Throughout the year, thousands of influenza 
isolates are collected from infected individuals. These strains are grown in cell culture or 
eggs to obtain a workable stock, antigenically characterized, and sequenced (Krauss et 
al., 2012; Stöhr et al., 2012). When antigenically distinct viruses are detected, the vaccine 
is updated. The most common method employed for determining antigenic differences 
compared to the current vaccine strain is the serological assay called the 
hemagglutination inhibition (HAI) assay (Stöhr et al., 2012). The HAI assay measures the 
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amount of antisera required to inhibit a virus from binding to its sialic acid receptor. The 
WHO and CDC mainly use antisera collected from previously naïve ferrets infected for 
the first time with the current influenza vaccine strain (Stöhr et al., 2012). This “primary 
ferret antisera” is then used in HAI assays and in in vitro neutralization assays to detect 
when circulating strains escape detection by the Abs elicited by the current vaccine strain. 
The in vitro neutralization assay is another serological assay and it measures the ability of 
antisera to neutralize the growth of virus in cell culture. It is a more reliable assay in 
identifying all functionally active Abs that neutralize virus, compared to the HAI assay 
which can only detect Abs that block virus-sialic acid interactions (Bachmann et al., 
1999; Zhu et al., 2011). For example, there are HA stalk-binding Abs that are HAI-
negative (do not affect binding) but still neutralize virus by blocking membrane fusion or 
inhibiting proteolytic cleavage of HA0 (Pica et al., 2012). Therefore, HAI assays and in 
vitro neutralization assays using mainly sera collected from previously naïve ferrets are 
used to characterize the antigenic properties of newly emerged viruses. 
 However, multiple factors can complicate the vaccine selection process. For 
example, one caveat is that the vaccine strains need to be chosen over nine months before 
the actual influenza season begins in order to manufacture enough vaccine doses. This 
means that between the time that the vaccine composition is selected and the time it is 
actually given to humans, the circulating viruses could acquire additional mutations and 
establish an HA identity that is undetectable by the vaccine-elicited Ab response. Every 
few years, antigenic drift that occurs leading up to an influenza season results in a 
vaccine mismatch where vaccine efficacy is drastically reduced (Carrat and Flahault, 
2007; Chambers et al., 2015; Xie et al., 2015). Another complicating factor is that there 
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are no established definitions for how much antigenic change is required before a vaccine 
update is called for. The HAI and in vitro neutralization assays can quantify the 
difference in ability of antisera to bind and neutralize different viruses. However, there is 
no set amount of antigenic change that triggers an automatic vaccine update. The choice 
to update the vaccine is left up to the consideration and conclusions of the WHO and 
CDC. In general, the H3N2 and influenza B components of the vaccine have been 
updated every 2-4 years on average (Fouchier and Smith, 2010; Smith et al., 2004). 
However, the current H1N1 vaccine strain has not been updated since 2009, when the 
pH1N1 viruses first emerged. The last major complication is that sera collected from 
previously naïve ferrets infected with influenza virus a single time are used to represent 
human immunity. Although ferrets are a great model of influenza infection and 
immunity, recent studies have challenged whether ferret antisera following a single 
infection can truly represent the spectrum of Ab response specificities found in the 
human population (Fonville et al., 2016; Li et al., 2013b). 
 
Ferrets and Mice as Models for Influenza Infection 
 Two of the most commonly used animal models for influenza virus infection and 
immunity are mice and ferrets. The effective use of mice (Shope, 1935) and ferrets 
(Shope, 1934) in influenza research was established immediately after the first isolation 
of influenza virus in 1933. As mice and ferrets will both be employed in the chapters that 
follow, it is important to establish both the pros and cons associated with both systems so 
that data can be accurately interpreted. Mice are a reliable, genetically stable, less 
expensive, and easily manipulated system used to study influenza virus infections. Mice 
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become infected when challenged with a sufficient dose of influenza virus and show 
multiple signs of illness. Weight loss, lethargy, and ruffled fur are all indications of 
infection severity and have been used as reliable measurements in many early vaccine 
and antiviral efficacy studies (Gubareva et al., 1998; Tumpey et al., 2002). Passive Ab 
transfer experiments that measure the ability of Abs to prevent severe infection are also 
commonly carried out in mice (Francis and Magill, 1935; Renegar and Small, 1991). 
However, using mice as a model for influenza research does present multiple drawbacks. 
Influenza strains often acquire mutations and become adapted to replicate well in mice 
(Keleta et al., 2008). For example, one of the most commonly used influenza lab strains, 
A/Puerto Rico/08/1934 (PR8), is a heavily mouse-adapted strain (Gerber et al., 1955). 
Comparisons between mouse-adapted and human-adapted strains cannot always be made 
with certainty due to adaptive mutations that have arisen in the virus when passaged in 
mice. A second main concern with mice is that their presentation of illness does not 
match the human response to an influenza infection. Mice do lose weight, but do not 
develop a fever during infection (Dybing et al., 2000). Viral replication and tissue 
damage is concentrated in the lower respiratory tract in mice, instead of the upper 
respiratory tract like it is in humans (Belser et al., 2010). Transmission studies with 
H1N1, H3N2, and H5N1 viruses have also proven unsuccessful in mice (Lowen et al., 
2006). Overall, mice are a good model for answering some experimental questions but 
cannot provide a true representation of human influenza infection. 
 All the limitations of the mouse model actually represent the strengths of the 
ferret model. Ferrets are easily infected with non-adapted human influenza viruses and 
pathogenesis presents in very similar ways compared to human infections (Herlocher et 
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al., 2001). For example, ferrets infected with influenza virus experience respiratory 
distress, fever, nasal discharge, anorexia, and lethargy similar to humans (Smith et al., 
1933). Developing classic clinical symptoms makes ferrets great models for testing 
antiviral efficacy (Govorkova et al., 2007; von Itzstein et al., 1993). Another major 
advantage to using ferrets is that they can transmit influenza virus via aerosols. Aerosol 
transmission is the major method of transmission in human influenza outbreaks. Many 
successful transmission studies have been conducted using the ferret model, including 
transmission of H7N2 (Belser et al., 2008), H9N2 (Wan et al., 2008), and the recent 
swine-origin pH1N1 of 2009 (Munster et al., 2009). The major downside to using the 
ferret model for influenza research is that they are expensive and require specialized 
animal facilities (Maher and DeStefano, 2004). 
 The ferret model is employed as the main animal model for virus surveillance and 
vaccine selection (Belser et al., 2011). And although recent studies have concluded that 
sera collected from previously naïve ferrets infected with influenza for the first time 
cannot represent the entire spectrum of anti-H1N1 Ab specificities found in humans, 
ferrets sequentially infected with antigenically distinct H1N1 strains do recapitulate the 
unique Ab responses seen in humans (Li et al., 2013b; Linderman et al., 2014). However, 
previously naïve ferrets infected with influenza a single time continue to be the main 
standard used in viral surveillance and vaccine strain selection. 
 
Main Experimental Questions 
 Surveillance for vaccine selection currently relies on collecting viral isolates, 
growing them in cell culture and eggs, characterizing their antigenic profile using sera 
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collected from previously naïve ferrets infected with influenza for the first time, and 
sequencing their HA gene (Stöhr et al., 2012). However, multiple steps could be taken to 
improve this process and select more effective influenza vaccine strains in the future. The 
chapters below will explore the main aspects of influenza surveillance and vaccine strain 
selection that need to be improved.   
 First, we will investigate whether antigenicity of recent H3N2 clinical isolates is 
affected by cell culture propagation. Recent H3N2 influenza viruses have poor receptor 
binding avidity and grow poorly in cell culture because they cannot bind well to their 
sialic acid receptors for entry (Gulati et al., 2013; Lin et al., 2012; Nobusawa et al., 
2000). We find that during propagation in cell culture, H3N2 clinical isolates rapidly 
acquire mutations in both HA and NA. These mutations result in increased receptor 
binding avidity, NA-dependent sialic acid receptor binding, and altered antigenic 
characteristics. 
 Second, we will explore how a single mutation in an antigenic site of HA can 
contribute to a major vaccine mismatch. The H3N2 vaccine component failed during the 
2014-2015 influenza season due to a mismatch between the vaccine strain and the viral 
strains that actually circulated. We determined that mutations that arose in the HA 
globular head were responsible for the antigenic drift that caused the vaccine mismatch. 
The main contribution was from a single mutation in HA antigenic site B, a region that 
has been implicated multiple times in the past for antigenic drift mutations that 
contributed to the evolution of H3N2 viruses (Koel et al., 2013; Popova et al., 2012). 
 Third, we will examine whether recent mutations in the pH1N1 virus subtype are 
being antigenically mischaracterized using sera collected from previously naïve ferrets 
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infected with influenza for the first time. Humans are infected and/or vaccinated with 
antigenically distinct influenza viruses multiple times throughout their lives. The Ab 
responses primed early in their lives are recalled during each subsequent secondary 
infection with antigenically related strains. We find that childhood sH1N1 infections 
shape the specificity of Ab responses elicited against pH1N1 viruses. Specifically, the Ab 
responses elicited by pH1N1 viruses are focused on epitopes conserved between the 
pH1N1 viruses and the sH1N1 viruses that individuals were likely infected with early in 
life. In Chapter 4, we will explore whether mutations that arise in these unique Ab 
binding epitopes are being antigenically mischaracterized by the current antigenic 
analyses used in surveillance that employ mainly antisera isolated from pH1N1-infected 
ferrets who do not have any prior H1N1 exposures.  
 Together, our studies demonstrate the importance of updating current surveillance 
and vaccine strain selection techniques in order to produce more effective seasonal 
influenza vaccines. We propagated clinical isolates in cell culture, sequenced HA genes, 
and conducted antigenic analyses with both ferret and human antisera to identify 
antigenically important mutations. We conclude that recent H3N2 viruses rapidly acquire 
mutations in MDCK cell culture, single mutations in HA can cause antigenic drift and 
subsequent vaccine mismatches, different humans have unique anti-pH1N1 Ab responses 
due to unique pre-exposure histories, and newly arisen mutations are being antigenically 
mischaracterized by sera isolated from ferrets recovering from primary infections. Due to 
all these concerns, multiple steps need to be taken to improve upon the current vaccine 
strain selection process. The use of “sequence-first” surveillance, new cell culture 
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systems, and sequentially infected ferret or clinical human antisera in antigenic analyses 
would likely increase vaccine effectiveness. 
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FIGURES FOR INTRODUCTION 
Figure 1 
 
 
 
 
 
 
 
Figure 1. Timeline of influenza A virus circulation in the human population over the 
past century.  
This timeline denotes the circulation of different influenza A virus subtypes in the human 
population since 1918. The emergence of a new subtype is associated with genetic 
reassortment and antigenic shift. The continued circulation of a subtype is associated with 
continuous antigenic drift. The seasonal H1N1 and pandemic H1N1 subtypes are 
abbreviated as sH1N1 and pH1N1, respectively. The two subtypes currently circulating 
on a seasonal basis, pH1N1 and H3N2, are highlighted in red. 
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Figure 2 
 
Figure 2. Previously identified antigenic sites mapped on the H3 and H1 crystal 
structures. 
The classic antigenic sites for both H3N2 viruses (Wiley et al., 1981) and H1N1 viruses 
(Caton et al., 1982) were originally identified in the early 1980s. Here, the five classic 
antigenic (Ag) sites of H3 HA (A) and the four classic antigenic sites of H1 HA (B) are 
mapped on the HA trimers (Protein Data Bank (PDB) entries 1HGG and 1RVX) in 
different colors identified by the legends. The sialic acid receptor is shown in white.  
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CHAPTER 2: RECENT H3N2 INFLUENZA VIRUS CLINICAL 
ISOLATES RAPIDLY ACQUIRE HEMAGGLUTININ OR 
NEURAMINIDASE MUTATIONS WHEN PROPAGATED FOR 
ANTIGENIC ANALYSES 
 
 
Parts of this chapter were previously published in: 
 
Chambers BS, Li Y, Hodinka RL, and Hensley SE. (2014) Recent H3N2 influenza virus 
clinical isolates rapidly acquire hemagglutinin or neuraminidase mutations when 
propagated for antigenic analyses. J Virol 88(18):10986-10989. 
 
 
SUMMARY 
 Influenza A viruses continuously acquire mutations in their surface glycoproteins, 
hemagglutinin (HA) and neuraminidase (NA), in order to escape neutralizing immune 
responses and continue circulating. Each year, influenza virus surveillance is required to 
determine the most antigenically relevant strains to include in the vaccine. Thousands of 
isolates are collected, expanded in cell culture, and then antigenically characterized and 
sequenced. Recent H3N2 viruses have drastically decreased receptor binding avidity and 
thus acquire adaptive mutations when grown in cell culture. We passaged 10 clinical 
isolates in cell culture and determined that HA and NA mutations are acquired rapidly. 
25	  
These mutations result in growth to higher infectious titers and increased agglutination of 
red blood cells. The NA mutations acquired during propagation led to NA-dependent 
binding of the sialic acid receptor, and the HA mutation led to increased receptor binding 
avidity. Both of these characteristics have profound effects on antigenic analyses, and 
could be negatively affecting annual influenza vaccine surveillance.  
 
INTRODUCTION 
 H3N2 influenza A viruses have circulated continuously in the human population 
since 1968. In that time, they have steadily acquired mutations in the antigenic sites of 
both of the glycoproteins present on their surface, hemagglutinin (HA) and 
neuraminidase (NA) (Yewdell, 2011). This process of acquiring mutations to evade 
neutralizing antibody (Ab) responses is called antigenic drift and has occurred in H3N2 
viruses since 1968 (Smith et al., 2004). HA is the major antigenic target of the humoral 
immune system, and thus acquires the majority of antigenic drift mutations (Smith et al., 
2004). Mutations in HA are able to change both antigenicity and receptor binding avidity 
simultaneously (Hensley et al., 2009; Underwood et al., 1987).  Recent H3N2 viruses 
have dramatically reduced receptor binding avidity and altered receptor specificity 
(Gulati et al., 2013; Lin et al., 2012). 
Due to antigenic drift, the influenza vaccine must be updated on an annual basis 
to include the most antigenically relevant strains. Surveillance is conducted continuously 
to monitor which strains are circulating and when an antigenically drifted strain emerges. 
Viral isolates are collected from infected individuals, expanded in cell culture to obtain a 
working stock, sequenced, and then antigenically profiled using serological assays with 
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sera collected from previously naïve ferrets infected with influenza for the first time 
(Krauss et al., 2012; Stöhr et al., 2012). The main serological assay used to determine 
antigenic change is the hemagglutination inhibition (HAI) assay. The HAI assay 
measures the amount of antisera required to inhibit the agglutination of red blood cells 
(RBCs) bound by virus (Hirst, 1942). HA is the sole attachment factor for the majority of 
influenza virus strains, and HA agglutinates RBCs by binding to sialic acid. HAI assays 
are therefore intended to quantify relative amounts of HA-specific antibodies. However, 
recent studies demonstrated that some H3N2 and H1N1 strains agglutinate RBCs through 
NA-sialic acid interactions (Hooper and Bloom, 2013; Lin et al., 2010; Zhu et al., 2012). 
 With drastically decreased receptor binding avidity, recent H3N2 viruses have 
difficulty growing in cell culture or eggs and have been shown to acquire mutations in 
HA and NA (Chen et al., 2010b; Nakowitsch et al., 2014; Nakowitsch et al., 2011; 
Skowronski et al., 2014; Wang et al., 2013). The extent of these mutations and their 
effect on antigenic analyses has not yet been investigated in depth. In this study, we 
completed a series of experiments to determine whether HA and/or NA mutations 
commonly arise when contemporary clinical H3N2 isolates are expanded in cell culture 
and the impact they have on antigenic testing. As expected, we observed the emergence 
of multiple mutations in both HA and NA after a single passage in cell culture. NA 
mutations resulted in NA-dependent agglutination and an HA mutation resulted in 
increased receptor binding avidity, both leading to the alteration of antigenic analyses. 
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RESULTS 
Expanded clinical H3N2 isolates bind cells in an NA-dependent manner 
 During the 2012-2013 influenza season, respiratory secretions were collected at 
the Children’s Hospital of Philadelphia from 10 children (ages 1 month to 7 years old) 
infected with H3N2 influenza virus. Remaining de-identified clinical samples were 
passaged two times on Madin-Darby canine kidney (MDCK) cells, which are routinely 
used by surveillance labs for isolating human viruses (Krauss et al., 2012). After each 
passage, supernatants were collected and analyzed. Infectious titer was quantified by a 
50% tissue culture infective dose (TCID50) assay and agglutination was measured using 
both turkey and guinea pig RBCs. 
 Following two passages, 9 of 10 MDCK cultures contained infectious virus 
(Table 1). However, only 5 of these isolates were able to agglutinate turkey RBCs. 
Recent studies have shown that some influenza strains bind more effectively to guinea 
pig RBCs than to turkey RBCs (Barr et al., 2010; Klimov et al., 2012; Nicholls et al., 
2008). When guinea pig RBCs were used for agglutination analysis, all 9 of the infectious 
virus isolates presented agglutination correlated with their measured infectious titers. To 
determine whether agglutination of each viral isolate was mediated by HA or NA, we 
repeated agglutination analyses in the presence of 10 µM oseltamivir, a compound that 
binds in the sialic acid binding site of NA (Collins et al., 2008). Adding in oseltamivir 
reduced the agglutination of four isolates (Table 1). Surprisingly, only one isolate (Isolate 
6) was able to agglutinate turkey RBCs through an NA-independent mechanism. Taken 
together, these results indicate that 9 of the 10 isolates were able to grow in cell culture, 
and that 4 of the expanded isolates bind to cells in an NA-dependent mechanism. 
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Mutations emerge in HA and NA during passage in cell culture 
 We grouped all the viral isolates into four categories: viruses that agglutinate via 
an NA-dependent mechanism (n = 4), a virus that agglutinates via an NA-independent 
mechanism (n = 1), viruses that agglutinate poorly (n = 4), and a virus that was not 
detected after expansion (n = 1) (Tables 1 and 2).  We sequenced the HA1 and NA genes 
from the primary clinical material and the MDCK-expanded virus of each isolate to 
identify mutations that may explain the increase in agglutination and the NA-dependent 
binding. We compared the HA1 and NA sequences to the A/Victoria/361/2011 
(A/Victoria/361/11) H3N2 vaccine strain (EpiFlu accession numbers EPI349103 and 
EPI349104). The primary isolates all contained multiple HA and NA sequence 
differences compared to the A/Victoria/361/11 vaccine reference strain (Table 2). All 
four of the viral isolates with NA-dependent agglutination acquired additional mutations 
at NA residue 151 during expansion, but did not acquire any HA mutations. Previous 
work in the field has already demonstrated that the two NA mutations we observe here, 
D151G and D151N, enable NA-dependent viral attachment (Lin et al., 2010; Zhu et al., 
2012). Also consistent with previous sequencing studies, we did not detect these NA 
mutations present at any level in the primary isolate (Lee et al., 2013). 
 The isolate that agglutinates through an NA-independent manner (Isolate 6) did 
not acquire any mutations in NA but did acquire a single HA mutation at residue 237 
during expansion (Table 2).  This isolate also contained one unique mutation, HA F209S, 
which was present in both the primary sample and the expanded isolate. We did not 
detect any new HA or NA mutations in the five MDCK-expanded viral isolates that grew 
to low titers and agglutinated RBCs poorly. 
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Characterizing the P237L HA mutation  
 Only the isolate with NA-independent agglutination (Isolate 6) contained 
mutations at HA residues 209 and 237. To determine if either of these HA mutations 
(F209S or P237L) was responsible for the increased growth and agglutination of Isolate 
6, we completed reverse-genetics studies by inserting F209S and P237L into both the 
A/Victoria/361/11 H3N2 vaccine strain and Isolate 2. We chose Isolate 2 for reverse-
genetics experiments because it agglutinates poorly after expansion and did not acquire 
any mutations (Tables 1 and 2). We rescued virus containing the mutated HA genes, the 
NA of either A/Victoria/361/11 or Isolate 2, and the PR8 internal genes by transfecting 
293T/MDCK co-cultures. Viruses containing the P237L mutation, but not the F209S 
mutation, grew to high titers and agglutinated RBCs in the presence of oseltamivir, 
demonstrating NA-independent binding (Table 3). HA residue 237 is located at the HA 
trimer interface (Fig. 3A), and thus may contribute to increased growth and agglutination 
by increasing HA stability. We determined the relative receptor binding avidities of 
viruses possessing P237 or L237 by measuring agglutination using RBCs pre-treated with 
receptor-destroying enzyme (RDE) that removes sialic acid receptors (Hensley et al., 
2009; Yewdell et al., 1986). The A/Victoria/361/11 virus with the P237L mutation 
efficiently agglutinated RBCs treated with larger amounts of receptor-destroying enzyme 
(RDE, a neuraminidase), indicating that viruses with L237 possess higher receptor 
binding avidities (Fig. 3B).  
Previous work has demonstrated that viruses with higher avidity are difficult to 
inhibit in HAI assays and may result in artificially lower HAI titers even if antigenicity 
has not changed. To test whether the P237L mutation impacts antigenic analyses, we 
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conducted an HAI assay using ferret antisera generated against the A/Victoria/361/11 
vaccine strain. Addition of the P237L mutation resulted in a twofold decrease in HAI 
titers compared to the WT virus (Fig. 3C), consistent with the idea that increased receptor 
binding avidity can alter the interpretation of antigenic analyses. 
Although standard Sanger sequencing could not detect the P237L HA mutation in 
the original clinical material of Isolate 6 (Table 2), low levels of the mutation were 
detected in the original clinical isolate by sequencing individual clones following TA 
cloning of PCR products (Fig. 3D). Out of the 21 total clones sequenced, ~5% contained 
L237. This indicates that the P237L mutation at the HA trimer interface was present in a 
small subset of the original clinical isolate and was able to grow out during expansion, 
presumably due to increased HA stability and receptor binding avidity. 
 
DISCUSSION 
 Taken together, our data indicate that recent clinical H3N2 strains replicate poorly 
in MDCK cells and rapidly acquire either HA or NA mutations when propagated in vitro 
prior to antigenic testing. These mutations increase viral growth and agglutination titers 
and can potentially skew HAI assays. The goal of HAI assays is to detect HA antigenic 
changes, and therefore it is difficult to interpret data when agglutination is mediated by 
mutated NAs. The addition of oseltamivir directly into HAI assays may circumvent this 
problem (Lin et al., 2010). We have previously shown that HA mutations that alter 
receptor binding avidity can skew antigenic maps based on HAI assays (Li et al., 2013a), 
and recent computational methods have been developed to create antigenic maps that 
account for variations in viral avidity (Bedford et al., 2014; Li et al., 2013a). Future 
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studies should focus on alternative cell-derived systems for propagating primary 
influenza isolates, such as MDCK cells engineered to express different types of sialic 
acid receptors (Krauss et al., 2012; Oh et al., 2008). Additional studies should also 
address if cell culture-derived mutations in vaccine strains impact immunogenicity, 
because recent studies suggest that egg-derived mutations in vaccine strains can have this 
effect (Skowronski et al., 2014). 
 In this study, we have displayed the relative ease that recent H3N2 clinical 
isolates mutate with when propagated in MDCK cell culture. Mutations arising in either 
HA or NA can alter antigenic properties of these viruses and mask the true identity of the 
originally collected isolate. Better strategies for expanding these poorly growing 
influenza isolates and for analyzing their antigenic properties are required in order to 
ensure accurate viral surveillance and proper selection of vaccine strains. 
 
MATERIALS AND METHODS 
Isolate Collection and Expansion 
Respiratory secretions were collected from the nasopharnyx of 10 sick children 
(ages 1 month to 7 years old) at the Children’s Hospital of Philadelphia for routine 
diagnostic purposes during the 2012-2013 influenza season. All samples were tested and 
confirmed to be infected with H3N2 influenza virus. Leftover, de-identified samples were 
then sent to us for expansion in MDCK cells, a common cell line used for influenza 
propagation (Krauss et al., 2012). Isolates were passaged twice on MDCK cells using 
serum-free Minimum Essential Medium (MEM) containing 0.1% L-(tosylamido-2-
phenyl) ethyl chloromethyl ketone (TPCK)-treated trypsin, 0.1% gentamicin, and 0.5% 1 
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M HEPES buffer. Cell expansions were incubated at 37°C with 5% CO2 for four days. 
Supernatant was collected and cell debris was removed via centrifugation at 2500 rpm for 
3 min.  
 
Hemagglutination Assays 
MDCK-expanded isolates were serially diluted twofold in a 96-well round-bottom 
plate. Then, 12.5 µL of a 2% (vol/vol) turkey RBC solution or a 2.5% (vol/vol) guinea 
pig RBC solution were added. Agglutination was read out after incubating for 1 h at room 
temperature. For hemagglutination assays looking to determine NA-dependent receptor 
binding, oseltamivir was added to each well at a final concentration of 10 µM. 
 
TCID50 Assays 
We plated MDCK cells in a 96-well flat-bottom plate at 40000 cells/well in MEM 
with 9% fetal bovine serum. Next day, cells were washed twice with serum-free MEM 
before adding 180 µL serum-free MEM containing 0.1% TPCK-treated trypsin, 0.1% 
gentamicin, and 0.5% 1 M HEPES buffer. MDCK-expanded isolates were then serially 
diluted tenfold across the plate. Isolates were run in quadruplicate and pipet tips were 
changed for each row. Plates were incubated for 4 d at 37°C with 5% CO2. All wells were 
checked for cytopathic effect and TCID50/mL values were calculated. 
 
Sequencing of Isolates 
We obtained the HA1 and NA reference sequences of the A/Victoria/361/2011 
H3N2 vaccine strain from the EpiFlu database (accession numbers EPI349103 and 
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EPI349104, respectively). We extracted RNA from the original clinical samples and the 
MDCK-expanded supernatant using the Qiagen QIAamp Viral RNA Mini Kit. One-Step 
RT-PCR (Qiagen) using H3N2 HA and NA specific primers was then used to amplify the 
influenza HA1 and NA genes of interest. After gel purification of PCR products, Sanger 
sequencing was used to sequence all samples. For Isolate 6, enhanced sequencing of the 
original clinical sample was performed using TA cloning (TOPO TA Cloning Kit; Life 
Technologies) of the PCR products. The P237L HA mutation was mapped on the 
crystallized H3 trimer structure (PDB entry 1HGG).  
 
Reverse-Genetics Derived Viruses 
We extracted RNA from the A/Victoria/361/2011 vaccine strain and from Isolate 
2, and then cloned the HA and NA of each virus into the pHW2000 reverse genetics 
plasmid. We inserted the F209S and P237L HA mutations using the QuikChange site-
directed mutagenesis kit (Stratagene). We rescued viruses containing the different HA 
genes, the NA of A/Victoria/361/2011 or Isolate 2, and the internal genes of PR8 by 
transfecting 293T/MDCK co-cultures as previously described (Hoffmann et al., 2000). 
All rescued viruses were then passaged two times in MDCK cells and sequence-
confirmed for stability. Supernatant collected after the second passage was used for 
receptor binding avidity and HAI assays. 
 
Receptor Binding Avidity Assays 
 As previously described (Hensley et al., 2009; Yewdell et al., 1986), guinea pig 
RBCs were pre-treated with different amounts of RDE for 1 h at 37°C. The RBCs were 
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then washed twice with PBS and added as 2% (vol/vol) solutions to four agglutinating 
doses of each virus (as determined using non-treated guinea pig RBCs). Extent of 
agglutination was measured after 1 h incubation at room temperature. The viruses with 
higher receptor binding avidities are able to bind to RBCs that are treated with higher 
amounts of RDE (Hensley et al., 2009; Yewdell et al., 1986). 
 
Hemagglutination Inhibition Assays with Ferret Antisera 
Ferret antiserum to A/Victoria/361/2011 (H3N2), FR-1079, was obtained through the 
Influenza Reagent Resource, Influenza Division, WHO Collaborating Center for 
Surveillance, Epidemiology and Control of Influenza, Centers for Disease Control and 
Prevention, Atlanta, GA, USA. Antiserum was serially diluted twofold in PBS in a 96-
well round-bottom plate. Four agglutinating doses of virus were then added to the diluted 
antiserum in a total volume of 100 µL. Next, 12.5 µL of a 2.5% (vol/vol) guinea pig RBC 
solution were added. Agglutination was read out after incubating for 1 h at room 
temperature. HAI titers are reported as the inverse of the highest dilution that inhibited 
hemagglutination of guinea pig RBCs. 
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FIGURES AND TABLES 
Figure 3 
 
 
Figure 3. Characterization of the P237L HA mutation. 
(A) The location of HA residue 237 is highlighted in orange on the H3 trimer structure 
and sialic acid is colored in white (PDB entry 1HGG). (B) The relative receptor binding 
avidities of the A/Victoria/361/11 WT and P237L reverse-genetics derived viruses were 
determined by agglutination of guinea pig RBCs pretreated with different amounts of the 
neuraminidase RDE. Data are expressed as the maximum concentration (µg/mL) of 
neuraminidase that still allowed full agglutination. Means and standard errors of the 
means of the results for triplicate samples are shown. Data are representative of two 
recent computational methods have been developed to create
antigenic maps that account for variations in viral avidity (20,
21). Future studies should focus on alternative cell-derived sys-
tems for propagating primary influenza isolates, such as
MDCK cells engineered to express different types of sialic acid
receptors (12, 22). Additional studies should also address if cell
culture-derived mutations in vaccine strains impact immuno-
genicity, since recent studies suggest that egg-derived muta-
tions in vaccine strains can have this effect (23).
Nucleotide sequence accession numbers. The nucleotide se-
quences determined in this study have been deposited inGenBank
under accession numbers KJ734801 to KJ734838.
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FIG 1 Characterization of the P237L HA mutation. (A) Residue 237 is high-
lighted in orange on theH3 structure and sialic acid is coloredwhite (ProteinData
Bank entry 1HGG). (B) Relative receptor binding avidities of reverse-genetics-
derived viruses were determined by agglutination of guinea pig RBCs pretreated
with increasing amounts of neuraminidase. Data are expressed as maximal
amounts of neuraminidase that allowed full agglutination. Means and standard
errors of themeans of the results for triplicate samples are shown.WT and P237L
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two ndependent experiments. (C) HAI assays were completed using anti-A/Vic-
toria/361/11 sera generated in ferrets. (D) P237 and L237 HA frequencies were
determined after TA cl ing the PCR product amplified from original clinical
material. We sequenced 21 plasmids following TA cloning.
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independent experiments. Viruses were compared using one-tailed, unpaired t tests. (C) 
HAI assays comparing the WT and P237L reverse-genetics derived viruses were 
performed using ferret antisera raised against the A/Victoria/361/11 H3N2 vaccine strain. 
Experiment was conducted three independent times and all raw HAI titers are displayed. 
(D) The frequencies of P237 (black) and L237 (orange) were determined after TA 
cloning of the PCR product amplified from the original clinical material of Isolate 6. A 
total of 21 clones were sequenced following TA cloning.  
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Table 1 
 
 
Table 1. Infectious and HAU titers of expanded clinical isolates. 
Clinical isolates collected from H3N2-infected children at the Children’s Hospital of 
Philadelphia were passaged twice on MDCK cells. Supernatant was collected and tested 
for infectious titer (TCID50/mL) and hemagglutination units (HAU). HAU titers are 
reported as the maximum dilution of expanded viral isolates that still results in full 
agglutination of 12.5 µL of 2% (vol/vol) turkey RBCs or 2.5% (vol/vol) guinea pig 
RBCs. Agglutination was also determined in the presence of 10 µM oseltamivir (Oselt.) 
to detect NA-dependent binding.  Each isolate was placed into one of four categories 
based on its ability to grow, to agglutinate RBCs, and whether agglutination was NA-
dependent or NA-independent. 
 
 
NA-dependent viral attachment (9, 10). These NA mutations
were not detected in the original clinical isolates, which is con-
sist nt with revious sequencing studies (17). The isolate tha
agglutinated RBCs via an NA-independent mechanism (isolate
6) did not acquire an NAmutation followingMDCK expansion
but did acquire a single HA mutation at residue 237. This iso-
late also uniquely possessed an F209S HA mutation, which was
present before and after MDCK expansion. We did not detect
HA or NA mutations in the five MDCK-expanded viral isolates
that grew to low titers and agglutinated RBCs poorly.
We com let d ad tion l revers -genetics studies to determine
if the P237L or F209S HA mutation promoted enhanced growth
and agglutination of isolate 6. We used a QuikChange kit
(Stratagene, La Jolla, CA) to introduce each of these mutations
into the HAs of the A/Victoria/361/11 H3N2 vaccine strain and
isolate 2. We chose isolate 2 for reverse-genetics experiments,
since this isolate agglutinates poorly (Table 1). We rescued
virus using A/Puerto Rico/8/1934 (PR8) internal genes and the
NA of either A/Victoria/361/11 or isolate 2 after transfecting
293T/MDCK cocultures as previously described (18). Viruses
engineered to have the P237L mutation, but not the F209S
mutation, grew to high titers and agglutinated RBCs in the
presence of oseltamivir (Table 3). P237 is located in the HA
trimer interface (Fig. 1A), and it is possible that this mutation
affects sialic acid binding by stabilizing the HA trimer. We
determined the relative receptor avidities of viruses possessing
either P237 or L237 by completing agglutination assays with
RBCs previously treated with neuraminidase (receptor-de-
stroying enzyme, cholera filtrate; Sigma, St. Louis, MO), which
removes sialic acid receptors (3, 19). A/Victoria/361/11 viruses
with the P237L HA mutation efficiently agglutinated RBCs
treated with larger amounts of receptor-destroying enzyme
(Fig. 1B), indicating that these viruses have higher receptor
binding avidities. We completed HAI assays using antisera gen-
erated against A/Victoria/361/2011 (Influenza Reagent Re-
source, Atlanta, GA) and found that viruses with the P237L HA
mutation had reduced HAI titers (Fig. 1C), which is consistent
with previous studies demonstrating that viruses with higher
avidity are difficult to inhibit in HAI assays (3, 19, 20). Using
Sanger sequencing, we did not detect the P237L HA mutation
in the original clinical material of isolate 6 (Table 2); however,
we were able to detect low levels of this mutation in the original
clinical isolate after sequencing individual clones following TA
cloning (TOPO TA Cloning kit; Life Technologies, Carlsbad,
CA) of PCR products (Fig. 1D).
Taken together, our data indicate that recent clinical H3N2
strains replicate poorly in MDCK cells and rapidly acquire ei-
ther HA or NA mutations when propagated in vitro prior to
antigenic testing. These mutations increase virus growth and
agglutination titers and can potentially skew HAI assays. The
goal of HAI assays is to detect HA antigenic changes, and there-
fore it is difficult to interpret data when agglutination is medi-
ated by mutated NAs. The addition of oseltamivir directly into
HAI assays may circumvent this problem (9). We have previ-
ously shown that HA mutations that alter receptor binding
avidity can skew antigenic maps based on HAI assays (20), and
TABLE 1 Infectious and HAU titers of expanded clinical isolatesa
Isolate
no. TCID50/ml
Turkey HAU
Guinea pig
HAU
Category!Oselt "Oselt !Oselt "Oselt
1 1.35E" 07 19 #2 48 16 NA dependent
2 4.07E" 06 #2 #2 4 4 Low
3 1.35E" 06 #2 #2 4 3 Low
4 4.07E" 06 #2 #2 6 6 Low
5 #1.00E" 02 #2 #2 #2 #2 Not detected
6 5.56E" 07 36 30 128 128 NA independent
7 6.88E" 07 3 #2 16 8 NA dependent
8 1.89E" 07 22 #2 64 12 NA dependent
9 4.07E" 06 2 #2 8 4 NA dependent
10 1.48E" 06 #2 #2 4 4 Low
a Shown are infectious (TCID50/ml) and agglutination (HAU) titers after clinical
isolates were passaged twice on MDCK cells. Oselt, oseltamivir.
TABLE 2 Differences in sequences of clinical isolates before and after MDCK expansiona
Isolate
no. Category
Differences in NA sequence from
that of the H3N2 vaccine strainb
NA mutations upon
MDCK expansion
Differences in HA sequence from that of the
H3N2 vaccine strainb
HA mutation upon
MDCK expansion
1 NA dependent V143 M, K258E, T329N D151G Q49R, N161S, N294K
7 NA dependent N141S, K258E, T329N D151N Q49R, T144A, R158G, N161S, Q189H, N294K
8 NA dependent K258E, T329N D151G Q49R, T144A, R158G, N161S, N294K
9 NA dependent K258E, T329N D151G R158G, N161S, N294K
6 NA independent K258E, T329N Q49R, T144A, R158G, N161S, F209S, N294K P237L
2 Low K258E, T329N T144A, R158G, N160S, N161S, N294K
3 Low K128R, V143M, K258E, T329N Q49R, N161S, N294K
4 Low P79S, G93D, E221D, K258E, T329N Q49R, N161S, N294K
10 Low K258E, T329N Q49R, N161S, N294K
a Mutations that arose upon MDCK expansion are in bold.
b Sequences were compared to that of the A/Victoria/361/11 2012-2013 vaccine strain (linear numbering).
TABLE 3 Infectious and HAU titers of reverse-genetics virusesa
Virus TCID50/ml
Turkey HAU Guinea pig HAU
!Oselt "Oselt !Oselt "Oselt
A/Victoria/361/11
WT HA
1.20E" 06 2 2 16 16
A/Victoria/361/11
F209S HA
2.58E" 04 #2 #2 #2 #2
A/Victoria/361/11
P237L HA
1.76E" 07 192 192 256 256
Isolate 2 WT HA 1.20E" 05 #2 #2 3 3
Isolate 2 F209S HA 1.76E" 02 #2 #2 #2 #2
Isolate 2 P237L HA 2.58E" 06 48 48 64 64
a Shown are infectious (TCID50/ml) and agglutination (HAU) titers. Oselt, oseltamivir.
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Table 2. Differences in sequences of clinical isolates before and after MDCK 
expansion. 
We sequenced the HA1 and NA genes of each original clinical isolate and twice MDCK-
expanded isolate and compared the sequences to the A/Victoria/361/11 H3N2 vaccine 
strain (EpiFlu accession numbers EPI349103 and EPI349104). Multiple differences in 
both HA and NA compared to the H3N2 vaccine strain were detected for all original 
clinical isolates. Upon expansion, mutations arose at NA residue 151 and HA residue 237 
(shown in bold). Isolates are grouped top to bottom depending on their agglutination 
“Category” (classifications described in Table 1). 
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Table 3 
 
 
Table 3. Infectious and HAU titers of reverse-genetics viruses. 
We used reverse genetics to rescue viruses with the WT, F209S, or P237L mutations in 
either the A/Victoria/361/11 or Isolate 2 HA. Rescued viruses were passaged twice on 
MDCK cells and sequence confirmed to verify no new mutations had arisen. The 
infectious titer (TCID50/mL) and hemagglutination unit (HAU) titers were determined 
and reported as in Table 1 above. Viruses possessing the P237L HA mutation are shown 
to grow to higher infectious titers and exhibit increased agglutination. 
 
 
 
 
 
 
NA-dependent viral attachment (9, 10). These NA mutations
were not detected in the original clinical isolates, which is con-
sistent with previous sequencing studies (17). The isolate that
agglutinated RBCs via an NA-independent mechanism (isolate
6) did not acquire an NAmutation followingMDCK expansion
but did acquire a single HA mutation at residue 237. This iso-
late also uniquely possessed an F209S HA mutation, which was
present before and after MDCK expansion. We did not detect
HA or NA mutations in the five MDCK-expanded viral isolates
that grew to low titers and agglutinated RBCs poorly.
We completed additional reverse-genetics studies to determine
if the P237L or F209S HA mutation promoted enhanced growth
and agglutination of isolate 6. We used a QuikChange kit
(Stratagene, La Jolla, CA) to introduce each of these mutations
into the HAs of the A/Victoria/361/11 H3N2 vaccine strain and
isolate 2. We chose isolate 2 for reverse-genetics experiments,
since this isolate agglutinates poorly (Table 1). We rescued
virus using A/Puerto Rico/8/1934 (PR8) internal genes and the
NA of either A/Victoria/361/11 or isolate 2 after transfecting
293T/MDCK cocultures as previously described (18). Viruses
engineered to have the P237L mutation, but not the F209S
mutation, grew to high titers and agglutinated RBCs in the
presence of oseltamivir (Table 3). P237 is located in the HA
trimer interface (Fig. 1A), and it is possible that this mutation
affects sialic acid binding by stabilizing the HA trimer. We
determined the relative receptor avidities of viruses possessing
either P237 or L237 by completing agglutination assays with
RBCs previously treated with neuraminidase (receptor-de-
stroying enzyme, cholera filtrate; Sigma, St. Louis, MO), which
removes s alic acid receptors (3, 19). A/V ctoria/361/11 viruses
with the P237L HA mutation efficiently agglutinated RBCs
treated with larger amounts of receptor-destroying enzyme
(Fig. 1B), indicating that these viruses have higher rec ptor
binding avidities. We completed HAI assays using antisera gen-
erated against A/Victoria/361/2011 (Influenza Reagent Re-
source, Atlanta, GA) and found that viruses with the P237L HA
mutation had reduced HAI titers (Fig. 1C), which is consistent
with previous studies demonstrating that viruses with higher
avidity are difficult to inhibit in HAI assays (3, 19, 20). Using
Sanger sequencing, we did not detect the P237L HA mutation
in the original clinical material of isolate 6 (Table 2); however,
we were able to detect low levels of this mutation in the original
clinical isolate after sequencing individual clones following TA
cloning (TOPO TA Cloning kit; Life Technologies, Carlsbad,
CA) of PCR products (Fig. 1D).
Taken together, our data indicate that recent clinical H3N2
strains replicate poorly in MDCK cells and rapidly acquire ei-
ther HA or NA mutations when propagated in vitro prior to
antigenic testing. These mutations increase virus growth and
agglutination titers and can potentially skew HAI assays. The
goal of HAI assays is to detect HA antigenic changes, and there-
fore it is difficult to interpret data when agglutination is medi-
ated by mutated NAs. The addition of oseltamivir directly into
HAI assays may circumvent this problem (9). We have previ-
ously shown that HA mutations that alter receptor binding
avidity can skew antigenic maps based on HAI assays (20), and
TABLE 1 Infectious and HAU titers of expanded clinical isolatesa
Isolate
no. TCID50/ml
Turkey HAU
Guinea pig
HAU
Category!Oselt "Oselt !Oselt "Oselt
1 1.35E" 07 19 #2 48 16 NA dependent
2 4.07E" 06 #2 #2 4 4 Low
3 1.35E" 06 #2 #2 4 3 Low
4 4.07E" 06 #2 #2 6 6 Low
5 #1.00E" 02 #2 #2 #2 #2 Not detected
6 5.56E" 07 36 30 128 128 NA independent
7 6.88E" 07 3 #2 16 8 NA dependent
8 1.89E" 07 22 #2 64 12 NA dependent
9 4.07E" 06 2 #2 8 4 NA dependent
10 1.48E" 06 #2 #2 4 4 Low
a Shown are infectious (TCID50/ml) and agglutination (HAU) titers after clinical
isolates were passaged twice on MDCK cells. Oselt, oseltamivir.
TABLE 2 Differences in sequences of clinical isolates before and after MDCK expansiona
Isolate
no. Category
Differences in NA sequence from
that of the H3N2 vaccine strainb
NA mutations upon
MDCK expansion
Differences in HA sequence from that of the
H3N2 vaccine strainb
HA mutation upon
MDCK expansion
1 NA dependent V143 M, K258E, T329N D151G Q49R, N161S, N294K
7 NA dependent N141S, K258E, T329N D151N Q49R, T144A, R158G, N161S, Q189H, N294K
8 NA dependent K258E, T329N D151G Q49R, T144A, R158G, N161S, N294K
9 NA dependent K258E, T329N D151G R158G, N161S, N294K
6 NA independent K258E, T329N Q49R, T144A, R158G, N161S, F209S, N294K P237L
2 Low K258E, T329N T144A, R158G, N160S, N161S, N294K
3 Low K128R, V143M, K258E, T329N Q49R, N161S, N294K
4 Low P79S, G93D, E221D, K258E, T329N Q49R, N161S, N294K
10 Low K258E, T329N Q49R, N161S, N294K
a Mutations that arose upon MDCK expansion are in bold.
b Sequences were compared to that of the A/Victoria/361/11 2012-2013 vaccine strain (linear numbering).
TABLE 3 Infectious and HAU titers of reverse-genetics virusesa
Virus TCID50/ml
Turkey HAU Guinea pig HAU
!Oselt "Oselt !Oselt "Oselt
A/Victoria/361/11
WT HA
1.20E" 06 2 2 16 16
A/Victoria/361/11
F209S HA
2.58E" 04 #2 #2 #2 #2
A/Victoria/361/11
P237L HA
1.76E" 07 192 192 256 256
Isolate 2 WT HA 1.20E" 05 #2 #2 3 3
Isolate 2 F209S HA 1.76E" 02 #2 #2 #2 #2
Isolate 2 P237L HA 2.58E" 06 48 48 64 64
a Shown are infectious (TCID50/ml) and agglutination (HAU) titers. Oselt, oseltamivir.
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CHAPTER 3 – IDENTIFICATION OF THE MUTATIONS 
RESPONSIBLE FOR THE ANTIGENIC DRIFT OF H3N2 
INFLUENZA VIRUSES DURING THE 2014-2015 SEASON 
 
 
Parts of this chapter were previously published in: 
 
Chambers BS, Parkhouse K, Ross TM, Alby K, and Hensley SE. (2015) Identification of 
hemagglutinin residues responsible for H3N2 antigenic drift during the 2014-2015 
influenza season. Cell Reports 12:1-6. 
 
 
SUMMARY 
 Influenza vaccines must be updated regularly because influenza viruses 
continuously acquire mutations in the antibody binding sites of hemagglutinin (HA). The 
majority of H3N2 strains circulating in the Northern Hemisphere during the 2014-2015 
season were antigenically mismatched to the A/Texas/50/2012 H3N2 vaccine strain. 
H3N2 strains that circulated during that season possessed several new HA mutations that 
arose after selection of the vaccine strain, and it was unknown which of these mutations 
contributed to the 2014-2015 vaccine mismatch. Here, we used reverse genetics to 
demonstrate that mutations in HA antigenic site B were primarily responsible for the 
vaccine mismatch. Antisera isolated from vaccinated humans and infected animals had 
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reduced hemagglutination inhibition and in vitro neutralization titers against reverse-
genetics-derived viruses possessing mutations in HA antigenic site B. These data provide 
an antigenic explanation for the low influenza vaccine efficacy observed during the 2014-
2015 influenza season. Furthermore, our data supported the World Health Organization’s 
decision to update the H3N2 component of the vaccine for the 2015-2016 influenza 
season. 
 
INTRODUCTION 
Most neutralizing influenza antibodies (Abs) target the hemagglutinin (HA) 
glycoprotein, and therefore, influenza vaccines are designed to elicit anti-HA Abs. 
However, these vaccines are ineffective when viruses acquire mutations in the Ab 
binding sites of HA (Yewdell, 2011). Mid-season influenza vaccine efficiency rates 
during the 2014–2015 Northern Hemisphere season were extremely low (Flannery et al., 
2015; Pebody et al., 2015), and the H3N2 strains that circulated during that season were 
antigenically distinct compared to the 2014-2015 A/Texas/50/2012 H3N2 vaccine strain 
(D'Mello et al., 2015b). The 2014-2015 H3N2 strains were grouped into three genetically 
distinct clades (Broberg et al., 2015). Viruses within each genetic clade possessed several 
shared and unique HA mutations, and it was unclear, at the time, which of these 
mutations were antigenically relevant. 
H3 HAs have at least five distinct antigenic sites, named HA antigenic sites A-E 
(Wiley et al., 1981). Seasonal influenza vaccine strains are routinely chosen based on 
antigenic analyses that utilize antisera prepared in previously naïve ferrets (Stöhr et al., 
2012). Koel and colleagues recently demonstrated that most Ab responses from 
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previously naïve ferrets infected a single time with an H3N2 virus are heavily focused on 
H3 antigenic sites A and B (Koel et al., 2013). Our studies and others have demonstrated 
that prior H1N1 influenza exposures can influence the specificity of Ab responses raised 
against new H1N1 influenza strains (Hensley, 2014; Li et al., 2013b; Linderman et al., 
2014). We found that ferret antisera do not always recapitulate the different types of 
H1N1 Ab specificities that are found in individual humans with vastly different pre-
exposure histories. Human Ab responses appear to be focused on HA antigenic site A of 
some H3 strains (Abe et al., 2004) and on HA antigenic site B of other H3 strains 
(Popova et al., 2012). 
It is important to determine which HA residues were responsible for the observed 
antigenic drift of 2014-2015 H3N2 strains. This information can be useful for guiding the 
selection of viral strains for future vaccine formulations. Here, we completed serological 
assays using A/Texas/50/2012 H3N2 viruses engineered to have specific HA mutations 
that were present in H3N2 strains that circulated during the 2014-2015 influenza season. 
We found that mutations in H3 antigenic site B significantly decrease the binding of 
ferret, sheep, and human Abs elicited by the A/Texas/50/2012 H3N2 vaccine strain. The 
World Health Organization (WHO) recommended that the H3 component of seasonal 
influenza vaccines should be updated to include A/Switzerland/9715293/2013-like strains 
(Anonymous, 2015). Our data supported this recommendation, although we note that the 
majority of H3N2 strains circulating at the time had a distinct HA antigenic site B 
compared to the A/Switzerland/9715293/2013 strain. 
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RESULTS 
 2014-2015 H3N2 viruses possessed several HA mutations 
 The H3N2 component of the 2014-2015 influenza vaccine was A/Texas/50/2012, 
which belongs to HA genetic clade 3C.1 (Broberg et al., 2015). During the 2014-2015 
season, H3N2 strains belonging to phylogenetic HA clades 3C.2a, 3C.3, and 3C.3a 
predominated (Broberg et al., 2015). Compared to the A/Texas/50/2012 vaccine strain, 
clade 3C.2a viruses possessed HA differences L3I, N144S, N145S, F159Y, K160T, 
N225D, and Q311H; clade 3C.3 viruses possessed HA differences T128A, R142G, and 
N145S; and clade 3C.3a viruses possessed HA differences T128A, A138S, R142G, 
N145S, F159S, and N225D (Table 4). HA clade 3C.2a and 3C.3a viruses were 
antigenically distinct compared to the A/Texas/50/2012 strain and the WHO 
recommended that the H3N2 component should be updated with an 
A/Switzerland/9715293/2013-like (HA clade 3C.3a) virus for the Northern Hemisphere 
2015-2016 vaccine (Anonymous, 2015). Analyses of HA sequences deposited in the 
Global Initiative on Sharing All Influenza Data (GISAID) database revealed that the 
majority of H3N2 viruses circulating in the United States in the fall and winter of 2014 
belonged to HA clade 3C.2a (Fig. 4A). We performed a similar analysis for Philadelphia-
area H3N2 viruses using clinical isolates collected from the Hospital of the University of 
Pennsylvania. Primary isolates were directly sequenced and revealed a similar 
distribution of circulating genetic clades during the 2014-2015 influenza season as 
compared to the GISAID database sequences (Fig. 4B).  
 To understand the antigenic basis for the extremely poor H3N2 vaccine match 
during the 2014–2015 influenza season, we created a panel of A/Texas/50/2012 viruses 
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that possessed the HA mutations found in HA clade 3C.2a, 3C.3, and 3C.3a viruses 
(Table 5). We then completed antigenic analyses using antisera isolated from ferrets, 
sheep, and humans exposed to the A/Texas/50/2012 H3N2 vaccine strain (Tables 6 and 
7). Our mutant viral panel included every mutation from Table 4 that is located in the HA 
globular head (Fig. 4C), with the exception of the F159Y and K160T mutations. We were 
able to successfully rescue A/Texas/50/2012 viruses that possessed the F159Y and 
K160T mutations, but these viruses failed to agglutinate red blood cells (RBCs) and 
quickly mutated at HA residue 160 when propagated for antigenic analyses. However, we 
were still able to assess the antigenic relevance of mutations in this epitope of HA 
because our mutant panel included a virus with the F159S HA mutation. 
 
Ferrets and sheep infected with A/Texas/50/2012 mount Abs against HA antigenic site B 
 We first completed hemagglutination-inhibition (HAI) assays with our mutant 
A/Texas/50/2012 virus panel and antisera collected from ferrets and sheep recovering 
from primary A/Texas/50/2012 infections (Table 6). As expected, anti-A/Texas/50/2012 
Ab titers were drastically decreased using the antigenically distinct 
A/Switzerland/9715293/2013 clade 3C.3a virus. Strikingly, anti-A/Texas/50/2012 Ab 
titers were reduced fourfold in HAI assays against viruses engineered to possess the 
F159S HA mutation (Table 6). HA residue 159 is located in a highly exposed region of 
HA antigenic site B in H3 HAs (Fig. 4C). Other HA mutations had more subtle effects on 
anti-A/Texas/50/2012 HAI titers. For example, the A138S and N145S HA mutations 
each lead to twofold decreases in HAI titers. We have previously shown that viruses that 
bind to RBCs with a high avidity can escape Abs in HAI assays independent of antigenic 
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change (Li et al., 2013a). We found that A138S and N145S HA mutant viruses bound to 
RBCs with a higher avidity (Table 5), and the apparent decrease in HAI titer using these 
viruses likely results from this increase in receptor binding avidity. We found that viruses 
possessing the F159S HA mutation bound to RBCs with a decreased avidity (Table 5), 
and for this reason, we concluded that reduced HAI titers using this virus were the result 
of a genuine antigenic change. 
 To verify the antigenic relevance of the F159S HA mutation, we completed direct 
Ab ELISA binding assays with plates coated with virus-like particles (VLPs) possessing 
A/Texas/50/2012-WT HA or A/Texas/50/2012-F159S HA (Fig. 5). As a control, we 
coated plates with VLPs possessing the antigenically distinct A/Port Chalmers/1/1973 
HA (an H3N2 virus from 1973) as well. Antisera isolated from ferrets infected with 
A/Texas/50/2012 had reduced binding to VLPs possessing A/Texas/50/2012-F159S HA 
compared to VLPs possessing A/Texas/50/2012-WT HA (Fig. 5A). We verified that 
equal amounts of VLPs were used in these assays by completing additional ELISA 
experiments with the F49 monoclonal antibody (mAb) that recognizes the conserved 
stalk region of H3 (Fig. 5B). Collectively, these studies indicate that ferrets and sheep 
mount Ab responses against an HA epitope involving HA residue F159 following 
infection with A/Texas/50/ 2012, and for this reason we focused the rest of antigenic 
analyses on this region of HA. 
 
Ferrets and sheep infected with A/Switzerland/9715293/2013 mount Ab responses that 
are not focused against the HA epitope involving HA residue 159 
 We also completed HAI assays using our mutant viral panel and antisera isolated 
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from sheep infected with A/Switzerland/9715293/2013 H3N2 virus. Antisera isolated 
from A/Switzerland/9715293/2013-infected animals reacted to all mutant 
A/Texas/50/2012 viruses, including viruses that possessed the HA antigenic site B F159S 
mutation (Table 6). Therefore, the F159S HA mutation results in an asymmetrical 
antigenic change. These data are important because A/Switzerland/9715293/2013 (an HA 
clade 3C.3a virus) was chosen as the H3 component of 2015-2016 seasonal vaccines 
(Anonymous, 2015), even though HA clade 3C.2a viruses predominated toward the end 
of the 2014-2015 influenza season (Fig. 4A) and have continued to dominate circulation 
since. And although HA antigenic site B differs between HA clade 3C.3a and 3C.2a 
viruses (Table 4), these initial results indicated that vaccinating with an 
A/Switzerland/9715293/2013-like virus should elicit an Ab response effective against the 
HA clade 3C.2a viruses dominating circulation. 
 
Antisera isolated from most humans vaccinated with A/Texas/50/2012 possess Abs 
against HA antigenic site B 
 Next, we wanted to determine whether human Abs elicited against 
A/Texas/50/2012 have the same specificity for HA antigenic site B as we observed in 
ferret and sheep antisera. We completed HAI assays using the A/Texas/50/2012-WT and 
A/Texas/50/2012-F159S viruses, along with human sera collected pre- and post-
vaccination with the 2014-2015 seasonal influenza vaccine, which contained the 
A/Texas/50/2012 H3N2 vaccine strain. Even before vaccination, over half of the 
individuals presented detectable titers against the A/Texas/50/2012-WT virus (Table 7). 
This is likely because the A/Texas/50/2012 strain had been in seasonal influenza vaccines 
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since the 2013-2014 season and thus many people would have been exposed to this strain 
previously. Following vaccination, most individuals (87.5%) either mounted or 
maintained Abs that had reduced reactivity against the A/Texas/50/2012-F159S mutant 
virus (Table 7). Even in a cohort that covers a fairly large age range (21-50 years old), the 
majority of individuals mounted anti-A/Texas/50/2012 Ab responses focused on HA 
antigenic site B. It is important to point out however, that some individuals (12.5%) in 
this cohort did not possess detectable levels of Abs against HA antigenic site B although 
they mounted high responses against the A/Texas/50/2012-WT virus (Table 7). It is 
possible that these individuals have an Ab response targeted against another HA antigenic 
epitope due to unique pre-exposure histories that shaped their Ab response, similar to 
what we have seen previously in certain age groups that possess altered 
immunodominance of H1N1 Ab responses (Li et al., 2013b; Linderman et al., 2014). 
 
Anti-A/Texas/50/2012 HA antigenic site B Abs are neutralizing 
Although we established that the majority of ferret, sheep, and human Abs against 
A/Texas/50/2012 targeted HA antigenic site B, it wasn’t known whether these Abs were 
neutralizing. To determine the functional consequence of the F159S HA mutation, we 
completed in vitro neutralization assays with A/Texas/50/2012-WT and 
A/Texas/50/2012-F159S viruses using sera samples isolated from humans 21 days post-
vaccination. We focused on samples that had the largest HAI differences using 
A/Texas/50/2012-WT and A/Texas/50/2012-F159S (Table 7). We also completed in vitro 
neutralization assays with antisera collected from ferrets 19 days after infection with 
A/Texas/50/2012. Overall, the in vitro neutralization data mirrored our HAI results, with 
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all seven human sera samples and the ferret sera sample presenting dramatically reduced 
neutralization titers against the A/Texas/50/2012-F159S virus compared to the 
A/Texas/50/2012-WT virus (Table 8). These results indicate that the anti-
A/Texas/50/2012 Abs targeted against HA antigenic site B in humans and ferrets are 
neutralizing, and that a single mutation at HA residue F159 can abrogate neutralization 
by these Abs.  
 
DISCUSSION 
There was a clear H3N2 vaccine mismatch during the 2014-2015 influenza season 
(Broberg et al., 2015; D'Mello et al., 2015a; Flannery et al., 2015; Pebody et al., 2015), 
and it is important to identify the specific HA mutations that led to this mismatch. This 
information could be crucial for properly selecting viral strains to be used in future 
vaccine formulations. In this report, we demonstrated that sheep, ferrets, and humans 
exposed to the 2014-2015 A/Texas/50/2012 H3N2 vaccine strain mount Ab responses 
that are targeted against HA antigenic site B. The majority of H3N2 viruses circulating 
during the 2014-2015 season possessed differences in HA antigenic site B compared to 
the vaccine strain (Fig. 4). 
Our previous studies indicate that the specificity of human H1N1 Ab responses is 
shaped by prior H1N1 exposures (Li et al., 2013b; Linderman et al., 2014). We found that 
most human H1N1 Ab responses are narrowly focused on epitopes that were present in 
viral strains that circulated during each individual’s childhood. It is unclear whether prior 
H3N2 exposures influence the development of Ab responses to drifted H3N2 strains in a 
similar manner. Our data indicate that most 21 to 50 year old humans mount anti-
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A/Texas/50/2012 Abs against HA antigenic site B following vaccination. It is important 
to note that some vaccinated individuals in our study (4 out of 32) mounted anti-
A/Texas/50/2012 Ab responses that were not directed against HA antigenic site B 
(antisera from these four individuals had <twofold change in HAI titer using the 
A/Texas/50/2012-WT and A/Texas/50/2012-F159S viruses). Current studies are under 
way to investigate whether these four individuals have evidence of unique H3N2 
exposures. 
The WHO recommended that the H3N2 component of the 2015-2016 seasonal 
vaccine should be updated to include the A/Switzerland/9715293/2013 strain 
(Anonymous, 2015). We note that this clade 3C.3a virus differs in HA antigenic site B 
compared to clade 3C.2a viruses, which predominated toward the end of the 2014-2015 
Northern Hemisphere influenza season (Fig. 4). Clade 3C.2a viruses possess an 
additional predicted glycosylation site in HA antigenic site B due to S159Y and K160T 
HA differences compared to A/Switzerland/9715293/2013. The addition of a new 
glycosylation site on top of the HA antigenic site B could potentially alter antigenicity 
and Ab access to this region of HA. In our studies, sera isolated from 
A/Switzerland/9715293/2013-infected animals reacted equally to the 
A/Switzerland/9715293/2013 strain and our A/Texas/50/2012 mutant panel; however, 
additional studies would need to be completed to precisely define the specificity of Abs 
elicited by A/Switzerland/9715293/2013 exposure. 
Taken together, our data suggest that mutations in HA antigenic site B of 2014-
2015 H3N2 strains led to a major antigenic change. This antigenic change is likely 
responsible for the low vaccine efficacy during the 2014-2015 season. Our studies 
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support the WHO’s decision to update the H3N2 component of the 2015-2016 influenza 
vaccine. 
 
MATERIALS AND METHODS 
HA Sequences 
We obtained HA sequence data from the GISAID website 
http://platform.gisaid.org/epi3/. We grouped all human isolates collected by United States 
surveillance labs between June 1, 2014 and January 31, 2015 into clades based on HA 
genetic sequence. All isolates from the Hospital of the University of Pennsylvania were 
sequenced and compared to the HA sequence of A/Texas/50/2012, EpiFlu accession 
number EPI408131. 
 
Clinical Isolates 
 Respiratory secretions were collected from H3N2-infected patients at the Hospital 
of the University of Pennsylvania between December 2014 and January 2015. RNA was 
extracted directly from clinical isolates using the Qiagen QIAamp Viral RNA Mini Kit 
and the HA1 gene was amplified via RT-PCR using H3-specific primers. Sequences were 
aligned to A/Texas/50/2012 for comparison of HA1 sequence differences. 
 
Viruses 
We obtained the A/Switzerland/9715293/2013 strain from the National Institute 
for Biological Standards and Control (NIBSC) in Hertfordshire, UK. We created reverse-
genetics derived viruses that possessed the A/Texas/50/2012 HA. Because we did not 
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have the A/Texas/50/2012 strain when we initiated these experiments, we extracted RNA 
from the A/Victoria/361/2011 strain and cloned the HA of this virus into the pHW2000 
reverse genetics plasmid. We then used QuikChange site-directed mutagenesis kits 
(Stratagene) to convert the A/Victoria/361/2011 HA sequence to the A/Texas/50/2012 
HA sequence (by adding T128N, G186V, S198P, S219F, N278K HA mutations). We 
then introduced the additional HA mutations from Table 5 into this A/Texas/50/2012 HA 
sequence. We rescued viruses that possessed the different mutated A/Texas/50/2012 HAs 
after transfecting 293T/MDCK cell co-cultures with the different HA plasmids and 
plasmids derived from PR8 that encoded for the rest of the influenza genome. All viruses 
used for antigenic analyses were propagated in 10-day-old fertilized chicken eggs. We 
used Sanger sequencing to verify that additional mutations did not arise during viral 
propagation. 
 
Antisera 
All sheep antisera used in this study were obtained from the National Institute for 
Biological Standards and Control (NIBSC) in Hertfordshire, UK. Antisera were collected 
from sheep 28 days post-infection. Ferret antisera used in this study were obtained from 
the Influenza Reagent Resource, Influenza Division, WHO Collaborating Center for 
Surveillance, Epidemiology and Control of Influenza, CDC, Atlanta, GA. Antisera were 
collected from ferrets 19 days post-infection. Antisera were also collected from humans 
prior to vaccination (d0) and 21 days following vaccination with the 2014-2015 seasonal 
influenza vaccine. All studies involving the collection and analysis of human sera were 
approved by the institutional review boards of the Wistar Institute and Vaccine and Gene 
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Therapy Institute of Florida (VGTI). All sera were treated with receptor-destroying 
enzyme (RDE) for 3 h prior to antigenic testing. 
 
HAI Assays 
HAI titrations were performed in 96-well round-bottom plates. Sera were serially 
diluted twofold and added to four agglutinating doses of virus in a total volume of 100 
µL. Next, 12.5 µL of a 2% (v/v) turkey RBC solution were added. Agglutination was read 
out after incubating for 1 h at room temperature. HAI titers were recorded as the inverse 
of the highest dilution that inhibited hemagglutination of turkey RBCs. Similar results 
were obtained using guinea pig RBCs. 
 
ELISA Assays 
VLPs expressing A/Texas/50/2012-WT HA, A/Texas/50/2012-F159S HA, or 
A/Port Chalmers/1/1973 HA were created. Codon-optimized sequences were cloned into 
the pCMV-Sport6 plasmid. VLPs were rescued by transfecting 293T cells with plasmids 
expressing HIV gag, PR8 NA, HAT (a human airway trypsin-like protease), and each 
HA. VLPs isolated from culture supernatants were concentrated using a 20% sucrose 
cushion and resuspended in PBS. VLP amounts were normalized in ELISAs using the 
F49 mAb (Clontech) that binds to a conserved region of the H3 stalk. Goat anti-ferret 
immunoglobulin G (IgG) conjugated to horseradish peroxidase (Abcam) was used to 
detect binding of A/Texas/50/2012 ferret antisera and goat anti-mouse IgG conjugated to 
horseradish peroxidase (MP Biomedicals) was used to detect the murine F49 mAb. 
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Neutralization Assays 
In vitro neutralization assays were performed in 96-well flat-bottom plates. Sera 
were serially diluted twofold and then added to 100 TCID50 units of A/Texas/50/2012-
WT or A/Texas/50/2012-F159S virus and incubated at room temperature for 30 min. The 
virus-sera mixtures were then incubated with MDCK cells for 1 h at 37°C. Next, cells 
were washed, and then serum-free media with TPCK-treated trypsin, HEPES, and 
gentamicin was added. We visually determined cytopathic endpoints 3 days later. Data 
are expressed as the inverse of the highest dilution that caused neutralization. 
 
Receptor Binding Assays 
As previously described (Hensley et al., 2009; Li et al., 2013a), turkey RBCs were 
pre-treated with different amounts of RDE (a neuraminidase) for 1 h at 37°C. The RBCs 
were washed with PBS and added (as 2% v/v solutions) to four agglutinating doses of 
each virus (as determined using non-treated RBCs). After incubating 1 h at room 
temperature, agglutination was measured. Viruses with higher receptor binding avidities 
are able to bind to RBCs that are treated with higher amounts of RDE (Hensley et al., 
2009; Li et al., 2013a; Yewdell et al., 1986). 
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FIGURES AND TABLES 
Figure 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Genetically distinct H3N2 viruses circulated during the 2014–2015 
influenza season in the United States. 
 (A) HA sequences deposited on the GISAID database were analyzed. All sequences 
deposited by United States laboratories between June 2014 and January 2015 were 
included in the analysis. Shown are the percent of viruses that belong to each HA clade 
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esting that some humans did not mount
Ab responses that were specific for
antigenic site B following vaccination.
Our previous studies suggest that influ-
enza pre-exposures can alter the immu-
nodominance of H1N1 Ab responses (Li
et al., 2013b; Linderman et al., 2014),
and it is possible that individuals who
do not mount site B-specific Ab re-
sponses have unique H3N2 pre-exposure
histories.
Anti-A/Texas/50/2012 Antigenic
Site B Abs Are Neutralizing
Next, we testedwhether anti-A/Texas/50/
2012 antigenic site B Abs identified in
ferrets and humans are neutralizing. We
completed in vitro neutralization assays
with A/Texas/50/2012 and A/Texas/50/
2012-F159S using sera samples isolated
from humans 21 days post-vaccination.
We focused on samples that had the largest HAI differences
using A/Texas/50/2012 and A/Texas/50/2012-F159S viruses
(Table 3). We also completed in vitro neutralization assays with
antisera isolated from ferrets recovering from infection with
the A/Texas/50/2012 strain. Our in vitro neutralization results
mirrored our HAI results (Table S2). All seven human sera
samples and the ferret sera sample tested had dramatically
decreased in vitro neutralization titers using the A/Texas/50/
2012-F159S virus compared to the A/Texas/50/2012-WT virus
(Table S2).
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that represent a fairly large age range (21–50 years old). It is inter-
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antigenic site B following vaccination.
Our previous studies suggest that influ-
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Anti-A/Texas/50/2012 Antigenic
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We focused on samples that had the largest HAI differences
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antisera isolated from ferrets recovering from infection with
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mirrored our HAI results (Table S2). All seven human sera
samples and the ferret sera sample tested had dramatically
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(Table S2).
DISCUSSION
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(as defined in the text). (B) Clinical isolates collected from patients at the Hospital of the 
University of Pennsylvania (December 2014-January 2015) were sequenced and 
compared to the HA sequence of A/Texas/50/2012 (EpiFlu accession number 
EPI408131). Shown is the fraction of clinical isolates that belong to each HA clade (as 
defined in the text). (C) The H3 structure (PDB entry 1HGG) is shown with residues 
from Table 4 highlighted in yellow and labeled.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
57	  
Figure 5 
 
Figure 5. ELISA experiments confirm that the F159S HA mutation abrogates 
binding of Abs in anti-A/Texas/50/2012 ferret antisera. 
ELISAs were completed with plates coated with VLPs containing A/Texas/50/2012-WT 
HA (A/TX/12-WT), A/Texas/50/2012-F159S HA (A/TX/12-F159S), or A/Port 
Chalmers/1/1973 HA (A/PC/73). ELISAs were completed with A/Texas/50/2012 ferret 
antisera (A) or the F49 mAb (B) that binds to a conserved region of the HA stalk. Shown 
are mean and SEM of triplicate samples. Data are representative of two independent 
experiments. 
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Table 4 
 
 
Table 4. HA sequence differences between newly emerged clades and the 
A/Texas/50/2012 vaccine strain. 
Shown are HA residues (in H3 numbering) that differ between the A/Texas/50/2012 
H3N2 vaccine strain and most HA clade 3C.2a, 3C.3, and 3C.3a viruses isolated during 
the 2014-2015 Northern Hemisphere influenza season. 
 
 
 
 
 
 
 
strains belonging to the phylogenetic 3C.2a, 3C.3, and 3C.3a HA
clades predominated (Broberg et al., 2015). Compared to the
A/Texas/50/2012 strain, 3C.2a viruses possess HA differences
at L3I, N144S, N145S, F159Y, K160T, N225D, and Q311H,
3C.3 viruses possess HA differences at T128A, R142G, and
N145S, and 3C.3a viruses possess HA differences at T128A,
A138S, R142G, N145S, F159S, and N225D (Table 1). HA clade
3C.2a and 3C.3a viruses are antigenically distinct compared to
the A/Texas/50/2012 strain and the World Health Organization
has recommended that the H3N2 component should be updated
with an A/Switzerland/9715293/2013-like (HA 3C.3a) virus for
the Northern Hemisphere 2015–2016 vaccine (Anonymous,
2015).
Analyses of HA sequences deposited in the GISAID database
revealed that the majority of H3N2 viruses circulating in the
United States in the fall and winter of 2014 belong to HA clade
3C.2a (Figure 1A). To understand the antigenic basis for the
extremely poor H3N2 vaccine match during the 2014–2015 influ-
enza season, we created a panel of A/Texas/50/2012 viruses
that possessed HA mutations found in clade 3C.2a, 3C.3, and
3C.3a viruses (Table S1), and we completed antigenic analyses
using sera isolated from ferret, sheep, and humans exposed to
the A/Texas/50/2012 H3N2 vaccine strain (Tables 2 and 3). Our
mutant viral panel includes every mutation from Table 1 that is
located in the HA globular head (Figure 1B), with the exception
of the F159Y and K160Tmutations. Wewere able to successfully
rescue A/Texas/50/2012 viruses that possessed the F159Y and
K160T mutations, but these viruses failed to agglutinate red
blood cells and quickly mutated when propagated for antigenic
analyses. However, we were still able to assess the antigenic
relevance of mutations in this area of HA since our mutant panel
included a virus with the F159S HA mutation.
Ferrets and Sheep Infected with A/Texas/50/2012
Mount Abs against HA Antigenic Site B
We first completed hemagglutination-inhibition (HAI) assays
with our mutant A/Texas/50/2012 virus panel and sera collected
from ferrets and sheep recovering from A/Texas/50/2012
infections (Table 2). As expected, anti-A/Texas/50/2012 Ab titers
were drastically decreased using the antigenically distinct
A/Switzerland/9715293/2013 clade 3C.3a virus. Strikingly, anti-
A/Texas/50/2012 Ab titers were decreased 4-fold in HAI assays
with viruses engineered to possess a single F159S HA mutation
(Table 2). Residue 159 is located in a highly exposed region of
antigenic site B of H3 HAs (Figure 1B). Other HA mutations had
more subtle effects on anti-A/Texas/50/2012 HAI titers. For
example, the A138S and N145S HA mutations each lead to
2-fold decreases in HAI titers.We previously showed that viruses
that bind to red blood cells with a high avidity can escape Abs in
HAI assays independently of antigenic change (Li et al., 2013a).
We found that A138S and N145S mutant viruses bound to red
blood cells with a higher avidity (Table S1), and the apparent
decreased HAI titers using these viruses likely result from this
increase in receptor binding avidity. We found that viruses
possessing the F159S mutation bound to red blood cells with a
decreased avidity (Table S1), and for this reason, we concluded
that reduced HAI titers using this virus were the result of a
genuine antigenic change.
To verify the antigenic relevance of the F159S HA mutation,
we completed additional direct Ab ELISA binding assays with
plates coated with viral like particles (VLPs) possessing
A/Texas/50/2012-WT HA or A/Texas/50/2012-F159S HA (Fig-
ure 1C). As a control, we coated plates with VLPs possessing
the antigenically distinct A/Port Chalmers/1/1973 HA (from
a 1973 H3 virus). Anti-sera isolated from ferrets infected
with A/Texas/50/2012 had reduced binding to VLPs possess-
ing A/Texas/50/2012-F159S HA compared to VLPs possessing
A/Texas/50/2012-WT HA (Figure 1C). We verified that equal
amounts of VLPs were used in these assays by completing
additional ELISA experiments with the F49 monoclonal anti-
body (mAb) that recognizes the conserved stalk region of H3
(Figure 1D). Collectively, these studies indicate that ferrets
and sheep mount Ab responses against an HA epitope
involving residue F159 following infection with A/Texas/50/
2012, and for this reason we focused the rest of antigenic an-
alyses on this region of HA.
Ferrets and Sheep Infected with A/Switzerland/
9715293/2013 Mount Ab Responses that Are Not
Focused against HA Epitope Involving Residue 159
We also completed HAI assays using our mutant viral panel and
anti-sera isolated from sheep infected with A/Switzerland/
9715293/2013 virus. Anti-sera isolated from A/Switzerland/
9715293/2013-infected animals reacted to all mutant A/Texas/
50/2012 viruses, including viruses that possessed the site B
F159S HA mutation (Table 2). Therefore, the F159S HA mutation
results in an asymmetrical antigenic change. These data are
important since A/Switzerland/9715293/2013 (an HA clade
3C.3a virus) has been chosen as the H3 component of 2015–
2016 seasonal vaccines, even though HA clade 3C.2a viruses
predominated toward the end of the 2014–2015 influenza sea-
son (Figure 1). Antigenic site B of HA clades 3C.3a and 3C.2a
viruses differ (Table 1), and future studies will need to be
completed to rigorously define the specificity of Abs elicited by
the A/Switzerland/9715293/2013 vaccine strain.
Table 1. HA Mutations in 2014–2015 H3N2 Viruses
Clades
3C.2a 3C.3 3C.3a
L3I
T128A T128A
A138S
R142G R142G
N144S
N145S N145S N145S
F159Y F159S
K160T
N225D N225D
Q311H
Shown are HA residues (H3 numbering) that differ between the A/Texas/
50/2012 H3N2 vaccine strain and most clade 3C.2a, 3C.3, and 3C.3a
viruses isolated during the 2014–2015 Northern Hemisphere influenza
season.
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Table 5 
 
Table 5. Our panel of A/Texas/50/2012 mutant viruses and their relative binding 
avidities. 
Shown is the panel of reverse-genetics derived mutant viruses that we created for our 
antigenic analyses. Relative receptor binding avidity is also shown (+++ indicates virus 
was able to agglutinate RBCs treated with > 1.0 ug/mL RDE; ++ indicates virus was able 
to agglutinate RBCs treated with 0.5-1.0 ug/mL RDE; + indicates virus was able to 
agglutinate RBCs treated with <0.5 ug/mL RDE). Data are representative of two 
independent experiments. 
 
 
 
 
 
 
 
 
viruses relative receptor binding avidity 
A/Texas/50/2012-WT ++ 
A/Texas/50/2012-N128A ++ 
A/Texas/50/2012-A138S +++ 
A/Texas/50/2012-R142G ++ 
A/Texas/50/2012-N144S+N145S ++ 
A/Texas/50/2012-N145S +++ 
A/Texas/50/2012-F159S + 
A/Texas/50/2012-N225D +++ 
A/Switzerland/9715293/2013 +++ 
!
Table S1: Mutant viral panel and receptor binding avidities, related to Table 2.  
Shown are the reverse genetics-derived utant panel that we created for our antige ic 
analyses.  Relative receptor binding avidity is also shown (+++ indicates virus was able to 
agglutinate red blood cells treated with > 1.0 ug/mL RDE; ++ indicates virus was able to 
agglutinate red blood cells treated with 0.5-1.0 ug/mL RDE; + indicates virus was able to 
agglutinate red blood cells treated with <0.5 ug/mL RDE).  Data are representative of 2 
independent experiments. 
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Table 6. Analyses of ferret and sheep antisera raised against the A/Texas/50/2012 
and A/Switzerland/9715293/2013 vaccine strains. 
HAI assays were completed using the A/Texas/50/2012-WT virus and the panel of 
A/Texas/50/2012 mutant viruses, as well as the A/Switzerland/9715293/2013 WT (HA 
clade 3C.3a) virus as a control. Antisera were collected from ferrets 19 days post-
infection and from sheep 28 days post-infection. Data are representative of three 
independent assays. 
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Table 7 
 
 
 
sera were treated with receptor-destroying enzyme (RDE) for 3 hr prior to
antigenic testing.
HAI Assays
HAI titrations were performed in 96-well round bottom plates. Sera were
serially diluted 2-fold and added to four agglutinating doses of virus in a total
volume of 100 ml. Next, 12.5 ml of a 2% (v/v) turkey red blood cell solution
was added. Agglutination was read out after incubating for 60 min at room
temperature. HAI titers were recorded as the inverse of the highest dilution
that inhibited hemagglutination of turkey red blood cells. Similar results were
obtained using guinea pig red blood cells.
ELISA Assays
VLPs expressing A/Texas/50/2012-WT HA, A/Texas/50/2012-F159S HA, or
A/Port Chalmers/1/1973 HA were created. Codon-optimized sequences
were cloned into the pCMV-Sport6 plasmid. VLPs were rescued by transfect-
ing 293T cells with plasmids expressing HIV gag, A/Puerto Rico/8/1934 NA,
HAT (human airway trypsin-like protease), and each HA. VLPs isolated from
culture supernatants were concentrated using a 20% sucrose cushion and
resuspended in PBS. VLP amounts were normalized in ELISAs using the F49
mAb (Clontech) that binds to a conserved region of the H3 stalk. Goat anti-
ferret immunogloublin G (IgG) conjugated to horseradish peroxidase (Abcam)
was used to detect binding of A/Texas/50/2012 ferret antisera and goat anti-
mouse IgG conjugated to horseradish peroxidase (MP Biomedicals) was
used to detect the murine F49 mAb.
Neutralization Assays
In vitro neutralization assays were performed in 96-well flat bottom plates.
Sera were serially diluted and then added to 100 TCID50 units of A/Texas/
50/2012-WT or A/Texas/50/2012-F159S virus and incubated at room temper-
ature for 30min. The virus-sera mixtures were then incubated with MDCK cells
for 1 hr at 37C. Next, cells were washed, and then serum-free media with
TPCK-treated trypsin was added. We visually determined cytopathic end-
points 3 days later. Data are expressed as the inverse of the highest dilution
that caused neutralization.
Receptor Binding Assays
As previously described (Li et al., 2013a), turkey red blood cells were pre-
treated with different amounts of RDE (a neuraminidase) for 1 hr at 37!C.
The red blood cells were washed with PBS and added (as 2% v/v solutions)
to four agglutinating doses of each virus (as determined using non-treated
red blood cells). After a 1-hr incubation, agglutination was measured. Viruses
with higher receptor binding avidities are able to bind to red blood cells that are
treated with high amounts of RDE (Li et al., 2013a).
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Table 3. Analyses of Sera Isolated from Humans Pre- and Post-
vaccination with the 2014–2015 Seasonal Influenza Vaccine that
Includes the A/Texas/50/2012 Vaccine Strain
Sample
ID
Age
(years)
Pre-vaccination Post-vaccination
A/Texas/
50/2012
A/Texas/50/
2012-F159S
A/Texas/
50/2012
A/Texas/50/
2012-F159S
01 21 240 40 160 40
02 23 640 240 320 160
03 24 240 80 240 80
04 25 240 80 240 80
05 26 80 <40 640 320
06 27 480 <40 320 <40
07 29 60 <40 120 40
08 30 60 40 80 40
09 30 <40 <40 640 320
10 30 320 240 640 480
11 31 320 80 320 120
12 31 40 <40 60 <40
13 31 <40 <40 40 <40
14 31 <40 <40 160 <40
15 31 40 <40 40 <40
16 34 480 60 640 80
17 35 480 80 320 120
18 35 160 80 160 160
19 35 320 240 640 320
20 35 160 <40 240 <40
21 36 60 <40 120 <40
22 38 <40 <40 120 <40
23 38 <40 <40 240 <40
24 39 240 80 320 80
25 41 320 240 320 240
26 44 <40 <40 80 40
27 44 40 <40 80 80
28 46 <40 <40 80 40
29 48 80 <40 160 40
30 48 <40 <40 60 <40
31 48 <40 <40 80 <40
32 50 80 40 160 80
Sera were collected from humans pre- and post-vaccination with the
2014–2015 seasonal influenza vaccine. HAI assays were completed
using A/Texas/50/2012 and A/Texas/50/2012 with the F159S HA muta-
tion. Data are representative of three independent assays.
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Table 7. Analyses of sera isolated from humans pre- and post-vaccination with the 
2014-2015 seasonal influenza vaccine. 
HAI assays were completed using the A/Texas/50/2012-WT and A/Texas/50/2012-F159S 
viruses. Sera were collected from 32 humans pre-vaccination (d0) and post-vaccination 
(d21) with the 2014-2015 seasonal influenza vaccine that contained the A/Texas/50/2012 
vaccine strain. Data are representative of three independent assays. 
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Table 8 
 
Table 8. In vitro neutralization titers using antisera isolated from vaccinated 
humans and infected ferrets. 
In vitro neutralization assays were completed in MDCK cells using the A/Texas/50/2012-
WT and A/Texas/50/2012-F159S viruses. Neutralization titers were determined for 
antisera isolated 21 days following vaccination of humans with the 2014-2015 influenza 
vaccine or antisera isolated 19 days following infection of ferrets with the 
A/Texas/50/2012 strain. Human sera samples used here displayed the largest reduction in 
HAI titers due to the F159S HA mutation (Table 7). Neutralization titers are expressed as 
the inverse of the maximum dilution of sera that results in full neutralization of viral 
growth. Data are representative of two independent assays. 
 
 
 
 
 
 
 
! A/Texas/50/2012-WT A/Texas/50/2012-F159S 
human ID 06 640 80 
human ID 14 1280 80 
human ID 20 640 <40 
human ID 21 320 40 
human ID 22 640 160 
human ID 23 320 80 
human ID 31 320 80 
ferret anti-A/Texas/50/2012 1280 40 
!
Table S2: In vitro neutralization titers using sera isolated from vaccinated humans 
and infected ferrets, related to Table 2 and Table 3.  In vitro neutralization assays 
were completed using sera isolated 21 days following vaccination of humans with the 
2014-2015 influenza vaccine or sera isolated 19 days following infection of ferrets with 
the A/Texas/50/2012 strain.  Data are representative of 2 independent assays. 
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CHAPTER 4: POTENTIAL ANTIGENIC EXPLANATION FOR 
ATYPICAL H1N1 INFECTIONS AMONG MIDDLE-AGED ADULTS 
DURING THE 2013-2014 INFLUENZA SEASON 
 
 
Parts of this chapter were previously published in: 
 
*Linderman SL, *Chambers BS, *Zost SJ, Parkhouse K, Li Y, Herrmann C, Ellebedy 
AH, Carter DM, Andrews SF, Zheng NY, Huang M, Huang Y, Strauss D, Shaz BH, 
Hodinka RL, Reyes-Terán G, Ross TM, Wilson PC, Ahmed R, Bloom JD, and Hensley 
SE. (2014) Potential antigenic explanation for atypical H1N1 infections among middle-
aged adults during the 2013-2014 influenza season. PNAS 111(44):15798-15803. 
(* = contributed equally) 
 
 
SUMMARY 
 Influenza viruses typically cause the most severe disease in children and elderly 
individuals. However, H1N1 viruses disproportionately affected middle-aged adults 
during the 2013-2014 influenza season. Although H1N1 viruses had recently acquired 
several mutations in the hemagglutinin (HA) glycoprotein, classic serological tests used 
by surveillance laboratories indicated that these mutations did not change antigenic 
properties of the virus. Here, we show that one of these mutations was located in a region 
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of HA targeted by antibodies elicited in many middle-aged adults. We found that over 
42% of individuals born between 1965 and 1979 possessed antibodies that recognize this 
region of HA. Our findings offer a possible antigenic explanation of why middle-aged 
adults were highly susceptible to H1N1 viruses during the 2013-2014 influenza season. 
Our data further suggest that a drifted H1N1 strain should be included in future influenza 
vaccines to potentially reduce morbidity and mortality in this age group. 
 
INTRODUCTION 
 Seasonal H1N1 (sH1N1) viruses circulated in the human population for much of 
the last century and, as of 2009, most humans had been exposed to sH1N1 strains. In 
2009, an antigenically distinct H1N1 strain began infecting humans and caused a 
pandemic (Dawood et al., 2009; Garten et al., 2009; Smith et al., 2009). Elderly 
individuals were less susceptible to 2009 pandemic H1N1 (pH1N1) viruses because of 
cross-reactive antibodies (Abs) elicited by infections with older sH1N1 strains (Garten et 
al., 2009; Jacobs et al., 2012; Manicassamy et al., 2010; Skountzou et al., 2010; Xu et al., 
2010). pH1N1 viruses have continued to circulate on a seasonal basis since 2009. 
Influenza viruses typically cause a higher disease burden in children and elderly 
individuals (Mertz et al., 2013), but pH1N1 viruses caused unusually high levels of 
disease in middle-aged adults during the 2013-2014 influenza season (Arriola et al., 
2014; Ayscue et al., 2014; Davila et al., 2014; Epperson et al., 2014). For example, a 
significantly higher proportion of individuals aged 30-59 years old were hospitalized in 
Mexico with laboratory-confirmed pH1N1 cases in 2013-2014 relative to 2011-2012 
(Davila et al., 2014). 
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 Most neutralizing influenza Abs are directed against the hemagglutinin (HA) 
glycoprotein. International surveillance laboratories rely primarily on ferret antisera for 
detecting HA antigenic changes (Stöhr et al., 2012). For these assays, sera are isolated 
from ferrets recovering from primary influenza infections. Seasonal vaccine strains are 
typically updated when human influenza viruses acquire HA mutations that prevent the 
binding of sera collected from previously naïve ferrets infected with influenza for the first 
time. Our laboratory and others have demonstrated that sera isolated from ferrets 
recovering from primary pH1N1 infections are dominated by Abs that recognize an 
epitope involving HA residues 156, 157, and 158 of the Sa HA antigenic site (Chen et al., 
2010b; Li et al., 2013b). The pH1N1 component of the seasonal influenza vaccine has not 
been updated since 2009 because very few pH1N1 isolates possess mutations in HA 
residues 156, 157, and 158. The majority of isolates from the 2013-2014 season have 
been labeled as antigenically similar to the A/California/07/2009 vaccine strain (Arriola 
et al., 2014). 
 It is potentially problematic that major antigenic changes of influenza viruses are 
mainly determined using antisera isolated from ferrets recovering from primary influenza 
infections. Unlike experimental ferrets, humans are typically reinfected with antigenically 
distinct influenza strains throughout their life (Miller et al., 2013). In the 1950s, it was 
noted that the human immune system preferentially mounts Ab responses that cross-react 
to previously circulating influenza strains, at the expense of new Ab responses that 
exclusively target newer viral strains (Davenport et al., 1953). This process, which 
Thomas Francis, Jr. termed “original antigenic sin,” has been experimentally 
recapitulated in ferrets (Li et al., 2013b; Webster, 1966), mice (Kim et al., 2009; 
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Virelizier et al., 1974a; Virelizier et al., 1974b), and rabbits (Fazekas de St and Webster, 
1966b). Our group and others recently demonstrated that the specificity of pH1N1 Ab 
responses can be shaped by prior sH1N1 exposures (Carter et al., 2013; Li et al., 2012; Li 
et al., 2013b; Pica et al., 2012; Wrammert et al., 2011). We found that ferrets sequentially 
infected with sH1N1 and pH1N1 viruses mount Ab responses dominated against epitopes 
that are conserved between the viral strains (Li et al., 2013b). These studies indicate that 
sera collected from previously naïve ferrets infected a single time with influenza may not 
be fully representative of human influenza immunity. 
 It has been proposed that increased morbidity and mortality of middle-aged adults 
during the 2013-2014 influenza season was primarily a result of low vaccination rates 
within these populations (Catania et al., 2014). An alternative explanation is that pH1N1 
strains that circulated during that season had acquired a true antigenic mutation that was 
mislabeled as “antigenically neutral” by assays that relied on sera collected from 
previously naïve ferrets infected a single time with the 2009 pH1N1 virus. Here, we 
completed a series of experiments to determine if pH1N1 strains that circulated during 
the 2013-2014 influenza season possessed a mutation that prevented binding of Abs in 
middle-aged humans who had been previously exposed to different sH1N1 strains. 
 
RESULTS 
Recent pH1N1 strains possess a mutation that prevents binding of human Abs 
 Antisera isolated from ferrets recovering from primary pH1N1 infections are 
highly specific for an epitope involving HA residues 156, 157, and 158 of the Sa 
antigenic site of H1 viruses (Chen et al., 2010b; Li et al., 2013b). Very few pH1N1 
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isolates possessed mutations in these Sa residues as of 2014 (Fig. 6); however, pH1N1 
viruses recently acquired a K166Q HA mutation, which is located at the interface of the 
Sa/Ca antigenic sites (Caton et al., 1982) (Fig. 7A). The K166Q HA mutation first arose 
during the 2012–2013 season and was present in over 99% of pH1N1 isolates during the 
2013-2014 season (Fig. 7B-C). Based on experiments using antisera isolated from ferrets 
infected for the first time, surveillance laboratories reported that pH1N1 viruses with the 
K166Q HA mutation were antigenically indistinguishable from the A/California/07/2009 
pH1N1 vaccine strain (Arriola et al., 2014). 
 To address if human Abs are capable of recognizing pH1N1 viruses with the 
K166Q HA mutation, we performed hemagglutination inhibition (HAI) assays using sera 
from healthy humans collected during the 2013–2014 influenza season in the United 
States. Remarkably, 27% of sera from individuals born between 1940 and 1984 possessed 
Abs specific for an epitope involving HA residue K166 (Fig. 8A and Table 9). Over 42% 
of individuals born from 1965 to 1979 had K166 HA-specific Abs in their sera (n = 54 
individuals). Sera isolated from individuals born between 1985 and 1997 (n = 49 
individuals) did not have detectable levels of K166 HA-specific Abs. Differences in 
K166 HA-specificity were statistically significant between sera isolated from individuals 
born between 1965 and 1979 and individuals born after 1985 (Fisher’s exact test; P < 
0.0001). Similar results were obtained when we analyzed sera from healthy humans 
collected during the 2013–2014 influenza season in Mexico (Fig. 9 and Table 10). 
 It is remarkable that HAI assays, which are relatively insensitive, were able to 
reproducibly detect K166 HA-specific Abs in so many individuals in our experiments. 
Fig. 8A and Fig. 9 show percentages of donors that had at least a twofold reduction in 
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HAI titer using the K166Q HA mutant virus in three independent assays. It is worth 
pointing out that many sera samples had over fourfold reduced HAI titers using a pH1N1 
virus engineered to possess the single K166Q HA mutation compared with the pH1N1 
vaccine strain (Table 9). Age-related differences in K166 HA-specificity among United 
States donors remained statistically significant using a fourfold reduction in HAI titer as a 
cut-off (Fisher’s exact test; P < 0.05 comparing donors born between 1965 and 1979 and 
donors born after 1985). Sera that had K166 HA-specificity based on HAI assays failed 
to efficiently neutralize K166Q-possessing viruses in in vitro neutralization assays as 
well (Table 11). K166 HA-specific sera were also unable to recognize a primary viral 
isolate collected in 2013 (A/CHOP/1/2013) that possesses the K166Q HA mutation 
(Table 11). 
 
A glycosylation site present in sH1N1 viruses circulating after 1985 shields the K166 
HA-epitope  
 Original antigenic sin Abs are originally primed by influenza strains that 
circulated in the past (Davenport et al., 1953; Fazekas de St and Webster, 1966a, b; Li et 
al., 2013b; Webster, 1966). We propose that K166 HA-specific Ab responses were likely 
primed by sH1N1 viruses circulating in humans before 1985 and then boosted by the 
2009 pH1N1 virus. Sera isolated from individuals born between 1965 and 1979 had the 
highest K166 HA-specificity (both in percent and in titer) (Fig. 8A and Table 9). sH1N1 
viruses that circulated in the late 1970s and early 1980s share extensive homology with 
pH1N1 viruses in the vicinity of K166 (Fig. 8B). sH1N1 viruses were absent from the 
human population from 1957 to 1976 and began infecting humans again in 1977. 
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Therefore, humans born between 1957 and 1976 likely had their first H1N1 encounter 
with a sH1N1 virus that shared homology with pH1N1 viruses in the vicinity of K166. 
 In 1986, sH1N1 viruses acquired a new glycosylation site at HA residue 129 that 
is predicted to shield the epitope involving K166 (Figs. 10 and 11). The absence of K166 
HA-specific Ab responses in individuals born after 1985 is likely because sH1N1 viruses 
glycosylated at HA residue 129 fail to prime K166 HA-specific responses. The lower 
number of K166 HA-specific responders born in the 1950s might also be attributed to 
unique glycosylation sites in sH1N1 viruses that circulated during this time period (Fig. 
10), although precise glycosylation statuses of viruses circulating before 1977 are 
uncertain because of limited numbers of sequenced viruses. Although we did not examine 
sera from very elderly individuals, it is possible that they also have immunodominant 
K166 HA-specific responses, because a recent study reported that a mAb isolated from a 
survivor of the 1918 H1N1 pandemic binds to pH1N1 in an epitope involving K166 (Xu 
et al., 2010). There is considerable homology between the 1918 H1N1 virus and the 2009 
pH1N1 virus in the vicinity of K166 (Xu et al., 2010). 
 To experimentally address if glycosylation sites present in previous sH1N1 strains 
shield the epitope involving K166, we used reverse-genetics to produce pH1N1 viruses 
that had glycosylation sites that were either present in sH1N1 strains from 1977-1985 
(sites 131+163) or 1986-2008 (sites 129+163). Western blot analysis revealed that HA 
residues 129 and 131, but not HA residue 163, were glycosylated in our reverse-genetics 
derived viruses (Fig. 11B). Consistent with the hypothesis that the K166 HA-epitope is 
shielded by glycosylation sites present in 1986-2008 sH1N1 viruses, K166 HA-specific 
human sera had reduced titers to pH1N1 viruses with the 129-glycosylation site, but 
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normal titers to pH1N1 viruses with the 131-glycosylation site (Fig. 11C). As a control, 
we also completed HAI assays with sera from donors that were born in the 1970s who did 
not have detectable levels of K166 HA-specific sera Abs. As expected, these sera did not 
have reduced titers to pH1N1 viruses with the 129-glycosylation site, but interestingly, 
these sera did have reduced titers to pH1N1 viruses with the 131-glycosylation site (Fig. 
11C). We previously demonstrated that Ab responses focused on an epitope near the 131-
glycosylation site can be elicited by sequential infections with a sH1N1 virus from the 
early 1990s and the pH1N1 virus (Li et al., 2013b). We speculate that donors in the “non-
K166 HA-specific” group were previously infected with antigenically distinct sH1N1 
strains compared with donors in the K166 HA-specific group (ie: A/Singapore/06/1986-
like strain instead of A/Chile/01/1983-like strain). Taken together, these data suggest that 
glycosylation sites on previously circulating sH1N1 viruses shield epitopes and influence 
the development of subsequent Ab responses against pH1N1 virus. 
 
Vaccination with current pH1N1 vaccine strain elicits K166 HA-specific Abs  
 The pH1N1 vaccine strain has not been updated since 2009. We determined 
whether this vaccine strain, which possesses an HA with K166, elicits K166 HA-specific 
Abs in humans. First, we analyzed sera from individuals vaccinated in 2009. All of the 
individuals in this cohort were born before 1984 and most did not have pH1N1 Ab titers 
before vaccination (Table 12). Sera from 5 of 17 individuals possessed detectable levels 
of K166 HA-specific Abs following vaccination (Fig. 12 and Table 12). Sera from all 
five of these individuals had <1:40 HAI titers against the K166Q HA mutant pH1N1 
virus (Table 12). One K166 HA-specific individual (subject #1) possessed K166 HA-
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specific Abs before vaccination (Fig. 12A and Table 12). It is possible that this individual 
was naturally infected with pH1N1 before vaccination. All of the K166 HA-specific 
donors had detectable pre-vaccination Ab titers against sH1N1 viruses from 1977 and 
1983; however, we also found titers against these strains in some donors that did not have 
detectable levels of K166 HA-specific serum Abs (Table 12). We also measured binding 
of 42 HA head-specific monoclonal Abs (mAbs) isolated from 12 adult donors (born 
1949-1985) that were vaccinated against the pH1N1 strain in 2009. Strikingly, 23% of 
these mAbs had reduced binding to pH1N1 engineered to have the K166Q mutation (Fig. 
12B). This finding is consistent with a previous report that identified several K166 HA-
specific mAbs derived from a donor that was born before 1977 (Krause et al., 2011). 
 We passively transferred a K166 HA-specific mAb (SFV009-3F05) or a control 
mAb that binds equally to WT and K166Q-HA pH1N1 viruses (SFV015-1F02) to 
BALB/c mice 12 h before infecting them with a lethal dose of WT or K166Q-HA pH1N1 
viruses. Control animals that did not receive a mAb before infection rapidly lost weight 
and died or needed to be euthanized (Fig. 12C). Mice receiving the control SFV015-1F02 
mAb before infection with WT or K166Q-HA pH1N1 viruses all survived with minimal 
weight loss (Fig. 12C). Mice receiving the K166 HA-specific SFV009-3F05 mAb 
survived following infection with WT pH1N1 but rapidly lost weight and died or needed 
to be euthanized following infection with K166Q-HA pH1N1 (Fig. 12C). These data 
suggest that K166 HA-specific Abs can be less efficient at preventing disease in a mouse 
model following infection with a pH1N1 virus possessing K166Q HA. 
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Can K166 HA-specific immunity be recapitulated in ferrets for surveillance purposes? 
 Current surveillance efforts rely heavily on antisera isolated from ferrets 
recovering from primary influenza virus infections. Ferret antisera could potentially be 
more reflective of human immunity if isolated from animals sequentially infected with 
antigenically distinct viral strains. We attempted to elicit K166 HA-specific Abs in ferrets 
by sequentially infecting animals with older sH1N1 strains and then the 
A/California/07/2009 pH1N1 strain. 
 We initially infected animals with a sH1N1 virus that circulated in 1977 
(A/USSR/90/1977), a sH1N1 virus that circulated in 1983 (A/Chile/01/1983), or a sH1N1 
virus that circulated in 1986 (A/Singapore/06/1986). After 84 d, we re-infected animals 
with the A/California/07/2009 pH1N1 strain. As controls, we infected some animals 
twice with A/California/07/2009 and other animals only once with A/California/07/2009. 
Three of eight ferrets sequentially infected with A/Chile/01/1983 and 
A/California/07/2009 mounted K166 HA-specific Abs detectable in HAI assays (Fig. 13 
and Table 13). The 22 ferrets in the other experimental groups did not mount detectable 
levels of K166 HA-specific Abs. The difference in K166 HA-specificity is statistically 
significant comparing the A/Chile/01/1983-A/California/07/2009 group with the rest of 
the groups (3 of 8 vs. 0 of 22; Fisher’s exact test P < 0.05). K166 HA-specific Abs were 
likely not elicited in the A/Singapore/06/1986-A/California/07/2009 group because the 
K166 HA-epitope is predicted to be shielded by a glycosylation site at HA residue 129 of 
A/Singapore/06/1986 (Fig. 11). It is interesting that K166 HA-specific Abs were not 
elicited by A/USSR/90/1977-A/California/07/2009 sequential infections. This result is 
likely because of variation at HA residue 125, which is close to HA residue 166 (Fig. 14). 
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A/Chile/01/1983 and A/California/07/2009 both possess S125, whereas A/USSR/01/1977 
possesses R125 (Fig. 14). 
 
New pH1N1 vaccine strain candidate is antigenically distinct compared to 
A/California/07/2009 
 Although the pH1N1 vaccine strain component has not been updated since 2009, 
a new strain was added to the list of “A/California/07/2009-like” candidate strains for the 
upcoming 2016-2017 influenza season (Anonymous, 2016). Despite being labeled as 
antigenically identical to the A/California/07/2009 vaccine strain, the new strain, A/South 
Africa/3626/2013, possesses the HA K166Q mutation compared to the current vaccine 
strain. This is the first virus added to list of H1N1 candidate vaccine strains that possesses 
a glutamine at HA residue 166. Based on our previous data indicating that a large 
percentage of middle-aged adult human sera possess Abs that are sensitive to the HA 
K166Q mutation, we hypothesized that A/South Africa/3626/2013 is actually an 
antigenically distinct virus compared to A/California/07/2009. We generated both the 
A/California/07/2009 X-179A (Cal X-179A) and A/South Africa/3626/2013 X-243 (S.A. 
X-243) vaccine strains using reverse genetics and PR8 internals. After rescue, the viruses 
were expanded in eggs similar to how the vaccine strains are produced.  
 We then performed HAI assays using antisera collected from middle-aged adults 
(born 1977-1985), both before (d0) and after (d21) vaccination with 
A/California/07/2009, during the 2013-2014 influenza season (Fig. 15). Even before 
vaccination, the majority of the 20 individuals from the cohort had anti-pH1N1 Ab titers. 
Of the 14 samples with titers against Cal X-179A, 36% had HAI titers reduced at least 
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twofold against S.A. X-243 (Fig. 15A). Following vaccination, the percentage of 
individuals with at least a twofold reduction in HAI titer against S.A. X-243 was 37% 
(Fig. 15B). These results are consistent with data from Fig. 8A, where the sera from 42% 
of the middle-aged adults (born 1965-1979) in our cohort had reduced HAI titers against 
a virus containing the K166Q HA mutation. Relative receptor binding avidities of the two 
viruses were calculated to have no significant difference (Fig. 15C), indicating that 
observed changes in HAI titers were likely due to antigenic differences.  
 Overall, the HAI data confirms our hypothesis that A/South Africa/3626/2013 is 
an antigenically distinct strain and should not be labeled as antigenically identical to the 
current A/California/07/2009 vaccine strain. This is important because vaccine 
preparations including Cal X-179A as the H1N1 component could produce different 
immunogenic responses than those vaccines including S.A. X-243 as the H1N1 
component. Middle-aged adults would likely benefit more from receiving a vaccine with 
the more recent S.A. X-243 vaccine strain because it does not include an intact K166 
HA-epitope and thus would presumably not elicit the K166 HA-specific Ab response that 
leaves them more susceptible to infection with current pH1N1 strains. 
 
DISCUSSION 
 Our studies show that pH1N1 viruses that circulated during the 2013-2014 
influenza season acquired a significant antigenic mutation that prevents binding of Abs 
elicited in a large number of middle-aged humans. For this reason, we propose that the 
pH1N1 vaccine strain should be updated. Conventional serological techniques used by 
most surveillance laboratories failed to recognize the K166Q HA mutation as 
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antigenically important (Arriola et al., 2014). HAI assays are based on serial sera 
dilutions and can only detect large antigenic changes. Many surveillance-based 
laboratories ignore twofold reductions in HAI titer because these laboratories typically 
process thousands of samples, which prohibit the experimental precision that is required 
to reliably detect twofold differences in these assays. However, a true twofold reduction 
in HAI titer against a mutated strain indicates an extremely immunodominant Ab 
response. Although we reproducibly detected as low as twofold HAI differences using 
K166Q HA mutated viruses (Tables 9 and 10 show results from three independent HAI 
experiments), our HAI assays likely underestimate the number of individuals that possess 
K166 HA-specific Abs. For example, we were able to isolate K166 HA-specific mAbs 
from pH1N1-vaccinated individuals whose sera yielded similar HAI titers using WT and 
K166Q mutated pH1N1 viruses. We also identified many human sera samples that had 
>fourfold reductions in HAI titer using pH1N1 viruses with the K166Q HA mutation, 
and it is worth noting that these results would likely have been missed if we pooled 
human sera samples or simply compared overall geometric means of HAI data with 
mutant viruses. 
 We attempted to recapitulate K166 HA-specific immunity in ferrets by 
sequentially infecting with sH1N1 strains and the A/California/07/2009 pH1N1 strain. 
Only three of eight ferrets sequentially infected with A/Chile/01/1983 and 
A/California/07/2009 mounted levels of K166 HA-specific Abs that could be detected by 
HAI assays. Outbred ferrets were used in these experiments, and the overall percentage 
of ferrets with K166 HA-specificity (Fig. 13) is similar to the overall percentage of 
humans born in the 1970s with K166 HA-specificity (Fig. 8A). We speculate that 
78	  
variation in K166 HA-specificity in humans is due to variations in pre-exposure histories 
and genetic differences that impact B-cell repertoires.  
 Our results offer a possible antigenic explanation for the increased disease burden 
observed in middle-aged adults during the 2013–2014 influenza season. Given that the 
specificity of Ab responses is altered by pre-exposure history, we propose that 
conventional serological techniques used to identify antigenically novel viruses should be 
reevaluated. The usefulness of arbitrary HAI titer cutoffs and dependence on antisera 
generated in previously naïve ferrets (Koel et al., 2013; Smith et al., 2004) should be 
reconsidered. Although we believe that the pH1N1 vaccine should be updated 
immediately to a more recent strain (one that possesses HA Q166, similar to A/South 
Africa/3626/2013), it is not clear if a pH1N1 vaccine strain with Q166 HA will be able to 
break the original antigenic sin that currently exists in some middle-aged individuals. 
Further studies should be designed to determine if an updated H1N1 vaccine strain with 
Q166 HA elicits more effective Ab responses in different aged humans with distinct 
sH1N1 exposure histories. 
 
MATERIALS AND METHODS 
Human Donors  
Studies involving human adults were approved by the Institutional Review Boards 
of Emory University, Vaccine and Gene Therapy Institute of Florida, the National 
Institute of Respiratory Diseases of Mexico, and the Wistar Institute. Informed consent 
was obtained. For all experiments, HAI and in vitro neutralization assays were completed 
at the Wistar Institute using preexisting and de-identified sera. We analyzed several sera 
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panels in this study. We analyzed sera from healthy donors collected at the New York 
Blood Center in February of 2014. We analyzed sera from healthy donors collected at the 
Center for Research in Infectious Diseases at the National Institute of Respiratory 
Diseases in Mexico. We analyzed sera and mAbs derived from healthy donors vaccinated 
with a monovalent pH1N1 vaccine in 2009 as previously described (Li et al., 2012). We 
analyzed sera collected from middle-aged adults (born 1977-1985) vaccinated with 
A/California/7/2009 at the Vaccine and Gene Therapy Institute of Florida (VGTI) during 
the 2013-2014 influenza season. 
 
Viruses 
 Viruses possessing WT pH1N1 HA or K166Q pH1N1 HA were generated via 
reverse-genetics using HA and NA genes from A/California/07/2009 and internal genes 
from PR8. All of these viruses were engineered to possess the antigenically neutral 
D225G HA mutation (Chen et al., 2010a), which facilitates viral growth in fertilized 
chicken eggs. Viruses were grown in fertilized chicken eggs and the HA genes of each 
virus stock were sequenced to verify that additional mutations did not arise during 
propagation. sH1N1 strains (A/USSR/90/1977, A/Chile/01/1983, A/Singapore/06/1986, 
A/Texas/36/1991, A/New Caledonia/20/1999, and A/Solomon Islands/03/2006) were 
also grown in fertilized chicken eggs. We isolated a pH1N1 virus from respiratory 
secretions obtained from a patient from the Children’s Hospital of Philadelphia in 2013 
(named A/CHOP/1/2013 in this report). For this process, de-identified clinical material 
from the Children’s Hospital of Philadelphia Clinical Virology Laboratory was added to 
Madin-Darby canine kidney (MDCK) cells (originally obtained from the National 
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Institutes of Health) in serum-free media with L-(tosylamido-2-phenyl) ethyl 
chloromethyl ketone (TPCK)-treated trypsin, HEPES, and gentamicin. Virus was isolated 
from the MDCK-infected cells 3 d later. We extracted viral RNA and sequenced the HA 
gene of A/CHOP/1/2013. We also used reverse-genetics to introduce glycosylation sites 
into A/California/07/2009 (pH1N1) HA. The consensus sequence for N-linked 
glycosylation (N-x-S/T) was added at HA residues 129, 131, and 163 by making the 
mutations D131T, D131N and N133T, and K163N, respectively. Similar results were 
obtained in HAI assays when we used glycosylation mutants grown in eggs or MDCK 
cells. Glycosylation at HA residues 129 and 131 was confirmed by treating concentrated 
virus with PNGase-F (New England Biolabs) under denaturing conditions. The CM1-4 
anti-HA1 antibody was used as a primary antibody, and a donkey anti-mouse fluorescent 
secondary antibody (Licor) was used. Blots were imaged using the Licor Odyssey 
imaging system at 800nm (secondary antibody) and 700 nm (molecular weight marker). 
 
Candidate Vaccine Strains 
The HA genes of A/California/7/2009 WT and A/CHOP/1/2013 WT were cloned 
into the reverse genetics vector pHW2000. Site-directed mutagenesis was then used to 
generate both the A/California/7/2009 X-179A (Cal X-179A) and A/South 
Africa/3626/2013 X-243 (S.A. X-243) egg-adapted vaccine strain HA gene sequences. 
K212T and Q226R were inserted into the A/California/7/2009 WT HA to generate Cal 
X-179A HA. Likewise, D131E and L697V were inserted into the A/CHOP/1/2013 WT 
HA to generate S.A. X-243 HA. Reverse genetics were then used to rescue virus by 
transfecting a co-culture of 293T and MDCK cells with the Cal X-179A or S.A. X-243 
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HA genes along with the neuraminidase (NA) gene from A/California/07/2009 and the 
six internal influenza genes from PR8. Rescued virus was expanded in eggs one time and 
then sequence confirmed. 
 
Animal Experiments 
 Murine experiments were performed at the Wistar Institute according to protocols 
approved by the Wistar Institute Institutional Animal Care and Use Committee. BALB/c 
mice (Charles River Laboratories) were injected with 25 µg of mAb intraperitoneally and 
then infected intranasally with 20,000 TCID50 of WT or K166Q-HA pH1N1 virus 12 h 
later. As controls, some mice received an intraperitoneal injection of PBS before 
infection. Weight loss and survival was recorded for 11 days. Severely sick mice were 
euthanized. Ferret experiments were performed at VGTI in accordance with the National 
Research Council’s Guide for the Care and Use of Laboratory Animals, the Animal 
Welfare Act, and the CDC/NIH Biosafety in Microbiological and Biomedical 
Laboratories handbook. Fitch ferrets (Marshall Farms) were infected with 1×106 PFU of 
sH1N1 virus and bled 14 and 84 d later. These ferrets were then infected with the 
A/California/07/2009 pH1N1 strain and bled 14 d later. Some ferrets were sequentially 
infected with A/California/07/2009 (84 d between infections) and other ferrets were 
infected with A/California/07/2009 only once and bled 14 d later. 
 
HAI Assays 
 Sera samples were pretreated with receptor-destroying enzyme (RDE, Key 
Scientific Products or Sigma-Aldrich) and HAI titrations were performed in 96-well 
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round-bottom plates (BD). Sera were serially diluted twofold and added to four 
agglutinating doses of virus in a total volume of 100 µL. Turkey red blood cells (RBCs, 
Lampire) were added [12.5 µL of a 2% (vol/vol) solution]. The RBCs were gently mixed 
with sera and virus and agglutination was read out after incubating for 60 min at room 
temperature. HAI titers were expressed as the inverse of the highest dilution that inhibited 
four agglutinating doses of turkey RBCs. Each HAI assay was performed independently 
on three different dates. Sera that had at least twofold reduced HAI titers using K166Q 
HA mutant viruses in three independent HAI assays were labeled as “K166 HA-specific.” 
For the HAI assays to compare the vaccine strains, sera that had at least a twofold 
reduction in HAI titer against S.A. X-243 in three separate experiments were counted as 
specific for Cal X-179A. 
 
ELISA Assays 
 Viruses for ELISAs were concentrated by centrifugation at 20,000 RPM for 1 h 
using a Thermo Scientific Sorvall WX Ultra 80 Centrifuge with a Beckman SW28 rotor. 
Concentrated viruses were then inactivated by beta-propiolactone (BPL; Sigma Aldrich) 
treatment. Viruses were incubated with 0.1% BPL and 0.1M HEPES (Cellgro) overnight 
at 4°C followed by a 90 min incubation at 37 °C. The 96-well Immulon 4HBX flat-
bottom microtiter plates (Fisher Scientific) were coated with 20 HAU of BPL-treated 
virus per well overnight at 4°C. Each human mAb was serially diluted in PBS and added 
to the ELISA plates and allowed to incubate for 2 h at room temperature. As a control, 
we added the 70-1C04 stalk-specific mAb to verify equal coating of WT and K166Q HA 
virus. Next, peroxidase-conjugated goat anti-human IgG (Jackson Immunoresearch) was 
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incubated for 1 h at room temperature. Finally, SureBlue TMB Peroxidase Substrate 
(KPL) was added to each well and the reaction was stopped with addition of 250 mM 
HCl solution. Plates were extensively washed with distilled water between each ELISA 
step. Affinities were determined by nonlinear regression analysis of curves of six mAb 
dilutions (18 µg/mL to 74 ng/mL) using Graphpad Prism. mAbs were designated as K166 
HA-specific if they had a Kd at least four times greater for the K166Q mutant than for the 
WT virus. 
 
In Vitro Neutralization Assays 
 Sera were serially diluted twofold and then added to 100 TCID50 units of virus 
and incubated at room temperature for 30 min. The virus-sera mixtures were then 
incubated with MDCK cells for 1 h at 37°C. Cells were washed and then serum-free 
media with TPCK-treated trypsin, HEPES, and gentamicin was added. Endpoints were 
determined visually 3 d later. Data are expressed as the inverse of the highest dilution that 
caused neutralization. All samples were repeated in quadruplicate and geometric mean 
titer is reported. 
 
Receptor Binding Avidity Assays 
Turkey RBCs (Lampire) were pretreated with various concentrations of α2-3,6,8 
neuraminidase (NEB) for 60 min at 37°C. The treated RBCs were washed two times with 
PBS and added (as 1% v/v solutions) to eight agglutinating does of each virus 
(determined using non-treated turkey RBCs). Hemagglutination was measured after 60 
min and receptor binding avidities were reported as the maximum concentration of 
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neuraminidase (units/mL) that still allows for full hemagglutination. Assay was 
completed three independent times.  
 
Structural Modeling of HA Glycosylation Sites  
Glycans were modeled onto positions 129 and 131 in the A/Solomon 
Islands/03/2006 HA crystal structure (PDB entry 3SM5) using the GLYCAM Web 
Glycoprotein Builder (www.glycam.org). The particular glycan used for modeling was an 
N-linked glycan with a trimannosyl core (DManpa1-6[DGlcpNAcb1-2DManpa1-
3]DManpb1-4DGlcpNAcb1- 4DGlcpNAcb1-OH in Glycam notation), and default 
rotamer settings were used for modeling. To model the 131-glycosylation site, a T131N 
mutation was introduced using the PyMol structure viewer before the structure was 
uploaded to the GLYCAM-Web server.  
 
Computational and Phylogenetic Analyses of HA Sequences  
 The occurrence of different amino acid identities at HA residues 166, 156, 157, 
and 158 (H3 numbering) was analyzed by downloading all full-length human pH1N1 
sequences present in the Influenza Virus Resource (Bao et al., 2008) as of February 23, 
2014. After purging sequences that were less than full-length, contained ambiguous 
nucleotide identities, lacked full (year, month, day) isolation dates, or were otherwise 
anomalous, the sequences were aligned. Each calendar year was broken into four equal 
partitions beginning with January 1, and the frequencies of different amino acids at each 
residue of interest for each partition was calculated and plotted. Only amino acids that 
reached a frequency of at least 1% in at least one of the year partitions are labeled in the 
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legend to the plot. For construction of phylogenetic trees, the sequence set was randomly 
subsampled to 10 sequences per quarter-year partition. BEAST (Drummond et al., 2012) 
was then used to sample from the posterior distribution of phylogenetic trees with 
reconstructed sequences at the nodes, after date stamping the sequences, using a Jones, 
Taylor, and Thornton (JTT) matrix (Jones et al., 1992) with a single rate category with an 
exponential prior, a strict molecular clock, and relatively uninformative coalescent-based 
prior over the tree. Fig. 7C shows a maximum clade credibility summary of the posterior 
distribution with branches colored according to the reconstructed amino acid identity at 
HA residue 166 with the highest posterior probability at their descendent nodes. The tree 
was visually rendered using FigTree. The input data and computer code used for this 
analysis can be found on GitHub at github.com/jbloom/pdmH1N1_ 
HA_K166_mutations. 
 
Statistical Analyses  
For all serum experiments, we excluded samples that did not have positive 
pH1N1 HAI titers. All samples that were pH1N1 HA-WT HAI-negative were also 
pH1N1 HA-K166Q HAI-negative. Samples were allocated to specific groups based on 
age of donor. The year of birth of each sample was available during the experiment, but 
this information was not assessed until after each experiment was completed. Variance of 
raw HAI titers was similar between different age groups. Fisher’s exact tests were 
completed using SAS v9.3 software. For the receptor binding avidity assay, mean and 
standard error were calculated. A paired, two-tailed t-test was performed using SAS v9.3 
software to determine significance.  
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Figure 6. Sequence variation of pH1N1 HA.  
The residues in the dominant antigenic site recognized by Abs elicited in previously 
naïve ferrets infected once with the A/California/07/2009 WT vaccine strain (HA 
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Fig. S1. Sequence variation of pH1N1 HA. The residues in the dominant antigenic site recognized by primary ferret anti-sera (residues 156, 157, and 158 of the
Sa antigenic site) are highly conserved in pH1N1 (A–C). No variation greater than 1% occurred at residue 156 and very little variation occurred at residues 157
and 158. For comparison, residue 166 (D; also shown in Fig. 1B) has undergone a complete change in the last year.
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residues 156, 157, and 158 of the Sa antigenic site) are highly conserved in recent pH1N1 
viruses (A–C). No variation greater than 1% has occurred at HA residue 156 and very 
little variation has occurred at HA residues 157 and 158. For comparison, HA residue 166 
(D; also shown in Fig. 7B) underwent a complete change during the 2013-2014 influenza 
season. 
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Figure 7 
Figure 7. pH1N1 viruses rapidly acquired the K166Q HA mutation during the 2013-
2014 influenza season.  
(A) Residue K166 (red) is shown on the A/California/04/2009 HA trimer [PDB entry 
3UBN (Xu et al., 2010)]. (B) Plotted is the frequency of different amino acid identities at 
HA residue 166 in pH1N1 HA sequences as a function of time. Nearly all pH1N1 isolates 
possessed K166 from 2009 to mid-2012, but most isolates possessed Q166 by the 2013–
2014 season. (C) A phylogenetic tree of pH1N1 viruses with branches colored according 
to amino acid identity at residue 166 illustrates the rapid fixation of K166Q in pH1N1 
isolates that circulated in 2013. 
sequentially infected with sH1N1 and pH1N1 viruses mount Ab
responses dominated against epitopes that are conserved be-
tween the viral strains (14). These studies indicate that primary
ferret antisera may not be fully representative of human in-
fluenza immunity.
It has been proposed that increased morbidity and mortality of
middle-aged adults during the 2013–2014 influenza season is
primarily a result of low vaccination rates within these pop-
ulations (27). An alternative explanation is that recent pH1N1
strains have acquired a true antigenic mutation that has been
mislabeled as “antigenically neutral” by assays that rely on pri-
mary ferret antisera. Here we complete a series of experiments
to determine if recent pH1N1 strains possess a mutation that
prevents binding of Abs in middle-aged humans who have been
previously exposed to different H1N1 strains.
Results
Recent pH1N1 Strains Possess a Mutation That Prevents Binding of
Human Antibodies. Antisera isolated from ferrets recovering from
primary pH1N1 infections are highly specific for an epitope in-
volving residues 156, 157, and 158 of the Sa HA antigenic site
(14, 15). Very few pH1N1 isolates possess mutations in these Sa
residues (Fig. S1); however, pH1N1 viruses recently acquired
a K166Q HA mutation, which is located at the interface of the
Sa/Ca (28) antigenic sites (Fig. 1A). The K166Q HA mutation
first arose during the 2012–2013 season and is now present
in over 99% of pH1N1 isolates (Fig. 1 B and C). Based on
experiments using primary antisera isolated from infected fer-
rets, surveillance laboratories have reported that pH1N1 viruses
with the K166Q HA mutation are antigenically indistinguishable
from the A/California/7/2009 pH1N1 vaccine strain (9).
To address if human Abs are capable of recognizing pH1N1
viruses with the K166Q HA mutation, we performed hemag-
glutination-inhibition (HAI) assays using sera from healthy
humans collected during the 2013–2014 influenza season in
the United States. Remarkably, 27% of sera from individuals
born between 1940 and 1984 possessed Abs specific for an epi-
tope involving K166 (Fig. 2A and Table S1). Over 42% of indi-
viduals born from 1965 to 1979 had K166 HA-specific Abs in
their sera (n = 54 individuals). Sera isolated from individuals
born between 1985 and 1997 (n = 49 individuals) did not have
detectable levels of K166 HA-specific Abs. Differences in K166
HA-specificity were statistically significant between sera iso-
lated from individuals born between 1965 and 1979 and indi-
viduals born after 1985 (Fisher’s exact test; P < 0.0001). Similar
results were obtained when we analyzed sera from healthy
humans collected during the 2013–2014 influenza season in
Mexico (Fig. S2 and Table S2).
It is remarkable that HAI assays, which are relatively in-
sensitive, were able to reproducibly detect K166-specific Abs in so
many individuals in our experiments. Fig. 2A and Fig. S2 show
percentages of donors that had at least a twofold reduction in HAI
titer using the K166Q HA mutant virus in three independent
assays. It is worth pointing out that many sera samples had over
fourfold reduced HAI titers using a pH1N1 virus engineered to
possess the single K166Q HAmutation compared with the pH1N1
vaccine strain (Table S1). Age-related differences in K166 HA-
specificity among United States donors remained statistically sig-
nificant using a fourfold reduction in HAI titer as a cut-off
(Fisher’s exact test; P < 0.05 comparing donors born between 1965
and 1979 and individuals born after 1985). Sera that had K166
HA-specificity based on HAI assays failed to efficiently neutralize
K166Q-possessing viruses in in vitro neutralization assays (Table
S3). K166 HA-specific sera were also unable to recognize a pri-
mary viral isolate collected in 2013 (A/CHOP/1/2013) that pos-
sesses a K166Q HA mutation (Table S3).
The K166 Epitope Is Shielded by a Glycosylation Site Present in sH1N1
Viruses Circulating After 1985. Original antigenic sin Abs are
originally primed by influenza strains that circulated in the past (14,
17, 18, 22, 29). We propose that K166 HA-specific Ab responses
were likely primed by sH1N1 viruses circulating in humans before
1985 and then boosted by the 2009 pH1N1 virus. Sera isolated from
individuals born between 1965 and 1979 had the highest K166 HA-
specificity (both in percent and titer) (Fig. 2A and Table S1). sH1N1
viruses that circulated in the late 1970s and early 1980s share ex-
tensive homology with pH1N1 viruses in the vicinity of K166 (Fig.
2B). sH1N1 viruses were absent from the human population from
1957 to 1976 and began infecting humans again in 1977. Therefore,
humans born between 1957 and 1976 likely had their first H1N1
encounter with a sH1N1 virus that shared homology with pH1N1
viruses in the vicinity of K166.
In 1986, sH1N1 viruses acquired a new glycosylation site at
HA amino acid 129 that is predicted to shield the epitope in-
volving K166 (Figs. S3 and S4). The absence of K166 HA-
specific responses in individuals born after 1985 is likely because
sH1N1 viruses glycosylated at HA amino acid 129 fail to prime
K166 HA-specific responses. The lower number of K166 HA-
specific responders born in the 1950s might also be attributed to
unique glycosylation sites in sH1N1 viruses that circulated during
this time period (Fig. S3), although precise glycosylation statuses
of viruses circulating before 1977 are uncertain because of lim-
ited numbers of sequenced viruses. Although we did not examine
sera from very elderly individuals, it is possible that they also
have immunodominant K166 HA-specific responses, because
a recent study reported that a mAb isolated from a survivor of
the 1918 H1N1 pandemic binds to pH1N1 in an epitope in-
volving K166 (6). There is considerable homology between the
1918 H1N1 and the 2009 H1N1 in the vicinity of K166 (6).
To experimentally address if glycosylation sites present in pre-
vious sH1N1 strains shield the epitope involving K166, we used
reverse-genetics to produce pH1N1 viruses that had glycosylation
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Fig. 1. pH1N1 viruses rapidly acquired HA mutation K166Q during the
2013–2014 influenza season. (A) Residue K166 (red) is shown on the
A/California/04/2009 HA trimer [PDB ID code 3UBN (6)]. (B) Plotted is the fre-
quency of different amino acid identities at HA residue 166 in pH1N1 HA
sequences as a function of time. Nearly all pH1N1 possessed K166 from 2009
to mid-2012, but most isolates possessed Q166 by the 2013–2014 season. (C)
A phylogenetic tree of pH1N1 viruses with branches colored according to
amino acid identity at site 166 illustrates the rapid fixation of K166Q in re-
cent pH1N1 isolates.
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Figure 8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
sites that were either present in sH1N1 strains from 1977 to 1985
(sites 131+163) or 1986–2008 (sites 129+163). Western blot analysis
revealed that residues 129 and 131, but not residue 163, were gly-
cosylated in our reverse-genetics derived viruses (Fig. S4B). Con-
sistent with the hypothesis that the K166 epitope is shielded by
glycosylation sites present in 1986–2008 sH1N1 viruses, K166 HA-
specific human sera had reduced titers to pH1N1 viruses with the
129 glycosylation site but normal titers to pH1N1 viruses with the
131 glycosylation site (Fig. S4C). As a control, we also completed
HAI assays with sera from donors that were born in the 1970s who
did not have detectable levels of K166 HA-specific sera Abs. As
expected, these sera did not have reduced titers to pH1N1 viruses
with the 129 glycosylation site, but interestingly, these sera did have
reduced titers to pH1N1 viruses with the 131 glycosylation site (Fig.
S4C). We previously demonstrated that Ab responses focused on an
epitope near the 131 glycosylation site can be elicited by sequential
infections with a sH1N1 virus from the early 1990s and the pH1N1
virus (14). We speculate that donors in the “non-K166 HA-specific”
group were previously infected with antigenically distinct
sH1N1 strains compared with donors in the K166 HA-specific
group (ie: A/Singapore/06/1986-like strain vs. A/Chile/01/1983-like
strain). Taken together, these data suggest that glycosylation
sites on previously circulating sH1N1 viruses shield epitopes
and influence the development of subsequent Ab responses
against pH1N1 virus.
Vaccination with Current pH1N1 Vaccine Strain Elicits K166 HA-
Specific Abs. The pH1N1 vaccine strain has not been updated
since 2009. We determined whether this vaccine strain, which
possesses an HA that has K166, elicits K166 HA-specific Abs in
humans. First, we analyzed sera from individuals vaccinated in
2009. All of the individuals in this cohort were born before 1984
and most did not have pH1N1 Ab titers before vaccination
(Table S4). Sera from 5 of 17 individuals possessed detectable
levels of K166 HA-specific Abs following vaccination (Fig. 3A
and Table S4). Sera from all five of these individuals had <1:40
HAI titers against the K166Q HA mutant pH1N1 virus (Table
S4). One K166 HA-specific individual (subject #1) possessed
K166 HA-specific Abs before vaccination (Fig. 3A and Table
S4). It is possible that this individual was naturally infected with
pH1N1 before vaccination. All of the K166 HA-specific donors
had detectable prevaccination Ab titers against sH1N1 viruses
from 1977 and 1983; however, we also found titers against these
strains in some donors that did not have detectable levels of
K166 HA-specific serum Abs (Table S4). We also measured
binding of 42 HA head-specific mAbs isolated from 12 adult
donors (born 1949–1985) that were vaccinated against the
pH1N1 strain in 2009. Strikingly, 23% of these mAbs had re-
duced binding to pH1N1 engineered to have the K166Q muta-
tion (Fig. 3B). This finding is consistent with a previous report
that identified several K166 HA-specific mAbs derived from
a donor that was born before 1977 (30).
We passively transferred a K166 HA-specific mAb (SFV009-
3F05) or a control mAb that binds equally to WT and K166Q-HA
pH1N1 viruses (SFV015-1F02) to BALB/c mice 12 h before
infecting with a lethal dose of WT or K166Q-HA pH1N1 viruses.
Control animals that did not receive a mAb before infection
rapidly lost weight and died or needed to be euthanized (Fig.
3C). Mice receiving the control SFV015-1F02 mAb before in-
fection with WT or K166Q-HA pH1N1 viruses all survived with
minimal weight loss (Fig. 3C). Mice receiving the K166 HA-specific
SFV009-3F05 mAb survived following infection with WT pH1N1
but rapidly lost weight and died or needed to be euthanized fol-
lowing infection with K166Q-HA pH1N1 (Fig. 3C). These data
suggest that K166 HA-specific Abs can be less efficient at pre-
venting disease in a mouse model following infection with a
pH1N1 virus possessing K166Q HA.
Can K166 HA-Specific Immunity Be Recapitulated in Ferrets for
Surveillance Purposes? Current surveillance efforts rely heavily
on antisera isolated from ferrets recovering from primary in-
fluenza virus infections. Ferret antisera could potentially be
more reflective of human immunity if isolated from animals
sequentially infected with antigenically distinct viral strains.
We attempted to elicit K166 HA-specific Abs in ferrets by
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Fig. 2. Adult humans possess Abs that bind to a region of HA that was
recently mutated in pH1N1. (A) Sera were isolated from healthy donors (n =
195) from the state of New York during the 2013–2014 influenza season. HAI
assays were performed using viruses with either WT A/California/07/2009 HA
or A/California/07/2009 HA with a K166Q HAmutation. For each sera sample,
we completed three independent HAI assays. Raw HAI data are reported in
Table S1. Percentages of samples that had at least a twofold reduction in HAI
titer using the mutant virus in three independent experiments are shown.
K166-specificity of sera from individuals born between 1965 and 1979 is
statistically significant compared with K166-specificity of sera from individ-
uals born after 1985 (Fisher’s exact test; *P < 0.0001). (B) Homology between
the A/Chile/01/1983 sH1 and the A/California/04/2009 pH1 are shown using
the crystal structure of the A/California/04/2009 HA [PDB ID code 3UBN (6)].
Residue K166 is colored green. Amino acids that differ between A/Chile/01/
1983 and A/California/04/2009 are shown in red. The glycan receptor is
shown in black.
15800 | www.pnas.org/cgi/doi/10.1073/pnas.1409171111 Linderman et al.
A 
B 
90	  
Figure 8. Middle-aged adults possess Abs that bind to a region of HA that became 
mutated in pH1N1 viruses during the 2013-2014 influenza season.  
(A) Sera were isolated from healthy donors (n = 195) from the state of New York during 
the 2013–2014 influenza season. HAI assays were performed using viruses with either 
WT A/California/07/2009 HA or A/California/07/2009 HA with a K166Q HA mutation. 
For each sera sample, we completed three independent HAI assays. Raw HAI data are 
reported in Table 9. Percentages of samples that had at least a twofold reduction in HAI 
titer against the mutant virus in three independent experiments are shown. K166 HA-
specificity of sera from individuals born between 1965 and 1979 is statistically 
significant compared with K166 HA-specificity of sera from individuals born after 1985 
(Fisher’s exact test; *P < 0.0001). (B) Homology between the A/Chile/01/1983 sH1 and 
the A/California/04/2009 pH1 are shown using the crystal structure of the 
A/California/04/2009 HA [PDB entry 3UBN (Xu et al., 2010)]. Residue K166 is colored 
green. Amino acids that differ between A/Chile/01/1983 and A/California/04/2009 are 
shown in red. The glycan receptor is shown in black. 
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Figure 9.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Mexican donors born before 1985 possess Abs that bind to the region of 
HA that became mutated in pH1N1 viruses during the 2013-2014 influenza season.  
Sera were isolated from healthy donors (n = 45) at the Center for Research in Infectious 
Diseases at the National Institute of Respiratory Diseases in Mexico during the 2013–
2014 influenza season. HAI assays were performed using viruses with either WT 
A/California/07/2009 HA or A/California/07/2009 HA with a K166Q HA mutation. For 
each sera sample, we completed three independent HAI assays. Raw HAI data are 
reported in Table 10. Percentages of samples that had at least a twofold reduction in HAI 
titer using the mutant virus in three independent experiments are shown. (Fisher’s exact 
test; *P < 0.05). 
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Fig. S2. Mexican donors born before 1985 possess Abs that bind to the region of HA that was recently mutated in pH1N1. Sera were isolated from healthy
donors (n = 45) at the Center for Research in Infectious Diseases at the National Institute of Respiratory Diseases in Mexico during the 2013–2014 influenza
season. HAI assays were performed using viruses with either WT A/California/07/2009 HA or A/California/07/2009 HA with a K166Q HA mutation. For each sera
sample, we completed three independent HAI assays. Raw HAI data are reported in Table S2. Percentages of samples that had at least a twofold reduction in
HAI titer using the mutant virus in three independent experiments are shown. (Fisher’s exact test; *P < 0.05).
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Fig. S3. Glycosylation status of H1N1 viruses. The crystal structures of sH1N1 (A) and pH1N1 (B) HAs are shown (PDB ID codes 3SM5 and 3UBN). Glycosylation
sites that have appeared from 1918 to 2008 in sH1N1 viruses are highlighted in orange and residue 166 is shown in green. (C) Glycosylation status of H1N1
viruses circulating during different time periods is shown as reported in Wei et al. (1). Very few viral sequences are available for 1930–1950 viruses and
variability of glycosylation sites in these viruses likely relates to egg adaptations. The majority of sH1N1 viruses circulating between 1977 and 1985 have the 131
and 163 glycosylation sites and the majority of sH1N1 viruses circulating between 1986 and 2008 have the 129 and 163 glycosylation sites. Of note, although
residues 129 and 131 are very close in the linear sequence, they are located on opposite sides of the Sa/Sb ridge. The 131 glycosylation site is not expected to
cover the K166 epitope, whereas the 129 glycosylation site potentially shields the K166 epitope.
1. Wei CJ, et al. (2010) Cross-neutralization of 1918 and 2009 influenza viruses: Role of glycans in viral evolution and vaccine design. Sci Transl Med 2(24):24ra21.
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Figure 10 
 
Figure 10. Glycosylation status of various H1N1 viruses.  
The crystal structures of sH1N1 (A) and pH1N1 (B) HAs are shown (PDB entries 3SM5 
and 3UBN). Glycosylation sites that have appeared from 1918 to 2008 in sH1N1 viruses 
are highlighted in orange and residue 166 is shown in green. (C) Glycosylation status of 
H1N1 viruses circulating during different time periods is shown as reported previously 
(Wei et al., 2010). Very few viral sequences are available for 1930–1950 viruses and 
variability of glycosylation sites in these viruses likely relates to egg adaptations. The 
majority of sH1N1 viruses circulating between 1977 and 1985 have the 131- and 163-
glycosylation sites and the majority of sH1N1 viruses circulating between 1986 and 2008 
have the 129- and 163-glycosylation sites. Of note, although HA residues 129 and 131 
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Fig. S2. Mexican donors born before 1985 possess Abs that bind to the region of HA that was recently mutated in pH1N1. Sera were isolated from healthy
donors (n = 45) at the Center for Research in Infectious Diseases at the National Institute of Respiratory Diseases in Mexico during the 2013–2014 influenza
season. HAI assays were performed using viruses with either WT A/California/07/2009 HA or A/California/07/2009 HA with a K166Q HA mutation. For each sera
sample, we completed three independent HAI assays. Raw HAI data are reported in Table S2. Percentages of samples that had at least a twofold reduction in
HAI titer using the mutant virus in three independent experiments are shown. (Fisher’s exact test; *P < 0.05).
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Fig. S3. Glycosylation status of H1N1 viruses. The crystal structures of sH1N1 (A) and pH1N1 (B) HAs are shown (PDB ID codes 3SM5 and 3UBN). Glycosylation
sites that have appeared from 1918 to 2008 in sH1N1 viruses are highlighted in orange and residue 166 is shown in green. (C) Glycosylation status of H1N1
viruses circulating during different time periods is shown as reported in Wei et al. (1). Very few viral sequences are available for 1930–1950 viruses and
variability of glycosylation sites in these viruses likely relates to egg adaptations. The majority of sH1N1 viruses circulating between 1977 and 1985 have the 131
and 163 glycosylation sites and the majority of sH1N1 viruses circulating between 1986 and 2008 have the 129 and 163 glycosylation sites. Of note, although
residues 129 and 131 are very close in the linear sequence, they are located on opposite sides of the Sa/Sb ridge. The 131 glycosylation site is not expected to
cover the K166 epitope, whereas the 129 glycosylation site potentially shields the K166 epitope.
1. Wei CJ, et al. (2010) Cross-neutralization of 1918 and 2009 influenza viruses: Role of glycans in viral evolution and vaccine design. Sci Transl Med 2(24):24ra21.
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are very close in the linear sequence, they are located on opposite sides of the Sa/Sb 
ridge. The 131-glycosylation site is not expected to cover the K166 HA-epitope, whereas 
the 129-glycosylation site potentially shields the K166 HA-epitope. 
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Figure 11 
 
Figure 11. Modeling glycosylation sites at HA residues 129 and 131.  
(A) Modeling of the putative glycosylation sites at residues 129 and 131 on the HA of 
A/Solomon Islands/6/ 2006 (PDB entry 3SM5) was completed using Glycam software. 
HA residues 129 and 131 are shown in orange and predicted sugars are shown in black. 
HA residue 166 is shown in green. The 129-glycosylation site present in most sH1N1 
isolates circulating after 1985 is predicted to shield the antigenic epitope involving HA 
residue 166. The 131-glycosylation site is not predicted to shield the antigenic epitope 
involving HA residue 166. (B) Viruses possessing A/California/07/2009 HA with 
different putative glycosylation sites were created by reverse-genetics. HA from viruses 
K166 HA-specific samples
sample # WT K166Q 131+163-GLY 129+163-GLY WT/K166Q WT/131+163-GLY WT/129+163-GLY
70-23 160 <20 120 60 >8.0 1.3 2.7
70-36 240 40 160 80 6.0 1.5 3.0
70-52 120 <20 80 <20 >6.0 1.5 >6.0
70-84 160 40 160 80 4.0 1.0 2.0
70-86 160 <20 160 60 >8.0 1.0 2.7
non-K166HA-specific samples
sample # WT K166Q 131+163-GLY 129+163-GLY WT/K166Q WT/131+163-GLY WT/129+163-GLY
70-16 160 160 160 160 1 1 1
70-17 160 160 80 160 1 2 1
70-18 160 160 60 160 1 2.7 1
70-24 160 160 <20 160 1 >8 1
70-44 160 160 40 160 1 4 1
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Fig. S4. Modeling 129 and 131 glycosylation sites. (A) Modeling of the putative glycosylation sites at residues 129 and 131 on the HA of A/Solomon Islands/6/
2006 (PDB ID code 3SM5) was completed using Glycam software (Materials and Methods). Residues 129 and 131 are shown in orange and predicted sugars
are shown in black. Residue 166 is shown in green. The 129 glycosylation site present in most sH1N1 isolates circulating after 1985 is predicted to shield
the antigenic site involving residue 166. The 131 glycosylation site is not predicted to shield the antigenic site involving residue 166. (B) Viruses possessing
A/California/07/2009 HA with different putative glycosylation sites were created by reverse-genetics. HA from viruses with putative glycosylation sites introduced
at residues 129+163 and 131+163 migrated slower compared with unmodified HA and HA from viruses with a putative glycosylation site at only residue 163.
This finding indicates that residues 129 and 131, but not residue 163 was glycosylated in the reverse-genetics derived viruses. HA from all viruses migrates
similarily following PNGase treatment. PNGase treatment was completed under reducing conditions, so HA migrated faster compared with no PNGase
treatment. (C) HAI assays wer completed using the r verse-genetics derived viruses possessing A/C lifornia/07/2009 with different glycosylation sites. Five
K166 HA-specific samples and five non-K166 HA-specific human samples were tested.
166125
Fig. S5. Homology betwen A/USSR/90/1977, A/Chile/01/1983, and A/California/07/2009. HA residues that differ between A/Chile/01/1983 and the A/California/
07/2009 are shown in red. A few additional HA residues differ between the HAs of A/USSR/90/1977 and A/California/7/2009, and these are colored yellow. Of
note, A/Chile/01/1983 and A/California/07/2009 both possess S125 whereas A/USSR/90/1977 possess R125. Residues 125 and 166 are next to each other in the
structure. PDB ID file 3UBN (A/California/04/2009 HA) was used to make this figure.
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with putative glycosylation sites introduced at HA residues 129+163 and 131+163 
migrated slower compared with unmodified HA and HA from viruses with a putative 
glycosylation site at only HA residue 163. This finding indicates that HA residues 129 
and 131, but not HA residue 163, were glycosylated in the reverse-genetics derived 
viruses. HA from all viruses migrates similarly following PNGase treatment. PNGase 
treatment was completed under reducing conditions, so HA migrated faster compared 
with no PNGase treatment. (C) HAI assays were completed using the reverse-genetics 
derived viruses possessing A/California/07/2009 with different glycosylation sites. Five 
K166 HA-specific samples and five non-K166 HA-specific human samples were tested. 
Data are representative of three independent experiments. 
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Figure 12.  
 
Figure 12. Vaccination of middle-aged adults with the current pH1N1 vaccine strain 
elicits Abs that bind to a region of HA that is now mutated in most pH1N1 isolates.  
(A) Healthy adult volunteers were vaccinated with a monovalent pH1N1 vaccine in 2009. 
Sera were isolated pre-vaccination and 30 d post-vaccination and HAI assays were 
performed using viruses with either WT A/California/07/2009 HA or 
A/California/07/2009 HA with a K166Q HA mutation. Shown are HAI titers for donors 
that possessed K166 HA-specific Abs following vaccination. Data are representative of 
three independent experiments. Raw HAI titers for all donors are shown in Table 12. (B) 
ELISAs were completed using mAbs isolated from healthy adult volunteers that were 
vaccinated with a monovalent pH1N1 vaccine in 2009. ELISAs were coated either with 
WT A/California/07/2009 or A/California/07/2009 with a K166Q HA mutation. Shown 
are percentage of mAbs that bound to both viruses and percentage of mAbs that bound to 
sequentially infecting animals with older sH1N1 strains and then
the A/California/07/2009 pH1N1 strain.
We initially infected animals with a sH1N1 virus that circu-
lated in 1977 (A/USSR/90/1977), a sH1N1 virus that circulated
in 1983 (A/Chile/01/1983), or a sH1N1 virus that circulated in
1986 (A/Singapore/06/1986). After 84 d, we reinfected ani-
mals with the A/California/07/2009 pH1N1 strain. As controls,
we infected some animals twice with A/California/07/2009 and
other animals only once with A/California/07/2009. Three of
eight of the ferrets sequentially infected with A/Chile/01/1983
and A/California/07/2009 mounted K166 HA-specific Abs de-
tectable in HAI assays (Fig. 4 and Table S5). The 22 ferrets in
the other experimental groups did not mount detectable levels
of K166 HA-specific Abs. The difference in K166 HA-specificity
is statistically significant comparing the A/Chile/01/1983-A/
California/07/2009 group with the rest of the groups (3 of 8 vs.
0 of 22; Fisher’s exact test P < 0.05). K166 HA-specific Abs were
likely not elicited in the A/Singapore/06/1986-A/California/07/
2009 group because the K166 HA epitope is predicted to be
shielded by a glycosylation site at residue 129 of A/Singapore/06/
1986 (Fig. S4). It is interesting that K166 HA-specific Abs were
not elicited by A/USSR/90/1977-A/California/07/2009 sequential
infections. This result is likely because of variation at residue
125, which is close to residue 166 (Fig. S5). A/Chile/01/1983 and
A/California/07/2009 both possess S125, whereas A/USSR/01/
1977 possesses R125 (Fig. S5).
Discussion
Our studies show that recent pH1N1 viruses have acquired a
significant antigenic mutation that prevents binding of Abs eli-
cited in a large number of middle-aged humans. For this reason,
we propose that the pH1N1 vaccine strain should be updated.
Conventional serological techniques used by most surveillance
laboratories have failed to recognize the K166Q HA mutation as
antigenically important (9). HAI assays are based on serial sera
dilutions and ca only detect large antigenic changes. Many
surveillance-based laboratories ignore twofold reductions in HAI
titer because these laboratories typically process thousands of
samples, which prohibit the experimental precision that is
required to reliably detect twofold differences in these assays.
However, a true twofold reduction in HAI titer against a mu-
tated strain indicates an extremely immunodomi ant Ab re-
sponse. Although we reproducibly detected as low as twofold
HAI differences using K166Q HA mutated viruses (Tables S1
and S2 show results from three independent HAI experiments),
our HAI assays likely underestimate the number of individuals
that possess K166Q Abs. For example, we were able to isolate
K166 HA-specific mAbs from pH1N1-vaccinated individuals
whose sera yielded similar HAI titers using WT and K166Q
mutated pH1N1 viruses. We also identified many human sera
samples that had >fourfold reductions in HAI titer using pH1N1
viruses with the K166Q HA mutation, and it is worth noting that
these results would likely have been missed if we pooled human
sera samples or simply compared overall geometric means of
HAI data with mutant viruses.
We attempted to recapitulate K166 HA-specific immunity
in ferrets by sequentially infecting with sH1N1 strains and the
A/California/07/2009 pH1N1 strain. Only three of eight ferrets
sequentially infected with A/Chile/01/1983 and A/California/07/
2009 mounted levels of K166 HA-specific Abs that could be
detected by HAI assays. Outbred ferrets were used in these
experiments, and the overall percentage of ferrets with K166
HA-specificity (Fig. 4) is similar to the overall percentage of
humans born in the 1970s with K166 HA-specificity (Fig. 2A).
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Fig. 3. Vaccination of middle-aged adults with the current pH1N1 vaccine strain elicits Abs that bind to a region of HA that is now mutated in most pH1N1
isolates. (A) Healthy adult volunteers were vaccinated with a monovalent pH1N1 vaccine in 2009. Sera were isolated prevaccination and 30 d postvaccination
and HAI assays were performed using viruses with either WT A/California/07/2009 HA or A/California/07/2009 HA with a K166Q HA mutation. Shown are HAI
titers for donors that possessed K166 HA-specific Abs following vaccination. Data are representative of three independent experiments. Raw HAI titers for all
donors are shown in Table S4. (B) ELISAs were completed using mAbs isolated from healthy adult volunteers that were vaccinated with a monovalent pH1N1
vaccine in 2009. ELISAs were coated either with A/California/07/2009 (WT) or A/California/07/2009 with a K166Q HA mutation. Shown are percentage of mAbs
that bound to both viruses and percentage of mAbs that bound to the WT virus but not the mutant virus (n = 42 mAbs). Data are representative of two
independent experiments. (C) A K166 HA-specific mAb (SFV009-3F05) or a mAb that recognizes both WT and K166Q-HA pH1N1 (SFV015-1F02) were injected
into BALB/c mice (n = 4 per group). Twelve hours later, mice were then infected with 20,000 TCID50 of WT or K166Q-HA virus and weight loss and survival
were recorded for 11 d. Data are representative of two independent experiments.
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the WT virus but not the K166Q mutant virus (n = 42 mAbs). Data are representative of 
two independent experiments. (C) A K166 HA-specific mAb (SFV009-3F05) or a mAb 
that recognizes both WT and K166Q-HA pH1N1 (SFV015-1F02) were injected into 
BALB/c mice (n = 4 per group). Twelve hours later, mice were then infected with 20,000 
TCID50 of WT or K166Q-HA virus and weight loss and survival were recorded for 11 d. 
Data are representative of two independent experiments. 
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Figure 13 
 
 
 
 
 
 
 
 
 
Figure 13. Ferrets sequentially infected with A/Chile/01/1983 and A/California/ 
07/2009 develop K166 HA-specific Abs.  
Ferrets were infected with a sH1N1 virus and then re-infected 84 d later with the 
A/California/07/2009 pH1N1 virus. Sera were collected 14 d after the second infection 
and HAI assays were completed using WT and K166Q-HA pH1N1 viruses. Shown are 
percentages of samples that had at least a twofold reduction in HAI titer using the K166Q 
HA mutant virus in three independent experiments. Raw HAI titers are shown in Table 
13. The difference in K166 HA-specificity is statistically significant comparing the 
A/Chile/01/1983-A/California/07/2009 group with the rest of the groups (3 of 8 vs. 0 of 
22; Fisher’s exact test P < 0.05). 
 
 
 
We speculate that variation in K166 HA-specificity in humans
is because of variations in pre-exposure histories and genetic
differences that impact B-cell repertoires. Studies are ongoing to
determine if genetic differences in B-cell repertoires among
ferrets influence K166 HA-specificity.
Our results offer a possible antigenic explanation for the increased
disease burden in middle-aged adults during the 2013–2014 in-
fluenza season. Given that the specificity of Ab responses is altered
by pre-exposures, we propose that conventional serological techni-
ques used to identify antigenically novel viruses should be reeval-
uated. The usefulness of arbitrary HAI titer cutoffs and dependence
on antisera generated in previously naïve ferrets (31, 32) should be
reconsidered. Although we believe that the pH1N1 vaccine should
be updated immediately, it is not clear if a pH1N1 vaccine strain
with Q166 HA will be able to break the original antigenic sin that
currently exists in some middle-aged individuals. Further studies
should be designed to determine if an updated H1N1 vaccine strain
with Q166 HA elicits more effective Ab responses in different aged
humans with distinct sH1N1 exposure histories.
Materials and Methods
Human Donors. Studies involving human adults were approved by the In-
stitutional Review Boards of Emory University, Vaccine and Gene Therapy In-
stitute of Florida, the National Institute of Respiratory Diseases of Mexico, and
theWistar Institute. Informed consentwas obtained. For all experiments, HAI and
in vitro neutralization assays were completed at the Wistar Institute using
preexisting and de-identified sera. We analyzed several sera panels in this study.
We analyzed sera fromhealthy donors collected at theNewYork BloodCenter in
February of 2014. We analyzed sera from healthy donors collected at the Center
for Research in Infectious Diseases at the National Institute of Respiratory Dis-
eases in Mexico. We analyzed sera and mAbs derived from healthy donors
vaccinatedwithamonovalentpH1N1vaccine in 2009aspreviously described (23).
Viruses. Viruses possessing WT pH1N1 HA or K166Q pH1N1 HA were gen-
erated via reverse-genetics using HA and NA genes from A/California/07/2009
and internal genes from A/Puerto Rico/08/1934. All of these viruses were
engineered to possess the antigenically neutral D225G HA mutation (15),
which facilitates viral growth in fertilized chicken eggs. Viruses were grown
in fertilized chicken eggs and the HA genes of each virus stock were se-
quenced to verify that additional mutations did not arise during propaga-
tion. sH1N1 strains (A/USSR/90/1977, A/Chile/01/1983, A/Singapore/06/
1986, A/Texas/36/1991, A/New Caledonia/20/1999, and A/Solomon Is-
lands/03/2006) were also grown in fertilized chicken eggs. We isolated
a pH1N1 virus from respiratory secretions obtained from a patient from the
Children’s Hospital of Philadelphia in 2013 (named A/CHOP/1/13 in this re-
port). For this process, de-identified clinical material from the Children’s
Hospital of Philadelphia Clinical Virology Laboratory was added to Madin-
Darby canine kidney (MDCK) cells (originally obtained from the National
Institutes of Health) in serum-free media with L-(tosylamido-2-phenyl) ethyl
chloromethyl ketone (TPCK)-treated trypsin, Hepes, and gentamicin. Virus
was isolated from the MDCK-infected cells 3 d later. We extracted viral RNA
and sequenced the HA gene of A/CHOP/1/13. We also used reverse-genetics
to introduce glycosylation sites into A/California/07/2009 (pH1N1) HA. The
consensus sequence for N-linked glycosylation (N-x-S/T) was added at HA
residues 129, 131, and 163 by making the mutations D131T, D131N and
N133T, and K163N, respectively. Similar results were obtained in HAI assays
when we used glycosylation mutants grown in eggs or MDCK cells. Glyco-
sylation at residues 129 and 131 was confirmed by treating concentrated
virus with PNGase-F (New England Biolabs) under denaturing conditions.
The CM1-4 anti-HA1 antibody was used as a primary antibody, and a donkey
anti-mouse fluorescent secondary antibody (Licor) was used. Blots were
imaged using the Licor Odyssey imaging system at 800nm (secondary anti-
body) and 700 nm (molecular weight marker).
Animal Experiments. Murine experiments were performed at the Wistar In-
stitute according to protocols approved by the Wistar Institute Institutional
Animal Care and Use Committee. BALB/cmice (Charles River Laboratories) were
injected with 25 μg of mAb intraperitoneally and then infected intranasaly
with 20,000 TCID50 of WT or K166Q-HA pH1N1 virus 12 h later. As controls,
some mice received an intraperitoneal injection of PBS before infection.
Weight loss and survival was recorded for 11 d. Severely sick mice were eu-
thanized. Ferret experiments were performed at the Vaccine and Gene Therapy
Institute of Florida in accordance with the National Research Council’s Guide for
the Care and Use of Laboratory Animals (33), the Animal Welfare Act, and the
CDC/NIH Biosafety in Microbiological and Biomedical Laboratories handbook.
Fitch ferrets (Marshall Farms) were infected with 1 × 106 PFU of sH1N1 virus and
bled 14 and 84 d later. These ferrets were then infected with the A/California/
07/2009 pH1N1 strain and bled 14 d later. Some ferrets were sequentially
infected with A/California/07/2009 (84 d between infections) and other ferrets
were infected with only A/California/07/2009 and bled 14 d later.
HAI Assays. Sera samples were pretreated with receptor-destroying enzyme
(Key Scientific Products or Sigma-Aldrich) and HAI titrations were performed
in 96-well round bottom plates (BD). Sera were serially diluted twofold and
added to four agglutinating doses of virus in a total volume of 100 μL. Turkey
erythrocytes (Lampire) were added [12.5 μL of a 2% (vol/vol) solution]. The
erythrocytes were gently mixed with sera and virus and agglutination was
read out after incubating for 60 min at room temperature. HAI titers were
expressed as the inverse of the highest dilution that inhibited four agglu-
tinating doses of turkey erythrocytes. Each HAI assay was performed in-
dependently on three different dates. Sera that had at least twofold
reduced HAI titers using K166Q HA mutant viruses in three independent HAI
assays were labeled as “K166 HA-specific.”
ELISAs. Viruses for ELISAs were concentrated by centrifugation at 20,000 RPM
for 1 h using a Thermo Scientific Sorvall WX Ultra 80 Centrifuge with
a Beckman SW28 rotor. Concentrated viruses were then inactivated by
B-Propiolactone (BPL; Sigma Aldrich) treatment. Viruses were incubated
with 0.1% BPL and 0.1M Hepes (Cellgro) overnight at 4C followed by a 90-
min incubation at 37 °C. The 96-well Immulon 4HBX flat-bottom microtiter
plates (Fisher Scientific) were coated with 20 HAU per well BPL-treated virus
overnight at 4 °C. Each human mAb was serially diluted in PBS and added to
the ELISA plates and allowed to incubate for 2 h at room temperature. As
a control, we added the 70-1C04 stalk-specific mAb to verify equal coating of
WT and K166Q HA virus. Next, peroxidase conjugated goat anti-human IgG
(Jackson Immunoresearch) was incubated for 1 h at room temperature. Finally,
Sureblue TMB Peroxidase Substrate (KPL) was added to each well and the re-
action was stopped with addition of 250 mM HCl solution. Plates were ex-
tensively washed with water between each ELISA step. Affinities were
determined by nonlinear regression analysis of curves of 6 mAb dilutions
(18 μg/mL to 74 ng/mL) using Graphpad Prism. mAbs were designated as K166-
specific if they had a Kd at least four times greater for the K166Q mutant than
for the WT virus.
In Vitro Neutralization Assays. Sera were serially diluted and then added to
100 TCID50 units of virus and incubated at room temperature for 30 min. The
virus-sera mixtures were then incubated with MDCK cells for 1 h at 37 °C.
Cells were washed and then serum-free media with TPCK-treated trypsin
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Fig. 4. Ferrets sequentially infected with A/Chile/01/1983 and A/California/
07/2009 develop K166 HA-specific Abs. Ferrets were infected with a sH1N1
virus and then reinfected 84 d later with the A/California/07/2009 pH1N1
virus. Sera were collected 14 d after the second infection and HAI assays
were completed using WT and K166Q-HA pH1N1 viruses. Shown are per-
centages of samples that had at least a twofold reduction in HAI titer using
the K166Q HA mutant virus in three independe t experiments. Ra HAI
titers are shown in Table S5. The difference in K166 HA-specificity is statis-
tically significant comparing the A/Chile/01/1983-A/California/07/2009 group
with the rest of the groups (3 of 8 vs. 0 of 22; Fisher’s exact test P < 0.05).
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Figure 14 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Homology between A/USSR/90/1977, A/Chile/01/1983, and 
A/California/07/2009.  
HA residues that differ between A/Chile/01/1983 and A/California/07/2009 are shown in 
red. A few additional HA residues differ between the HAs of A/USSR/90/1977 and 
A/California/07/2009, and these are colored yellow. Of note, A/Chile/01/1983 and 
A/California/07/2009 both possess S125 whereas A/USSR/90/1977 possess R125. HA 
residues 125 and 166 are adjacent to each other in the structure. PDB entry 3UBN 
(A/California/04/2009 HA) was used to make this figure. 
 
 
 
K166 HA-specific samples
sample # WT K166Q 131+163-GLY 129+163-GLY WT/K166Q WT/131+163-GLY WT/129+163-GLY
70-23 160 <20 120 60 >8.0 1.3 2.7
70-36 240 40 160 80 6.0 1.5 3.0
70-52 120 <20 80 <20 >6.0 1.5 >6.0
70-84 160 40 160 80 4.0 1.0 2.0
70-86 160 <20 160 60 >8.0 1.0 2.7
non-K166HA-specific samples
sample # WT K166Q 131+163-GLY 129+163-GLY WT/K166Q WT/131+163-GLY WT/129+163-GLY
70-16 160 160 160 160 1 1 1
70-17 160 160 80 160 1 2 1
70-18 160 160 60 160 1 2.7 1
70-24 160 160 <20 160 1 >8 1
70-44 160 160 40 160 1 4 1
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Fig. S4. Modeling 129 and 131 glycosylation sites. (A) Modeling of the putative glycosylation sites at residues 129 and 131 on the HA of A/Solomon Islands/6/
2006 (PDB ID code 3SM5) was completed using Glycam software (Materials and Methods). Residues 129 and 131 are shown in orange and predicted sugars
are shown in black. Residue 166 is shown in green. The 129 glycosylation site present in most sH1N1 isolates circulating after 1985 is predicted to shield
the antigenic site involving residue 166. The 131 glycosylation site is not predicted to shield the antigenic site involving residue 166. (B) Viruses possessing
A/California/07/2009 HA with different putative glycosylation sites were created by reverse-genetics. HA from viruses with putative glycosylation sites introduced
at residues 129+163 and 131+163 migrated slower compared with unmodified HA and HA from viruses with a putative glycosylation site at only residue 163.
This finding indicates that residues 129 and 131, but not residue 163 was glycosylated in the reverse-genetics derived viruses. HA from all viruses migrates
similarily following PNGase treatment. PNGase treatment was completed under reducing conditions, so HA migrated faster compared with no PNGase
treatment. (C) HAI assays were completed using the reverse-genetics derived viruses possessing A/California/07/2009 with different glycosylation sites. Five
K166 HA-specific samples and five non-K166 HA-specific human samples were tested.
166125
Fig. S5. Homology betwen A/USSR/90/1977, A/Chile/01/1983, and A/California/07/2009. HA residues that differ between A/Chile/01/1983 and the A/California/
07/2009 are shown in red. A few additional HA residues differ between the HAs of A/USSR/90/1977 and A/California/7/2009, and these are colored yellow. Of
note, A/Chile/01/1983 and A/California/07/2009 b th poss ss S125 whereas A/USSR/90/1977 possess R 25. Residues 125 and 166 are next to each other in the
structure. PDB ID file 3UBN (A/California/04/2009 HA) was used to make this figure.
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Figure 15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Vaccinated human sera demonstrate the new candidate H1N1 vaccine 
strain, A/South Africa/3626/2013, is antigenically distinct from 
A/California/07/2009. 
Sera were collected from vaccinated middle-aged adults (born 1977-1985) during the 
2013-2014 influenza season at the Vaccine and Gene Therapy Institute of Florida (n = 
20). Both (A) pre- and (B) post-vaccination HAI titers were determined against the Cal 
X-179A and S.A. X-243 vaccine strains. Displayed is the fraction of individuals who had 
titers against Cal X-179A and at least a twofold decrease in HAI titer against S.A. X-243 
Cal X-179A S.A. X-243
19.5
39.1
78.1
156.3
312.5
625
1250
2500
VirusM
ax
im
um
 N
eu
ra
m
in
id
as
e 
C
on
c.
 (U
/m
L)
 
th
at
 g
iv
es
 fu
ll 
ag
gl
ut
in
at
io
n
p=0.0535
Pre-vaccination (d0)
n=14
>2-fold reduction against A/South Africa/3626/2013
No reduction against A/South Africa/3626/2013
36%
Post-vaccination (d21)
n=19
>2-fold reduction against A/South Africa/3626/2013
No reduction against A/South Africa/3626/2013
37%
A B 
C 
101	  
in three independent experiments. (C) Relative binding avidity between the two viruses 
was determined by pre-treating turkey RBCs with different dilutions of α2-3,6,8 
neuraminidase before measuring hemagglutination. Neuraminidase concentration is 
reported as the maximum units/mL of neuraminidase that still allows for full 
hemagglutination. Mean and standard error bars are shown. The difference in receptor 
binding avidity between Cal X-179A and S.A. X-243 is insignificant following three 
independent assays (p=0.0535, paired two-tailed t-test).  
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Table 9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 9. HAI titers using sera collected from healthy human donors from the United 
States. 
Sera were isolated from 195 healthy donors from the state of New York during the 2013-
2014 influenza season. HAI assays were performed using viruses with either WT 
A/California/07/2009 HA or A/California/07/2009 HA with a K166Q HA mutation. For 
Table S1. HAI titers using sera from healthy donors from the United States
Sample ID YOB
Exp. 1 Exp. 2 Exp. 3
HAI titers Ratio HAI titers Ratio HAI titers Ratio
WT K166Q WT/K166Q WT K166Q WT/K166Q WT K166Q WT/K166Q
40–60 1940 160 80 2.00 160 80 2.00 160 60 2.67
40–49 1943 80 <20 >4.00 60 <20 >3.00 80 <20 >4.00
40–05 1948 160 80 2.00 160 80 2.00 160 80 2.00
40–02 1948 120 60 2.00 60 30 2.00 80 30 2.67
40–44 1948 320 80 4.00 320 80 4.00 320 80 4.00
40–14 1949 240 80 3.00 240 80 3.00 240 80 3.00
40–16 1949 240 <20 >12.00 160 <20 >8.00 160 <20 >8.00
50–55 1952 160 80 2.00 160 60 2.67 160 80 2.00
50–11 1952 120 40 3.00 80 30 2.67 80 30 2.67
50–43 1953 80 40 2.00 80 40 2.00 80 40 2.00
50–06 1959 120 60 2.00 80 40 2.00 80 30 2.67
60–04 1963 80 40 2.00 80 40 2.00 80 40 2.00
60–10 1963 160 80 2.00 240 80 3.00 160 60 2.67
60–13 1964 240 120 2.00 320 120 2.67 240 120 2.00
60–25 1964 60 20 3.00 80 30 2.67 60 20 3.00
60–14 1967 160 80 2.00 120 60 2.00 120 60 2.00
60–23 1967 320 120 2.67 320 160 2.00 320 160 2.00
60–44 1968 160 80 2.00 160 80 2.00 160 80 2.00
60–28 1969 320 160 2.00 320 160 2.00 320 160 2.00
60–41 1969 120 60 2.00 160 80 2.00 160 80 2.00
60–63 1969 120 60 2.00 120 60 2.00 120 60 2.00
60–35 1969 80 40 2.00 80 30 2.67 80 30 2.67
70–56 1971 80 40 2.00 80 30 2.67 80 40 2.00
70–52 1971 160 <20 >8.00 120 <20 >6.00 80 <20 >4.00
70–60 1972 160 80 2.00 160 80 2.00 160 80 2.00
70–74 1972 160 80 2.00 240 80 3.00 240 80 3.00
70–36 1972 240 60 4.00 240 30 8.00 320 30 10.67
70–84 1973 120 40 3.00 160 30 5.33 160 40 4.00
70–86 1973 160 40 4.00 160 30 5.33 160 40 4.00
70–13 1975 640 320 2.00 640 320 2.00 640 320 2.00
70–54 1975 160 80 2.00 80 30 2.67 120 60 2.00
70–25 1975 160 80 2.00 80 30 2.67 120 40 3.00
70–10 1975 160 30 5.33 80 30 2.67 80 30 2.67
70–23 1975 160 <20 >8.00 120 <20 >6.00 160 <20 >8.00
70–82 1976 160 80 2.00 160 60 2.67 160 80 2.00
70–50 1976 240 80 3.00 160 60 2.67 120 60 2.00
70–80 1978 320 160 2.00 320 160 2.00 320 160 2.00
70–19 1978 80 <20 >4.00 80 <20 >4.00 80 <20 >4.00
80–16 1980 80 30 2.67 60 20 3.00 80 40 2.00
80–48 1983 640 120 5.33 640 80 8.00 640 80 8.00
Sera were isolated from 195 healthy donors from the state of New York during the 2013–2014 influenza
season. HAI assays were performed using viruses with either WT A/California/07/2009 HA or A/California/07/2009
HA with a K166Q HA mutation. For each sera sample, we completed three independent HAI assays. Shown are
samples that had at least a twofold reduction in HAI titer using the mutant virus in three independent experi-
ments. YOB, year of birth.
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each sera sample, we completed three independent HAI assays. Shown are samples that 
had at least a twofold reduction in HAI titer using the K166Q mutant virus in all three 
independent experiments. YOB, year of birth. 
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Table 10 
 
 
 
 
Table 10. HAI titers using sera collected from healthy human donors from Mexico. 
Sera were isolated from 45 healthy donors from Mexico during the 2013-2014 influenza 
season. HAI assays were performed using viruses with either WT A/California/07/2009 
HA or A/California/07/2009 HA with a K166Q HA mutation. For each sera sample, we 
completed three independent HAI assays. Shown are samples that had at least a twofold 
reduction in HAI titer using the K166Q mutant virus in all three independent 
experiments. 
 
 
 
 
 
 
 
 
 
Table S2. HAI titers using sera from healthy donors from Mexico
Exp. 1 Exp. 2 Exp. 3
HAI titers Ratio HAI titers Ratio HAI titers Ratio
Sample ID YOB WT K166Q WT/K166Q WT K166Q WT/K166Q WT K166Q WT/K166Q
N-33 1973 160 60 2.67 120 40 3.00 80 30 2.67
N-42 1975 40 <10 >4.00 30 <10 >3.00 30 <10 >3.00
N-93 1977 120 30 4.00 60 30 2.00 60 20 3.00
N-72 1979 30 <10 >3.00 30 <10 >3.00 20 <10 >2.00
N-70 1980 160 80 2.00 120 60 2.00 120 40 3.00
Sera were isolated from 45 healthy donors from Mexico during the 2013–2014 influenza season. HAI assays
were performed using viruses with either WT A/California/07/2009 HA or A/California/07/2009 HA with a K166Q
HA mutation. For each sera sample, we completed three independent HAI assays. Shown are samples that had at
least a twofold reduction in HAI tit r using the mutant virus in three independe t experiments.
Table S3. Characterization of K166 HA-specific sera
HAI titers In vitro neutralization titers
Sample ID YOB A/CAL/07/09-WT HA A/CHOP/1/2013 A/CAL/07/09-WT HA A/CAL/07/09-K166Q HA
40–49 1943 20 <10 24 12
40–44 1948 160 30 453 95
40–16 1949 80 <10 160 20
70–52 1971 40 <10 190 28
70–36 1972 120 10 381 95
70–84 1973 40 <10 160 57
70–86 1973 60 20 190 67
70–23 1975 80 <10 226 20
70–19 1978 30 <10 95 10
80–48 1983 320 30 1,076 80
80–10 1986 160 160 761 1,810
80–26 1986 80 80 113 160
80–74 1986 40 40 135 113
80–30 1987 20 10 67 113
80–34 1987 160 160 381 538
80–56 1988 20 <10 17 34
90–01 1990 40 10 48 80
90–24 1991 60 20 34 95
90–12 1992 160 60 190 226
90–13 1992 80 80 190 320
We further characterized several sera samples that had immunodominant K166 HA-specific Abs (light gray:
K166 HA-specific sera from individuals born before 1985; darker gray: sera from individuals born after 1985). HAI
assays were completed using viruses with the A/California/07/2009 HA-WT and a primary pH1N1 virus isolated
from the Children’s Hospital of Philadelphia (CHOP) in 2013. Additional in vitro neutralization assays were
completed using the reverse-genetics derived viruses. Data are representative of two independent experiments.
For each neutralization assay, each sample was titered four times, and geometric mean of these quadruplicate
samples is reported.
Linderman et al. www.pnas.org/cgi/content/short/1409171111 6 of 8
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Table 11 
 
 
Table 11. Characterization of K166 HA-specific human sera. 
We further characterized several sera samples that had immunodominant K166 HA-
specific Abs (light gray: K166 HA-specific sera from individuals born before 1985; 
darker gray: sera from individuals born after 1985). HAI assays were completed using 
viruses with A/California/07/2009 HA-WT and a primary pH1N1 virus isolated from the 
Children’s Hospital of Philadelphia (CHOP) in 2013 (A/CHOP/1/2013) that contains 
Q166. Additionally, in vitro neutralization assays were completed using the reverse-
genetics derived viruses. Data are representative of two independent experiments. For 
each neutralization assay, each sample was titered four times, and the geometric mean of 
these quadruplicate samples is reported. 
 
Table S2. HAI titers using sera from healthy donors from Mexico
Exp. 1 Exp. 2 Exp. 3
HAI titers Ratio HAI titers Ratio HAI titers Ratio
Sample ID YOB WT K166Q WT/K166Q WT K166Q WT/K166Q WT K166Q WT/K166Q
N-33 1973 160 60 2.67 120 40 3.00 80 30 2.67
N-42 1975 40 <10 >4.00 30 <10 >3.00 30 <10 >3.00
N-93 1977 120 30 4.00 60 30 2.00 60 20 3.00
N-72 1979 30 <10 >3.00 30 <10 >3.00 20 <10 >2.00
N-70 1980 160 80 2.00 120 60 2.00 120 40 3.00
Sera were isolated from 45 healthy donors from Mexico during the 2013–2014 influenza season. HAI assays
were performed using viruses with either WT A/California/07/2009 HA or A/California/07/2009 HA with a K166Q
HA mutation. For each sera sample, we completed three independent HAI assays. Shown are samples that had at
least a twofold reduction in HAI titer using the mutant virus in three independent experiments.
Table S3. Characterization of K166 HA-specific sera
HAI titers In vitro neutralization titers
Sample ID YOB A/CAL/07/09-WT HA A/CHOP/1/2013 A/CAL/07/09-WT HA A/CAL/07/09-K166Q HA
40–49 1943 20 <10 24 12
40–44 1948 160 30 453 95
40–16 1949 80 <10 160 20
70–52 1971 40 <10 190 28
70–36 1972 120 10 381 95
70–84 1973 40 <10 160 57
70–86 1973 60 20 190 67
70–23 1975 80 <10 226 20
70–19 1978 30 <10 95 10
80–48 1983 320 30 1,076 80
80–10 1986 160 160 761 1,810
80–26 1986 80 80 113 160
80–74 1986 40 40 135 113
80–30 1987 20 10 67 113
80–34 1987 160 160 381 538
80–56 1988 20 <10 17 34
90–01 1990 40 10 48 80
90–24 1991 60 20 34 95
90–12 1992 160 60 190 226
90–13 1992 80 80 190 320
We further characterized several sera samples that had immunodominant K166 HA-specific Abs (light gray:
K166 HA-specific sera from individuals born before 1985; darker gray: sera from individuals born after 1985). HAI
assays were completed using viruses with the A/California/07/2009 HA-WT and a primary pH1N1 virus isolated
from the Children’s Hospital of Philadelphia (CHOP) in 2013. Additional in vitro neutralization assays were
completed using the reverse-genetics derived viruses. Data are representative of two independent experiments.
For each neutralization assay, each sample was titered four times, and geometric mean of these quadruplicate
samples is reported.
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Table 12 
 
Table 12. Vaccination elicits K166 HA-specific Ab responses in humans.  
HAI assays were completed using sera isolated from healthy donors before and after 
vaccination with the monovalent pH1N1 virus in 2009. Post-vaccine sera were collected 
30 d after vaccination. HAI assays using post-vaccination sera were completed three 
independent times and assays using pre-vaccine sera were completed two independent 
times. Red indicates HAI titers equal to or less than 10 and yellow indicates HAI titers 
greater than 10. 
 
 
 
 
 
 
Table S4. Vaccination elicits K166 HA-specific responses
Visit 1 (prevaccine) Visit 2 (postvaccine)
ID YOB USSR/77 Chile/83 Texas/91 NC/99 SI/06 CAL/09 CAL/09-K166Q CAL/09-WT CAL/09-K166Q
K166-specific donors
1 1979 240 160 320 60 80 120 20 160 20
6 1966 160 120 240 120 240 <10 <10 40 10
7 1966 40 60 30 10 60 <10 <10 120 <10
13 1982 80 40 80 40 60 10 <10 160 10
21 1958 60 30 80 40 80 <10 <10 60 20
Other donors
2 1976 80 80 120 <10 <10 60 60 80 60
5 1949 10 <10 <10 10 40 10 <10 40 40
8 1961 40 <10 30 80 120 <10 <10 80 80
9 1977 80 80 80 <10 <10 <10 <10 120 80
10 1983 80 <10 320 240 320 <10 <10 240 320
15 1961 <10 <10 <10 <10 <10 <10 <10 80 80
17 1956 40 <10 30 80 120 10 <10 20 20
19 1961 80 40 160 80 80 <10 <10 20 20
20 1945 40 <10 <10 <10 <10 <10 <10 240 320
22 1956 30 30 60 <10 <10 <10 <10 240 240
23 1975 40 <10 240 80 120 <10 <10 160 160
24 1968 <10 <10 30 <10 <10 <10 <10 60 60
HAI assays were completed using sera isolated from healthy donors before and after vaccination with the monovalent pH1N1 virus in
2009. Postvaccination sera were collected 30 d after vaccination. HAI assays using postvaccine sera were completed three independent
times and assays using prevaccine sera were completed two independent times. Red indicates HAI titers equal to or less than 10 and
yellow indicates HAI titers greater than 10.
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Table 13 
 
 
 
 
 
 
 
Table 13. Analyses of sera from ferrets sequentially infected with sH1N1 viruses and 
pH1N1. 
Ferrets were infected with a sH1N1 virus and bled 14 d and 84 d later. Animals were then 
infected with a pH1N1 strain and bled 14 d after second infection (98 d post-first 
infection). Sera were isolated and HAI assays were completed using WT and K166Q-HA 
pH1N1 viruses. Data are representative of three independent HAI assays. The three 
ferrets with K166 HA-specific Ab responses had at least a twofold reduction in HAI titer 
against the K166Q mutant virus in three independent experiments. Red highlights 
twofold or greater reductions in HAI titer using K166Q-HA pH1N1 virus compared to 
WT-HA pH1N1 virus. ND, not determined. 
 
Table S5. Sera from ferrets sequentially infected with sH1N1 viruses and pH1N1
Day 14 Day 84
Day 98 (14 d after
second infection)
First infection Second infection Group Animal no. WT K166Q WT K166Q WT K166Q
USSR/90/77 A/California/07/09 Group 1 7982 <10 <10 <10 <10 800 800
Group 1 7983 <10 <10 <10 <10 800 800
Group 1 7984 <10 <10 <10 <10 300 300
Group 1 7985 <10 <10 <10 <10 800 600
Group 1 7991 <10 <10 <10 <10 2,400 2,400
Group 1 7993 <10 <10 <10 <10 800 1,200
Group 1 7994 <10 <10 <10 <10 600 600
Group 1 7995 <10 <10 <10 <10 400 600
A/Chile/01/83 A/California/07/09 Group 2 7987 <10 <10 <10 <10 1,200 800
Group 2 7988 <10 <10 <10 <10 800 400
Group 2 7989 <10 <10 <10 <10 800 400
Group 2 7990 <10 <10 <10 <10 1,600 1,600
Group 2 7996 <10 <10 <10 <10 1,200 400
Group 2 7997 <10 <10 <10 <10 240 160
Group 2 8000 <10 <10 <10 <10 600 800
Group 2 8001 <10 <10 <10 <10 800 800
A/Singapore/06/86 A/California/07/09 Group 3 1487 <10 <10 80 120 6,400 6,400
Group 3 1488 <10 <10 <10 <10 3,200 3,200
Group 3 1481 <10 <10 <10 <10 2,400 3,200
Group 3 1504 <10 <10 60 80 4,800 6,400
Group 3 8002 <10 <10 <10 <10 1,600 2,400
Group 3 8009 <10 <10 <10 <10 1,600 2,400
Group 3 8010 <10 <10 <10 <10 4,800 6,400
Group 3 8012 <10 <10 <10 <10 1,600 2,400
A/California/07/09 A/California/07/09 Group 4 8013 400 400 200 200 160 160
Group 4 8014 800 800 400 400 2,400 2,400
Group 4 8015 800 800 300 200 2,400 1,600
None A/California/07/09 Group 5 1486 ND ND ND ND 1,600 2,400
Group 5 1497 ND ND ND ND 1,600 1,600
Group 5 1492 ND ND ND ND 1,200 1,600
Ferrets were infected with a sH1N1 virus and bled 14 and 84 d later. Animals were then infected with a pH1N1 strain and bled 14 d later (98 d post first
infection). Sera were isolated and HAI assays were completed using WT and K166Q-HA pH1N1 viruses. Data are representative of three independent HAI
assays. The three ferrets with K166 HA-specific Ab responses had >twofold changes in HAI titer using the K166Q virus in three independent experiments. Red
highlights twofold or greater reductions in HAI titer using K166Q-HA pH1N1 virus compared to WT-HA pH1N1 virus. ND, not determined.
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CHAPTER 5 – OVERALL CONCLUSIONS, DISCUSSION, 
AND FUTURE DIRECTIONS 
 
 In our studies, we explored multiple aspects of the current influenza virus 
surveillance and vaccine strain selection process. First, we found that recent H3N2 
viruses rapidly acquire mutations when propagated in cell culture. Mutations arose in 
both HA and NA after a single passage of clinical isolates in MDCK cells. We identified 
NA mutations that resulted in NA-dependent sialic acid binding and an HA mutation that 
increased receptor binding avidity. Both HA and NA mutations increased viral infectivity 
and hemagglutination titers. We found that these mutations altered HAI assays that are 
commonly used for the antigenic characterization of influenza virus isolates. Second, we 
determined that a single mutation in HA antigenic site B of H3N2 viruses contributed to 
the influenza vaccine mismatch during the 2014-2015 season. Inclusion of the F159S HA 
mutation in HA antigenic site B drastically decreased the ability of ferret, sheep, and 
human Abs to bind and neutralize the virus. Because a single mutation in an antigenic site 
can result in a vaccine mismatch, accurate surveillance and correct antigenic 
characterization of circulating strains is vital in producing an effective influenza vaccine 
each year. Third, we examined how different sH1N1 pre-exposure histories can result in 
unique anti-pH1N1 Ab repertoires. Over 40% of middle-aged adult blood donors (born 
1965-1979) were found to possess Abs specific for an HA epitope that recently acquired 
a mutation (K166Q). Vaccinated middle-aged adults also possessed Abs with this 
specificity, which left them more susceptible to influenza infection with pH1N1 strains 
containing Q166. Sera isolated from ferrets recovering from a primary pH1N1 infection 
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did not possess Abs that recognized this epitope, but sera from ferrets sequentially 
infected with a 1983 sH1N1 virus and then challenged with the 2009 pH1N1 virus did 
possess Abs that were sensitive to the K166Q mutation. Therefore, Abs in the sera of 
ferrets recovering from primary influenza virus infections do not have the same 
specificity of Abs isolated from humans who have been sequentially exposed to different 
influenza virus strains.  
 
Mutations acquired during viral propagation complicate influenza surveillance 
 Cell culture-derived mutations have been shown to alter HA stability (Nakowitsch 
et al., 2014; Nakowitsch et al., 2011), reduce immunogenicity (Chen et al., 2010b), and 
affect NA activity (Wang et al., 2013). Over the past two decades, H3N2 influenza 
viruses have seen a steady decline in their receptor binding avidity (Gulati et al., 2013; 
Lin et al., 2012). This has led to poor growth during cell culture propagation because the 
viruses are unable to bind to their sialic acid receptors and infect cells for replication. We 
passaged 10 clinical isolates from H3N2-infected children on MDCK cells, and observed 
a high rate of mutations in both HA and NA. The P237L HA mutation increased receptor 
binding avidity, possibly by stabilizing the HA trimer because HA residue 237 is located 
at the trimer interface. The D151G and D151N NA mutations that arose were responsible 
for NA-dependent binding of sialic acid, as has been seen previously (Lin et al., 2010; 
Zhu et al., 2012). Both types of mutations are likely to effect antigenic analyses, as we 
showed specifically with the P237L HA reverse genetics virus in an HAI assay, and as 
other groups have shown with NA-dependent binding in HAI assays (Lin et al., 2010). 
110	  
 This rapid acquisition of mutations in HA and NA during viral passage presents a 
major problem for surveillance. For example, HA antigenic clade 3C.2a H3N2 viruses 
acquire mutations when grown in MDCK cell culture (Skowronski et al., 2016). When 
attempting to choose the correct viral strain to include in the influenza vaccine each year, 
it is important to isolate and characterize the viruses that are actually circulating. If 
isolates are acquiring mutations during propagation (before any analyses are completed), 
the sequencing data and antigenic characteristics actually represent the cell culture-
adapted H3N2 viruses, not the naturally occurring H3N2 viruses of interest.  
 Now that cell culture-derived mutations have been established as a major 
complication to surveillance and vaccine selection, steps are being implemented to grow 
and sequence influenza viruses more reliably. Previously, surveillance has been done 
with a “passage-first” mentality where clinical isolates are immediately expanded in cell 
culture to obtain a workable stock, then antigenically characterized, and finally 
sequenced if an antigenic difference is detected (Krauss et al., 2012; Stöhr et al., 2012). 
Now, the CDC is working on shifting to a “sequence-first” approach to surveillance, 
where clinical isolates are immediately sequenced directly from the primary isolate 
before any propagation or antigenic analyses are completed (Dormitzer et al., 2013). This 
method eliminates the possibility that cell culture adaptive mutations will arise before 
sequencing can be completed. The other main change in surveillance is the discovery that 
using a different cell culture system can actually decrease the amount of mutations that 
arise during propagation. Instead of using the classic MDCK cells for viral propagation, 
using MDCK-SIAT1 cells for viral propagation allows recent H3N2 viruses to grow 
without the need for adaptive mutations (Abdoli et al., 2016; Krauss et al., 2012; Oh et 
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al., 2008). MDCK-SIAT1 cells are a form of MDCK cells that have been engineered to 
express a higher concentration of α2,6-linked sialic acids on their surface (Matrosovich et 
al., 2003), which serve as the receptor for human influenza viruses. With more receptor 
present, even the H3N2 viruses with very low receptor binding avidity are able to infect 
the cells and grow well. So by using a “sequence-first” approach and MDCK-SIAT1 cells 
for viral propagation, the previous complications seen in H3N2 surveillance due to cell 
culture-adaptive mutations should be avoided. 
 
NA-dependent receptor binding is a recent observation in the influenza field 
 For as long as the influenza research field has existed, the central dogma is that 
HA is responsible for binding and entry, and NA is responsible for release. However, 
multiple groups have now begun to identify viruses that bind to sialic acid through NA 
instead of HA (Lin et al., 2010; Zhu et al., 2012). The caveat here is that, so far, NA-
dependent binding has only been detected following propagation in cell culture. Similar 
to what we found in Chapter 2, other groups have concluded that primary isolates do not 
contain the D151G or D151N NA mutations responsible for the NA-binding phenotype 
(Lee et al., 2013; Okomo-Adhiambo et al., 2010). The question now is whether a 
continued reduction of HA receptor binding avidity in H3N2 viruses will result in the 
need for NA-dependent sialic acid binding even in naturally circulating viruses. Lin and 
colleagues demonstrated through reverse genetics that only a single mutation at NA 
residue 151 is required for NA-dependent binding. They inserted the D151G or D151N 
NA mutations and observed increased receptor binding via higher levels of NA-
dependent agglutination (Lin et al., 2010). With only a single mutation required for this 
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NA-dependent binding phenotype, it seems possible that a circulating isolate with NA-
dependent binding could emerge. However, mutations at D151 decrease NA sialidase 
activity and may hinder the virus without compensatory mutations (Zhu et al., 2012). 
Overall, NA-dependent binding of sialic acid is a major shift in the dogma of the 
influenza community. It is currently just a cell culture-derived phenomenon that has yet 
to be observed in a primary isolate, but it can still have an impact on surveillance and 
vaccine selection, which rely on the propagation of primary isolates in cell culture. 
 
Reduced receptor binding avidity of H3N2 viruses presents difficulties in vaccine 
manufacturing and production 
 Another complication presented by the poor growth of H3N2 viruses in cell 
culture and eggs, is the effect it has on vaccine manufacturing and production. Although 
MDCK-SIAT1 cells appear to be a good alternative to MDCK cells for cell culture 
propagation, egg-based propagation still requires adaptive mutations for H3N2 viruses to 
grow. And because almost all influenza vaccines are currently produced in eggs, this 
limits the effectiveness of H3N2 vaccines. For example, the choice of the H3N2 vaccine 
component for the 2015-2016 influenza season was heavily influenced by which clade of 
H3N2 viruses could grow well in eggs. Although HA antigenic clade 3C.2a was 
dominating circulation, a virus from HA antigenic clade 3C.3a was chosen as the vaccine 
strain (Anonymous, 2015). This is because the HA Y159+T160 epitope present in HA 
antigenic site B of Clade 3C.2a viruses cannot grow in eggs, consistent with our findings 
that we were unable to rescue and grow the A/Texas/50/2012-F159Y+K160T mutant 
virus in Chapter 3 without it acquiring mutations. When grown in eggs, these viruses 
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quickly acquire mutations at HA residue 160, resulting in a loss of a glycosylation at 
residue 158, thus drastically altering the antigenicity of HA antigenic site B in these 
viruses (Chambers et al., 2015). Egg-adaptive mutations that emerge during vaccine 
production are a common concern and have even been implicated as the reason for the 
H3N2 vaccine mismatch during the 2012-2013 influenza season (Skowronski et al., 
2014). One way around this issue is to focus more on cell-based vaccine production. 
Recent work shows that MDCK-SIAT1 cells can be successfully used to produce high 
quality vaccines without mutations (Abdoli et al., 2016; Oh et al., 2008). Although this 
would be a difficult shift for vaccine producers, it would likely result in a more reliable, 
uniform, and effective influenza vaccine. 
 
The immunodominance of HA antigenic site B in neutralizing Ab responses against 
H3N2 influenza viruses and the possible role of glycosylation  
 Influenza viruses constantly accumulate mutations in Ab binding epitopes 
scattered around the globular head of HA in order to escape prior immunity and continue 
circulating. This process is termed antigenic drift and is responsible for the vaccine strain 
updates that are required every few years for each influenza subtype. In Chapter 3, we 
identified a mutation that emerged in H3N2 viruses during the 2014-2015 influenza 
season and resulted in a vaccine mismatch. The mutation was located in HA antigenic 
site B, and accounted for almost all of the antigenic distinction between the 2014-2015 
vaccine strain and the newly emerged 2014-2015 viruses. HA antigenic site B has been 
repeatedly implicated as an important site for antigenic drift mutations throughout the 
evolution of H3N2 viruses (Koel et al., 2013; Popova et al., 2012). Although most of the 
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previous work has been done utilizing antisera collected from previously naïve ferrets 
infected for the first time with influenza, our study demonstrated that the majority of 
human Ab responses against current H3N2 viruses are also directed against HA antigenic 
site B.  
 So why is HA antigenic site B such an immunodominant epitope for Ab responses 
against H3N2 viruses? The term immunodominant refers to the majority of the response 
being focused on a specific epitope (Popova et al., 2012; Rajnavolgyi et al., 1997). One 
hypothesis regarding the importance of HA antigenic site B is that this antigenic site is 
one of the few sites on H3 viruses that are not glycosylated (Meyer and Wilke, 2015). 
H3N2 viruses have continuously gained glycosylation sites in HA since being introduced 
into humans in 1968 (Suzuki, 2011; Tate et al., 2011; Vigerust et al., 2007). The large N-
linked glycosylations attached to the HA surface present a high level of steric hindrance 
to binding Abs (Pentiah et al., 2015; Tate et al., 2014). Only the HA surfaces left open 
and exposed can act as Ab binding epitopes, thus focusing the Ab response to specific 
epitopes over time as more glycosylation sites are added. This fits well with the 
hypothesis we made in Chapter 4 regarding the sharp decline of K166 HA-specific H1N1 
Ab responses in humans born after 1986. A new glycosylation site was added to sH1N1 
viruses beginning in 1986 and it is predicted to act as an umbrella-like shield that covers 
and hides the K166 HA-epitope from Ab binding. Multiple studies have already 
implicated the addition of glycosylation sites in antigenic change and abrogation of Abs 
that previously bound to HA (Tate et al., 2014). For example, inserting two or four 
additional glycosylation sites into the 1968 H3N2 pandemic strain reduced neutralizing 
Ab titers and increased immunopathology compared to the WT virus in previously naïve 
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mice (Wanzeck et al., 2011). Therefore, it is likely that glycan shielding plays an 
important role in limiting the antigenic sites available to anti-H3N2 Abs. 
 Other possible explanations of the HA antigenic site B immunodominant response 
against H3N2 viruses include the location of site B directly at the top of the HA head and 
its proximity to the receptor binding site. It is clear that future influenza virus 
surveillance should monitor H3N2 viruses for the emergence of new mutations in HA 
antigenic site B that could signal antigenic drift. This approach of closely monitoring HA 
antigenic site B mutations can even be taken a step further. Multiple groups have recently 
shown that growth of a historical influenza virus in vitro, in the presence of polyclonal 
sera, will actually elicit escape mutations that recapitulate the antigenic drift that has 
occurred in nature (DeDiego et al., 2016; Li et al., 2016). Passaging of the H3N2 virus 
A/Victoria/361/2011 in the presence of polyclonal human antisera elicited mutations in 
HA antigenic site B at residue 156, the exact residue that was mutated in antigenically 
drifted H3N2 viruses of the 2012-2013 influenza season (DeDiego et al., 2016). Li and 
colleagues also concluded that residues 153-156 in HA antigenic site B play a key role in 
influenza antigenicity (Li et al., 2016). By growing the current H3N2 vaccine strain in the 
presence of polyclonal human sera, we may be able to predict future mutations that will 
arise in HA antigenic site B. This information could then be used to create antigenically 
drifted vaccine strains. This work in association with recent observations of “back-
boosting,” where infection with an antigenically drifted H3N2 virus actually boosts Ab 
titers even higher against previously seen strains (Fonville et al., 2014), may present a 
new vaccination strategy: using escape mutations to generate artificially drifted influenza 
strains, and then using a prime-boost vaccine regimen where the currently circulating 
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strain is the first vaccination and the artificially drifted strain is the second vaccination. 
This would in theory boost titers against the currently circulating strain even higher than 
multiple vaccinations with just the current strain. 
 However, it is important to remember that antigenic sites other than HA antigenic 
site B may be important for H3N2 antigenic drift as well. Similar to Ab responses elicited 
against pH1N1 viruses, anti-H3N2 Ab responses may have different specificities in 
different individuals due to unique pre-exposure histories. This topic will be discussed in 
more detail later in this chapter. 
 
The human Ab response against pH1N1 viruses is determined by pre-exposure 
history to sH1N1 viruses 
 While the majority of human anti-H3N2 Ab responses are focused on a single 
antigenic epitope, human anti-H1N1 Ab responses can be targeted to multiple antigenic 
sites on the HA surface. The exact target site is determined by an individual’s pre-
exposure history and the conserved epitopes shared between previous strains and the 
currently infecting strain (Li et al., 2013b; Linderman et al., 2014). Additionally, more 
antigenic sites are available on the surface of H1 viruses because there are less 
glycosylation residues present (Zhang et al., 2013b). As discussed in the previous section, 
H3 viruses are heavily glycosylated (Suzuki, 2011; Tate et al., 2011; Vigerust et al., 
2007) and HA antigenic site B may be the only epitope accessible for Ab binding (Meyer 
and Wilke, 2015; Pentiah et al., 2015; Tate et al., 2014). Recent H1 viruses, on the other 
hand, have very few glycosylation sites. In fact, the pH1N1 viruses that emerged in 2009 
contained only a single potential glycosylation site on the HA head (Job et al., 2013). 
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Studies have demonstrated that the addition of more glycosylation sites into the pH1N1 
head results in resistance to neutralizing Abs (Job et al., 2013) and that different 
glycosylation sites can alter antigenicity of H1N1 viruses (Sun et al., 2013). However, 
there are currently very few potential glycosylation sites in circulating pH1N1 strains, 
resulting in a wide array of exposed Ab binding epitopes across the HA head.  
 The data presented in Chapter 4 demonstrates that different sH1N1 pre-exposure 
histories elicit unique Ab responses against distinct HA epitopes of the pH1N1 virus. 
Different aged individuals within the human population have unique Ab specificities (Li 
et al., 2013b; Linderman et al., 2014). Individuals are infected early in life by H1N1 
viruses that circulate during their respective childhoods. When they are challenged later 
in life with an antigenically distinct pH1N1 virus, there are a limited number of 
conserved epitopes shared between the current pH1N1 virus and the sH1N1 virus seen 
early in life. Memory B cells specific for conserved epitopes are recalled and produce the 
majority of the Abs in the secondary response. Humans born during different decades 
have been exposed to different sH1N1 viruses early in life, thus explaining why different 
age groups elicit Ab responses with different specificities against pH1N1 viruses. 
 
H1N1 pre-exposure history elicits a unique Ab response in middle-aged adults 
against pH1N1 virus that correlates with higher susceptibility to infection 
 Influenza surveillance and vaccine strain selection have always relied heavily on 
the use of antisera collected from previously naïve ferrets infected only one time with 
influenza virus. Previous work from our lab has demonstrated that Abs elicited in 
previously naïve ferrets infected with the 2009 pH1N1 virus a single time do not have the 
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same specificity as anti-pH1N1 Abs elicited in young adults (born 1983-1996) (Li et al., 
2013b). The data presented in Chapter 4 demonstrates that the use of sera collected from 
previously naïve ferrets infected with a single influenza virus is also leading to the 
antigenic mischaracterization of newly emerged HA mutations. Specifically, we found 
that a K166Q HA mutation that became fixed in pH1N1 viruses during the 2013-2014 
influenza season abrogates the binding of Abs in the sera of a large portion of middle-
aged adults (born 1965-1979). It was hypothesized that this Ab specificity for the HA 
epitope including residue K166 is present in middle-aged adults because the K166 HA-
epitope is conserved between the pH1N1 virus of 2009 and the sH1N1 strains that 
circulated during their childhoods (the 1970s and early 1980s). To test this hypothesis, 
we sequentially infected ferrets with a sH1N1 virus from 1983 and then the 2009 pH1N1 
virus. We found that these animals mounted Abs that recognized the HA epitope 
involving residue K166 that is conserved between the 1983 sH1N1 virus and the 2009 
pH1N1 virus. The functional consequence of these K166 HA-specific Abs was also 
determined using passive transfer experiments in mice where mAbs specific for the 
epitope involving K166 did not protect mice against viruses possessing Q166.  
 This conclusion that Abs specific for the K166 HA-eptitope make the individual 
more susceptible to severe infection correlates well with the observation that middle-aged 
adults experienced a drastically increased burden of severe influenza infections during 
the 2013-2014 season. According to WHO reports, middle-aged individuals (defined by 
the WHO as 18-64 years old) experienced 61.2% of influenza-related hospitalizations and 
62% of influenza-related deaths during the 2013-2014 influenza season (Arriola et al., 
2014). Typically, those values are between 20-35% for an individual influenza season. 
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The majority of severe influenza infections usually affect those with weaker immune 
systems: the very young (0-4 years old) and the elderly (>65 years old). We recently 
completed additional experiments where we defined the specificity of sera collected from 
323 individuals prior to the 2013-2014 influenza. We found that individuals that 
possessed Abs focused on the K166 HA-epitope were more prone to pH1N1 infection 
during the 2013-2014 influenza season (Petrie et al., under review).  
 
Identification of the unique anti-pH1N1 Ab responses in other age groups 
 Our group has now identified the specificities of anti-pH1N1 Abs that are 
common among individuals in two separate age groups. As explained above, the unique 
pre-exposure history of individuals in each age group to different sH1N1 viruses early in 
life led to different anti-pH1N1 Ab responses. Young adults (born 1983-1996) possess an 
Ab response targeted to the HA epitope involving residue K133 (Li et al., 2013b). 
Middle-aged adults (born 1965-1979) possess an Ab response targeted against the K166 
HA-epitope (Huang et al., 2015; Linderman et al., 2014). The epitope involving K133 
was present in sH1N1 viruses circulating between 1983-1996 and the epitope involving 
K166 was present in sH1N1 viruses circulating prior to 1983. 
 It is possible that there are different Ab specificities that are common among 
individuals in other age groups as well. For example, it would be very interesting to 
investigate the anti-pH1N1 Ab specificity of children. School-aged children have been 
implicated as the main population responsible for transmission during annual influenza 
circulation (Petrie et al., 2013; Viboud et al., 2004). Being the main population for 
transmission would exhibit a large immune pressure that may have already forced the 
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virus to adapt and mutate to avoid the unique Ab specificity present in young children. 
However, none of the mutations that have emerged in pH1N1 viruses since 2009 appear 
to have an effect on the Ab binding of sera isolated from influenza-exposed children 
(unpublished data from our lab). Likewise, although the Ab specificity of young adults is 
against the epitope involving HA residue K133, this epitope has not yet acquired a 
mutation in circulating pH1N1 viruses. There could be many forces at play that we do not 
yet understand on how influenza viruses continuously circulate. Different age groups may 
allow for transmission in different geographical locations, or each age group may be 
partially responsible for circulation. Nonetheless, the population that controls the 
majority of transmission and circulation should have the largest immune pressure on 
forcing antigenic drift mutations in the pH1N1 HA gene segment. 
 
Do these unique secondary Ab responses represent original antigenic sin? 
 Pre-exposure history has been shown here to elicit unique Ab responses against 
pH1N1 influenza virus in different age groups of the human population. The specificity 
of these unique Ab responses is determined by the HA epitopes conserved between the 
sH1N1 strains these individuals were infected with early in life and the pH1N1 virus they 
are being challenged with now. Whenever a secondary Ab response is altered and 
characterized depending on previous infections, it is necessary to establish whether 
original antigenic sin (OAS) is playing a role. In general, OAS describes the observation 
that even when infected with a novel influenza strain, humans will produce Abs against 
previously encountered strains at the expense of mounting effective responses against the 
current novel strain (Davenport et al., 1953; Francis, 1960). In that sense, our 
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observations of different pre-exposure histories leading to unique Ab repertoires would 
not fall under the category of OAS for one major reason: there is no so-called “sin” 
observed in our studies. Take the middle-aged adult age group with Abs specific for the 
K166 HA-epitope for example. Although these individuals preferentially mount an Ab 
response that is specific for an epitope present in the sH1N1 strains they saw early in life, 
they still mount sufficiently high responses against the A/California/07/2009 pH1N1 
strain. If this were an example of OAS, the Ab response would be high against past 
sH1N1 strains at the expense of high titers against the currently infecting strain. As long 
as the K166 HA-epitope is intact, the Ab response against the current strain is protective. 
It’s only when HA residue 166 is mutated that this K166 HA-specific Ab response is 
deleterious. It remains to be seen whether viruses possessing Q166 recall Ab responses 
that target the K166 HA-epitope in individuals with sH1N1 pre-exposures from the early 
1980s. 
 Another question along the lines of OAS to consider is whether an individual’s 
first influenza exposure is really the most important in shaping lifelong immunity. An 
alternate way to look at this is whether these unique Ab responses we have discovered in 
different age groups are actually fully dependent on the epitopes conserved between the 
current pH1N1 strain and the very first sH1N1 strain with which they were infected. So 
not just “strains they saw early in life,” but rather “their very first sH1N1 infection.” This 
could help explain why only 42% of our middle-aged adult sera possessed Abs sensitive 
to the K166Q mutation. The individuals without this Ab specificity for the K166 HA-
epitope may have been first infected with an A/USSR/90/1977-like virus which does not 
have the K166 HA-epitope intact. Even if they were later infected with a sH1N1 strain 
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with an intact K166 HA-epitope (like A/Chile/1/1983), they would still not mount an Ab 
response specific for the K166 HA-epitope. Only those infected for the first time with a 
sH1N1 virus with the K166 HA-epitope intact would produce this unique specificity later 
in life. Previous studies have suggested that an individual’s first influenza exposure 
confers an antigenic seniority to their response, which is continually boosted with 
repeated sequential infections (Kucharski et al., 2015; Lessler et al., 2012; Miller et al., 
2013). Overall, the unique Ab responses mounted against pH1N1 viruses in different age 
groups generally do not represent true OAS. Although the specificity of the response is 
dictated by sH1N1 strains seen early in life, the response is still sufficient enough to 
protect against the current pH1N1 strain. Only when a mutation arises in that specific 
epitope does sin truly occur in that the response is highly effective against past strains, 
but low in effectiveness against the current strain. 
 
Does pre-exposure history have as much of an impact on shaping the anti-H3N2 
influenza response? 
 Our data suggests that pre-exposure to different sH1N1 strains can affect the Ab 
specificity against pH1N1 infections later in life. This presents a new factor that must be 
taken into account during vaccine selection and antigenic characterization of newly 
emerged mutations. However, it will also be important to determine whether pre-
exposure history shapes unique Ab responses against subsequent H3N2 influenza 
infections as well. One major difference between H1N1 and H3N2 viruses is the level of 
antigenic distinction between the strains seen early in life and those currently circulating. 
Although sH1N1 and pH1N1 viruses are classified as the same subtype of influenza, they 
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are thought of as two entirely different pandemics because pH1N1 viruses emerged after 
obtaining a genetically divergent HA gene segment from a classical swine lineage 
(Garten et al., 2009). Approximately 20-30% of the amino acid residues in HA are 
different between sH1N1 viruses and pH1N1 viruses (Li et al., 2012). This substantial 
difference, especially in the variant globular head domain, does not leave many 
conserved epitopes shared between sH1N1 and pH1N1 viruses. A limited availability of 
conserved epitopes may be required for the focusing of an immunodominant response on 
a specific HA epitope, similar to what we found in the middle-aged adult sera regarding 
the K166 HA-epitope. On the other hand, H3N2 viruses of the 1960s and 1970s are at 
most 8-12% different in their HA sequences compared to H3N2 viruses of today 
(Bedford et al., 2010; Broberg et al., 2015; Smith et al., 2004). This results in many more 
conserved epitopes between H3N2 strains, which may limit the ability of the secondary 
Ab response to be focused on a single shared epitope.  
 H3N2 viruses have been circulating constantly in humans since 1968. In that time 
they have acquired multiple mutations in each of the five antigenic sites of H3N2 HA 
(Smith et al., 2004). Derek Smith’s group has completed elegant work to take an in-depth 
look at the evolution of H3N2 viruses and the requisition of antigenic drift mutations. 
Through the use of previously naïve ferret antisera, they identified a set of several 
residues in HA antigenic site B that are responsible for the majority of antigenic drift in 
H3N2 viruses over the past 50 years (Koel et al., 2013). However, many other mutations 
have become fixed in the other H3 antigenic sites as well during that time. Our 
hypothesis is that mutations are elicited in these other sites in order to escape other Ab 
responses mounted in individuals with unique H3N2 pre-exposure histories. So similar to 
124	  
the H1N1 pre-exposure history observations, individuals with different H3N2 pre-
exposure histories might possess anti-H3N2 Abs against different epitopes of HA; and 
H3N2 viruses might acquire mutations in all these epitopes in order to escape population 
immunity and continue circulating. So although Derek Smith and his colleagues have 
carried out great investigations into H3N2 antigenic drift, their answers are potentially 
skewed and limited by their use of only sera collected from previously naïve ferrets to 
antigenically characterize historic H3N2 viral isolates. Pre-exposure history in the human 
population could have shaped unique Ab responses to epitopes other than HA antigenic 
site B. This hypothesis is also supported by our human sera data from Chapter 3, where 
although the majority of our human sera cohort possessed Abs against HA antigenic site 
B, about 12.5% had high titer Ab responses targeted elsewhere on HA. 
 We are currently conducting studies to determine the importance of H3N2 pre-
exposure history on the Ab response against gradually drifted H3N2 viruses, and how it 
compares to what we observed with H1N1 pre-exposure histories. As we have shown 
previously with H1N1 infections, ferrets sequentially infected with antigenically distinct 
influenza strains will recapitulate the unique Ab responses observed in humans (Li et al., 
2013b; Linderman et al., 2014). For our H3N2 study, ferrets were sequentially infected 
with antigenically distinct H3N2 viruses in order to determine if Ab specificities would 
be shifted to epitopes conserved between the two strains. Preliminary data indicates a 
possible shift in the Ab binding epitope between different ferret groups, but more data 
and experiments are needed before making final conclusions regarding H3N2 pre-
exposure history and the impact it has on shaping Ab responses.  
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Concluding Remarks 
 Overall, my work has investigated multiple factors that complicate viral 
surveillance and selection of effective vaccine strains for the annual influenza vaccine. 
Poorly growing H3N2 isolates acquire mutations quickly during cell culture propagation 
and hinder antigenic characterization, vaccine selection, and even vaccine production. 
Unique Ab repertoires elicited by different pre-exposure histories are not represented 
through the use of sera collected from previously naïve ferrets infected with influenza for 
the first time in current surveillance techniques. This leads to mischaracterization of the 
antigenic importance of newly emerging HA mutations. And as we demonstrated with the 
single HA antigenic site B mutation in H3N2 viruses during the 2014-2015 influenza 
season, even single mutations can lead to antigenic drift and complete vaccine 
mismatches. 
 Even though the future of influenza vaccination may be destined to include more 
universal approaches, such as recombinant proteins, peptide antigens, and DNA-based 
vaccines, it is still important to continue improving our current vaccination techniques. 
Steps are already being taken to improve viral surveillance. The adoption of a “sequence 
first” strategy will ensure that sequencing data matches that of circulating strains, without 
the danger of cell culture-adaptive mutations. The utilization of MDCK-SIAT1 cells for 
propagation will decrease the number of cell culture-adaptive mutations and allow recent 
H3N2 viruses to grow well enough for true antigenic characterization and vaccine 
selection. However, more steps need to be taken. The current egg-based vaccine 
manufacturing process results in egg-adaptive mutations during production, possible 
vaccine mismatches, and a limit on which viruses can be selected for inclusion in the 
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influenza vaccine. Adoption of a cell culture-based vaccine manufacturing process could 
reduce the level of variation in vaccine stocks and also allow for some viral clades with 
low fitness to be included when relevant.  
 Another vital factor in improving the influenza vaccine will be making sure that 
antigenic characterizations of newly emerged mutations are correct. As we have 
demonstrated multiple times, sera collected from previously naïve ferrets infected with 
influenza a single time do not detect all the antigenically important mutations that 
emerge. Different human age groups have different Ab repertoires against the same virus 
due to unique pre-exposure histories. This does not call for personalized vaccine strains 
based on age; that would be too difficult and too expensive to be feasible. However, what 
is required is a more stringent detection system that will accurately characterize the 
antigenic importance of every mutation. One approach that could improve antigenic 
characterization of newly emerged mutations would be the use of sequentially infected 
ferret antisera. As we have demonstrated multiple times (Li et al., 2013b; Linderman et 
al., 2014), ferrets infected sequentially with the same strains as humans are able to 
recapitulate the immunodominant specificities observed in human Ab responses. Using a 
set of differentially pre-exposed ferret groups, where each group is primed with a 
different historic influenza virus and then re-challenged with the same current strain, 
would hopefully allow us to represent all the unique Ab repertoires present in the human 
population.  
 An alternative approach would be to simply use human antisera raised against 
influenza virus. Collecting antisera from different aged humans and testing samples 
individually could determine the antigenic effect of a newly emerged mutation on the 
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entire spectrum of unique human Ab responses against the pH1N1 virus. In fact, based 
upon the work and the conclusions presented above, the WHO has recently (within the 
last month) changed the way they conduct viral surveillance and will now use human 
antisera to determine antigenic change moving forward (Anonymous, 2016b). 
Additionally, based upon the results they obtained using human antisera instead of 
antisera from previously naïve ferrets, the WHO has elected to update the pH1N1 vaccine 
strain for the first time since 2009 (Anonymous, 2016b). Using human antisera for 
surveillance and vaccine strain selection moving forward will help ensure that the vaccine 
strains are updated to more effective strains that better protect humans of all ages. 
 Annual vaccination against influenza virus is an important tool in fighting off a 
disease that causes millions of infections and thousands of deaths in the United States 
each year (Kostova et al., 2013; Reed et al., 2015). It is vital that the best strains are 
chosen each year in order to get maximum vaccine effectiveness. Sometimes, vaccine 
mismatches cannot be avoided due to the quick emergence of antigenically drifted 
viruses. However, the continued use of sera collected from previously naïve ferrets 
following a single influenza infection and MDCK-based cell culture propagation has 
been putting the field at a disadvantage by not correctly characterizing the antigenic 
importance of new HA mutations. Implementation of a “sequence-first” surveillance 
program, an MDCK-SIAT1 cell culture system for primary isolates and vaccine 
production, and the use of clinical human antisera for antigenic characterization of new 
mutations are the next steps towards improving the annual influenza vaccine. 
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